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Investigations on the structure-toxicity
relationship of different α-synuclein ag-
gregates associated with Parkinson’s
disease
Marta Castellana Cruz
Parkinson’s disease is characterized by the disruption of motor functions as a con-
sequence of the degeneration of the dopaminergic neurons of the substantia nigra pars
compacta. This neuronal degeneration is preceded by the formation of α-synuclein ag-
gregates denoted Lewy bodies and neurites. Due to their potential value for the un-
derstanding of Parkinson’s disease (PD) and the development of effective treatments, a
number of mouse models of PD have been developed. A particular PD model, referred
to as the preformed fibrils (PFF) PD mouse model, has been shown to reproduce many
features of PD, although a great variability of phenotypes has been reported. Here, we
studied how the preparation and storage of different α-synuclein conformers can influence
this model. We concluded that only freshly prepared short α-synuclein fibrils were able
to induce a strong phenotype in mice. After this, the difference in toxicity between kinet-
ically trapped oligomers derived from different α-synuclein variants was explored. From
these experiments it was concluded that WT and G51D oligomers induce a stronger tox-
icity than other α-synuclein mutational variants. It was also possible to determine that
different α-synuclein fibrillar species are able to recruit endogenous α-synuclein at differ-
ent rates. Finally, it was intended to explore the cellular toxicity of these different fibrillar
α-synuclein aggregates through the widely used MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. While performing these experiments it was observed
that, α-synuclein fibrils and other unrelated amyloid aggregates were able to induce the
formation of formazan crystals that resulted in a false-positive result. The nature of this
phenomena, the time scale in which it happens, and which species were able to induce
it were explored. It was concluded that amyloid fibrils, but not monomers or kinetic-
ally trapped oligomers, were able to induce the formation of these crystals at nanomolar
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concentrations and in a timescale of hours after the initial exposure. By exploring how
structural characteristics of amyloid aggregates influence cell toxicity, I have been able
to identify key attributes that can be used in improving in vivo models of Parkinson’s
disease, find new secondary structural markers that correlate with cellular toxicity and
to provide an insight of how to measure cell viability in a reliably way.
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Disorders such as Alzheimer’s disease, Parkinson’s disease (PD), spongiform encephalo-
pathies, type II diabetes and systemic amyloidoses, amongst others, can all be classified
as protein misfolding diseases. This term encompasses a variety of pathologies associated
with the conversion of physiological soluble proteins, of variable primary sequences and
tertiary structure, into toxic aggregates and fibrils that share a common amyloid core
[1, 2].
1.1 Amyloid fibril formation
Under optimal conditions proteins find the lowest energy point in their physiological nat-
ive state, being that a folded one, in the case of globular protein, or a disordered one, in the
case of intrinsicaty disordered proteins (IDP). However if these conditions were to change
(i.e. increment of concentration, temperature, protein fragmentation, non-physiological
post-translational modifications...) states of a lower energy may arise [3] (Figure 1.1). Un-
der these pathological conditions proteins can misfold, exposing hydrophobic residues to
the solvent, and self-assemble into several aggregate structures, including large, insoluble
fibrillar entities known as amyloids. The study of amyloids through different biophysical
methods (electronic microscopy (EM), atomic force microscopy (AFM), Fourier trans-
formed infrared spectroscopy (FT-IR), solid state nuclear magnetic resonance (ssNMR)
and x-ray crystallography) has highlighted several features. Amyloids are unbranched
thread-like structures that posses a cross-β structure in which the β strands are perpen-
dicular to the fibrillar axis, these fibrils are composed of protofilaments that associate
to form larger fibrils of 7-13 nm in diameter and microns in length [1]. Diverse proteins
of different size and sequence, from IDPs as α-synuclein or Aβ to globular proteins as
lysozyme or insulin, can aggregate into these amyloid structures [3]. In fact, since many
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proteins, pathological or not, can form amyloid fibrils, it has been suggested that under
certain conditions, any protein is capable of forming an amyloid [4, 3].
Figure 1.1: Energy landscape of protein folding and aggregation. In purple, the the mul-
titude of conformations ‘funneling’ to the native state and in the pink, the conformations
moving toward amorphous aggregates or amyloid fibrils. Both parts of the energy surface
overlap. Reproduced from [3]
The process of the monomer aggregation into amyloid fibrils can be monitored by
several compounds like Thioflavin T, a fluorescent dye that binds specifically to the
amyloid structure. Although its mechanism of binding still has to be fully elucidated,
the most accepted theory hypothesises that Thioflavin T binds to the surface of amyloid
fibrils, specifically to the spaces left between the structures form by the interaction of
the side-chains of the amino acids present in the cross-β structure. Once bound to
these regions, the Thiofalvin T molecules are immobilised into specific conformations
with a higher fluorescence than the free form [5]. The use of Thioflavin T has allowed
the monitoring of the bulk aggregation reaction of different proteins like Aβ42, Aβ40, α-
synuclein, tau or lysozyme. The kinetic profiles of fibril formation in vitro shows typically
a sigmoidal behaviour characteristic of a nucleation-polymerisation process where three
phases can be macroscopically differentiated: a nucleation or lag phase, characteristic
of de novo formation of new aggregates directly from monomers, an exponential phase,
that reflects the greater ease of addition of monomer onto existing aggregates, and a
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plateau phase, consequence of the depletion of monomer from the solution (Figure 1.2).
The application of chemical kinetics to the data obtained in bulk reaction has allowed
to further study the processes that occur during the lag phase. Specifically, the kinetic
analysis pointed the nucleation phase was not only dominated by primary nucleation, the
process by which monomer form small nuclei, but also by secondary processes such as
secondary nucleation, in which the existing amyloid fibrils act as catalytic surfaces for
the formation of new amyloid nuclei, or fibril fragmentation, that directly increases the
number of ends available for elongation. However, the aggregation pathway of different
proteins are influenced by these processes on different ways, for example, the aggregation
kinetics of Aβ42 is largely influenced by secondary nucleation processes while they only
affects α-synuclein aggregation at acidic pHs [2, 1, 6, 7]. Recent studies [8, 9] on this small
nucleai, denominated oligomers and which are in nature transient species, do not convert
into fibrils but dissociate back into monomers. Moreover, this oligomer population is
heterogeneous in size and probably composed by both on-pathway (oligomers with the
right structure to progress into fibrils) and off-pathway oligomers( oligomers that will not
covert into fibrils and that may be kinetically trapped). Together this illustrate the high
complexity of the amyloid aggregation and the difficulties that may arise to successfully
isolate and study specific elements of it.
1.2 Parkinson’s Disease
The aggregation of α-synuclein is related to several neurodegenerative diseases called sy-
nucleinopathies, such as Parkinson’s disease (PD), dementia with Lewis bodies and mul-
tiple system atrophy (MSA). PD is the second most common neurodegenerative disease
in humans and its clinical symptoms include the disruption of motor functions (resting
tremor, muscular rigidity, impaired postural, reflexes, and bradykinesia), depression and
a general slowing of intellectual processes; although the severity of these symptoms dif-
fers between patients. Pathologically, PD is characterised by the degeneration of the
dopaminergic neurons of the substantia nigra pars compacta (SNpc), which provokes a
drop in the dopamine levels in its striatal projections and consequently, results in the
motor impairment characteristic of the disease. This degeneration of the dopaminer-
gic neurons is preceded by the formation of insoluble cytoplasmic (Lewy bodies) and
neuritic (Lewy neurites) aggregates. These Lewys bodies and neurites are filamentous
by EM, hyperphosphorylated, ubiquitinated and insoluble in anionic detergent. They
are primarily composed by the amyloid form α-synuclein, although a plethora of other
proteins (ubiquitin, tau, tubulin, synphilin-1, tyrosine hydroxylase, synaptophysin, p35,
p38, parkin...) and lipids can also be found inside them [10, 11]. The Lewy bodies and
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Figure 1.2: Schematic representation of the different processes that can lead to the form-
ation of amyloid fibrils. The figure have been taken from [1].
neurites occur first in the anterior olfactory nucleus and dorsal motor nucleus, then in
the pedunculopontine nucleus, raphe nucleus and SNpc and finally in the hippocampus
and cortex (Figure 1.4)[12].
PD is primarily a sporadic disease in which symptoms appear between the age of 50
and 60 and its aetiology remains broadly unknown, due to the large number of predispos-
ing genes and environmental factors involved. Although they only represent around the
10 % of the cases, there are also hereditary variants of the disease, usually with an earlier
onset, caused by mutations in several genes, like SCNA (that encodes for α-synuclein,
which structure and function will be addressed in section 1.3), LRRK2 (a kinase with GT-
Pase activity involved in the regulation of a variety of cellular processes like endocytosis,
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Figure 1.3: α-Synuclein immunoreactivity of Lewy bodies at different maturation stages in
the substantia nigra. (A) No α-synuclein immunoreactivity. (B) Diffuse, pale cytoplasmic
staining. (C) Irregularly shaped, uneven staining. (D) Discrete staining corresponding to
the pale body. (E) Abnormal α-synuclein aggregate displaying both pale body (asterisk)
and Lewy body (arrow). (F) Donut-shaped Lewy body. Scale bar correspond to 10 µM.
Reproduced from [11]
autophagy, or the formation of the neurites cytoskeleton), PINK 1 (a serine/threonine
kinase involve in the induction of autophagy of depolarised mitochondria), or Parkin (an
E3 ubiquitin ligase also involved in the induction of mitophagy). In fact, several muta-
tions in α-synuclein (A30P, E46K, A53T, G51D and H50Q) have been identified as the
direct causes of the disease [13, 10]. The truncation of α-synuclein has also been related
to increased aggregation and Parkinson’s disease [14].
1.3 α-Synuclein and its role in disease
As it has been mention before α-synuclein is the main component of the Lewy bodies
and neurites, moreover mutations in this gene have been proven to be directly linked to
genetic forms of PD. Due to this direct association α-synuclein structure, function and
aggregation pathway have been extensively studied.
The human physiological isoform of α-synuclein contains 140 amino acid (aa) residues.
Its primary sequence can be divided into three domains: the N-terminal domain, the
NAC (non-amyloid-β-component) domain and the C-terminal domain (Figure 1.5). The
25
Figure 1.4: Schematic representation of Lewy bodies and neurites spreading within the
brain (white arrows). The image have been adapted from [12].
N-terminal domain (aa 1-65) contains six imperfect KTKEGV repeats that allow this
region to form an amphipathic α-helix able to bind lipids [15]. The amyloidogenic ability
of α-synuclein resides in the NAC domain (aa 66-95) [16], which under physiological
conditions remains protected by establishing intra-molecular interactions with the C-
terminal domain (aa 96-140), that contains several negative charged residues [17]. α-
Synuclein is abundantly expressed in the brain, and under physiological conditions, it is
mainly localised in the presynaptic terminals. Although the role of α-synuclein within the
cell has not been fully elucidated, in part because it is believe that other isoforms (β- and
γ-synuclein) are able to partially fulfil its role, there is strong evidence that it is involved
in the regulation of synaptic trafficking and homeostasis [10]. Specifically, α-synuclein has
been reported to inhibit phospholipases D1 and D2 which suggest that it may be involved
in the cleavage of membrane lipids and its biogenesis. It has also being identified as an
inhibitor of the tyrosine hydroxylase (TH) and hence the dopamine synthesis, as well as
to perturb the traffic between the endoplasmatic reticulum and the Golgi. Moreover it
assists in the assembly of the synaptic SNARE complex, this function is key to the long-
term functioning of neurons, as α-, β-, γ-synuclein triple-knockout mice showed reduced
assembly of the SNARE complex accompanied by neurological impairment and reduced
lifespan [18]. Together this suggest the α-synuclein is indeed involved in the mediation
of neurotransmitter release and synaptic plasticity.
The aggregation of α-synuclein from monomer to oligomers to fibrils and bigger in-
tracellular inclusions have been linked with several diseases including PD, dementia with
Lewis bodies and multiple systemic atrophy. This highlights the importance of under-
standing the aggregation pathway of α-synuclein and to determine the origins of its
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Figure 1.5: Schematic representation of α-synuclein and comparison between the human
and mouse α-synuclein sequences. Amino acids which differ between the two species
are coloured in red and the six imperfect KTKEGV repeats in green. The N-terminal
domain is shadowed in yellow, the NAC region in blue and the C-terminal domain in
green. Coloured in blue, the E used to generate the E110C α-synuclein cysteine mutants.
The N used to generate the N122C human mutant of α-synuclein is colour in red since
its correspond to one of the amino acids that differ between the two species (N122S) and
signalised with a black arrow
toxicity. In bulk, primary nucleation of α-synuclein is extremely slow under quiescent
conditions, remaining a monomeric solution even after weeks of incubation at 37 °C even
at concentrations as high as 100 µM. Because of this, in order to study the aggregation
pathway of α-synuclein is necessary to add external factors such us shacking conditions,
negatively charge phospholipids or to seed the reaction at lower pH [7]. The study of the
aggregation pathway under shacking condition gives us an idea of how prone a specific
variant of α-synuclein is to aggregate. However, due to the unpredictability factor in-
troduced by the agitation itself it is only possible to fit theses kinetics globally, but not
to evaluate how different processes (primary nucleation, fragmentation and secondary
nucleation) contribute to the aggregation process [19]. Using this method it has been
determined that the pathological variants of α-synuclein A53T, E46K, H50Q [20, 21, 22]
and several truncates (1-108, 1-124, 1-135, 1-133, 1-122) [14, 23, 24, 25] of α-synuclein
accelerate aggregation compared to the WT (wild type) protein while the G51D variant
slows it [26]. In order to study the primary nucleation processes in more detail it is pos-
sible to induce the aggregation of α-synuclein under quiescent conditions by the addition
of negatively charge phospholipids (Dimyristoyl phosphatidylserine [DMPS]) vesicles to
the mixture [27]. Under these conditions of aggregation α-synuclein A53T, A30P and
1-119 variants of α-synuclein presented an increase rate of aggregation respect of the WT
while E46K, H50Q and G51D decreased it. Differences between these results and the ones
observed under shacking conditions can be attributed to the enhancement of primary nuc-
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leation and fragmentation induced by the shaking itself as well as to differences between
the lipid-binding abilities of the different mutants [28, 29]. At mildly acidic pH 4.8, a con-
dition relevant in the context of endocytosis or degradation of α-synuclein, it is possible
to observe secondary nucleations processes driving the aggregation of α-synuclein. In this
context all variants except of H50Q and G51D displayed a similar aggregation kinetics
than the WT while H50Q and G51D showed very slow aggregation rates [28, 29]. Finally
the last aspect to take into account when studying the aggregation process of α-synuclein
is the elongation rate. All variants showed a similar elongation rates although the cross-
seeding between monomers and seeds of different variants slowed the elongation process
[28, 29]. This is specially relevant in a cellular context where different truncation forms
of α-synuclein and in the genetic cases of PD different α-synuclein variants will coexist.
Furthermore, the slower aggregation rate displayed by H50Q and G51D across the dif-
ferent aggregation experiments does not necessarily correlate with a lower toxicity. As it
has been mentioned before, oligomers are formed during the lag phase of the aggregation
pathway and a longer lag phases may translate into an increment of the number of these
species, suspected to be highly toxic.
The question of which α-synuclein species presents greater cellular toxicity and triggers
the development of these diseases is still a highly debated topic, with results supporting
both, the oligomers [30, 31, 20] and the fibrils [32, 33] as the main toxic species. A study of
the conformers present during the aggregation process of α-synuclein has allowed the isol-
ation and characterisation of two types of oligomers, denominated “Type A” and “Type
B” [30]. “Type A” oligomers appear earlier in the aggregation process, present a primar-
ily disordered structure, are sensitive to proteinase K degradation, and are essentially
benign when exposed to primary neuronal cells. In contrast, type B oligomers posses
a β-sheet folding core, are resistant to proteinase K degradation and highly neurotoxic.
Given the importance of the two oligomeric species types, our group developed a method
to produce enriched samples of kinetically trapped oligomers that display similar struc-
tural and toxic features to the “Type B” on pathway oligomers previously identified [34].
Kinetically trapped oligomer similar to "Type A" can be generated by the incubation of
α-synuclein with (-)-epigallocatechin-3-gallate (EGCG) [35, 36] (Figure 1.6). Kinetically
trapped "Type B" oligomers share the same FRET pattern that on-pathway "Type B"
oligomers and their biophysical characterisation showed that they posses an hydrophobic
antiparallel β-sheet core with and intermediate β-sheet content (35 ± 5 %) between a
fibril (65 ± 10 %) and a monomer [34]. These results were further confirmed by ss-
NRM, that in addition was able to identified an unfolded free 26 residues region a the
N-terminal and a 40 residues region at the C-terminal [36]. Two different populations can
be identified within these stabilised oligomers, one of 10S composed by 11-25 α-synuclein
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monomers, and another one of 15S composed by 19-39 α-synuclein monomers. Using
cryoEM it was possible to determinate that both population are composed by cylindrical
oligomers with a low electron density region running through the cylinder. EGCG sta-
bilised "Type A" oligomers also shared the same FRET pattern than their on-pathway
counterparts, however both FT-IR and ssNMR revealed that they posses an unstructured
core with an exposed 43 residues region in the C-terminal. Analytical ultracentrifuga-
tion revealed that they are composed by a single population of approximately 13S [36].
Further studies revealed that both, the presence of an unstructured N-terminal and an
hydrophobic core determines oligomeric toxicity; the N-terminal region is able to form an
α-helical structure binding to the extracellular membrane and anchoring the hydrophobic
core, that in turn gets inserted into the lipid bilayer disrupting its integrity (Figure 1.6 f
and g). In fact, the blocking of the N-terminal interaction with the membrane is enough
to prevent toxicity associated the kinetically trapped "Type B" oligomer [36, 37]. The
permeabilisation of the membrane then provokes an influx of calcium inside the cell that
with time, triggers the activation of caspase 3 and cellular death [34, 38, 36]. Moreover
stabilised "Type B" oligomers but not "Type A" ones are able to induce the production
of intracellular reactive oxygen species (ROS), leading to cellular stress and eventually to
cellular death [34, 39, 36] (Figure 1.6 b and e).
Other species of α-synuclein extensively studied in the context of disease are fibrils.
Even though the atomic structure of α-synuclein fibrils still has to be unambiguously
determined, largely due to the large number of polymorphs existent, most of the exper-
imental data support a model in which the core of the monomeric α-synuclein adopt an
antiparallel in register β-sandwich fold, with both the N-terminal and the C-terminal
remaining unfolded, and these monomeric units stacked in parallel to form the protofila-
ments, which will associate between them to form mature fibrils [40, 41]. Although in a
lower degree than oligomers, fibrils have been reported to being able to disturb the plas-
matic membrane and enhance the intracellular ROS production [30, 34, 39, 42]. Moreover,
upon binding with the membrane α-synuclein fibrils have been shown to interact with
different receptors such us heparan sulphates [43, 44], the sodium potassium ATPasa
(NKA) [45] or lymphocyte-activation gene (Lag) 3 [46], that are proposed to mediate
their internalisation via endocytosis. Once internalised, fibrils are able to disrupt the
endocytotic vesicles [47] and release into the cytoplasm were they seed the aggregation
of endogenous α-synuclein [48, 49, 50]. Furthermore, α-synuclein fibrils have been shown
to have prion-like properties, being able to propagate cell to cell and thus, expanding the
disease to unaffected brain areas [50, 51, 52, 53]. Another common feature with prion
disease is the existence of different fibrillar polymorphs, or strains. In vitro, differences
in the shacking conditions, pH or ion strength can lead to the formation of different
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Figure 1.6: Biophysical analysis of kinetically trapped oligomers. (a) FRET profile from
on-pathway "Type A" and "Type B" oligomers. (b) ROS production on the presence of on-
pathway oligomers. (c) The kinetically trapped "Type A" and "Type B" oligomers share
similar FRET profiles with their on-pathway counterparts of the "Type B" oligomers,
indicating that they share a similar structure. (d) Secondary structure kinetically trapped
"Type A" and "Type B" oligomers as determined by FT-IR. (e) Stabilised "Type A"
and "Type B" oligomers induce similar ROS production levels than their on-pathway
counterparts. Schematic representation of kinetically trapped "Type A" (f) and "Type B"
(g) oligomers to membranes. (a and b) have been reproduce from [30], (c, d, e, f, g) have
been taken from [36].
α-synuclein fibrillar polymorphs [54]. Moreover, the aggregation of different pathogenic
variants of α-synuclein under the same aggregation conditions have been shown to pro-
duce different strains of fibrils [55]. This structural differences arise from differences in
the packing of the protofilamets that come together to for an amyloid fibril [54]. Although
these could be considered small structural changes, different α-synuclein fibrillar poly-
morphs have been associated with different synucleinopathies in in vivo models [52, 56].
Potentially, differences in cellular environments like pH, port-translational modifications
or relative concentration of α-synuclein could also lead to the formation of different fib-
rillar strains. Indeed, the fibrillar polymorphs have been identified in patients with MSA,
dementia with Lewy bodies or PD [57, 58, 59]. Moreover the injection of α-synuclein
patient-derived fibrils into the brain of mice induced the development of α-synuclein ag-
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gregates and neuronal degeneration [60]. Importantly, the structural analysis of these
patient-derived fibrils are different to those currently generated in vitro [59, 61]. Since
fibril polymorphism seem to be related with the development of different synucleinopath-
ies, this highlights the importance of exploring different conditions for the aggregation of
α-synuclein in vitro.
1.4 Modelling Parkinson’s Disease
Since its aetiology has not been yet fully elucidated it is specially important to develop
models of PD (from cellular to more complex in vivo models) that allow us to study the
different characteristics of the disease (form both, the sporadic and the hereditary form
of the disease) and explore different therapeutic pathways.
1.4.1 In vitro models of PD
Although they are not able to reproduce the disease in all its complexity, simple in vitro
cell models allow us to study the altered cellular processes behind the development of the
disease in a more simple, control environment.
Immortalised cellular lines
The use of immortalised cells lines allows for easy genetic manipulation at the same
time that guarantees an homogenous population of cells. Moreover they provide a good,
fast and cheap system to test new hypothesis and different conditions before taking the
most promising ones to more advance models like primary neurons or human induce
pluripotent stem cells (iPSC). As in PD the first cells to start degenerating and dying
are dopaminergic neurons, cell lines with the potential to be differentiated into a more
dopaminergic neuronal-like phenotype are usually used to study this disease. However,
even though once differentiated these cells present neurites and express markers like TH,
their synaptic activity is limited which impedes its use to study phenomena like syn-
aptic plasticity. Examples of cell lines used in the study of PD include Lund human
mesencephalic (LUHMES), rat pheochromocytoma PC12 and the extensively used hu-
man neuroblastoma SH-SY5Y [62, 63]. Although SH-SY5Y do not express endogenous
α-synuclein they have been widely employed to explore the toxicity of extracellular ag-
gregates like oligomers and fibrils through membrane disruption [64, 36]. Genetically
modified SH-SY5Y to express an α-synuclein variant, like WT or A53T, fused to a re-
porter like green fluorescent protein (GFP) or yellow fluorescent protein (YFP) have also
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been used to study aggregation in the presence of factors related to PD, like mitochondrial
stressors [65] or proteasome inhibitors [66].
Primary neurons
Mice and rat primary neuronal cultures have been extensively used to study PD as
they allow a more physiological approach. When grown in the absence of serum, they are
mainly composed by neurons, with glia cells present to support the neuronal network.
One of the main advantages of using this type of cultures is the possibility of detecting and
study changes in synaptic activity at a single cell level. However, genetical alteration of
these cultures is significantly more complicated than in immortalised cell lines. Although
genetic alteration via conventional transfection methods like the use of lipofectamine or
electroporation has limited results, gene modification it is still possible via viral vector
like lentiviruses [63]. However, since the establishment of a cell line it is not possible this
type of cultures present a higher variability than immortalised cell lines. It is important
to highlight that primary dopaminergic cultures, obtained from the midbrain of E13
embryos, only contain between a 5 and a 10 % of TH positive neurons, which can lead to
erroneous conclusions since specific changes occurring in the dopaminergic neurons may be
masked by those happening in the non-dopaminergic ones [63]. Due to this, many groups
have adopted the use of primary cortical and hippocampal neuronal cultures, better
characterised in the literature, in order to study different aspects of PD. In particular, this
method has been broadly used to explore the variety of effects that the addition of external
α-synuclein aggregates induces in the neurons, such as impaired axonal transport [67],
altered dendritic spine morphology and function [48, 68] or mitochondria fragmentation
and depolarisation [69].
Human induced pluripotent stem cells derived dopaminergic neurons
The discovery in 2006 by S. Yamanaka that by delivering four genes encoding pluripo-
tency factors (OCT4, SOX2, c-MYC and KLF-4) [70] it was possible to reprogram adult
mouse cells into embryonic like pluripotent stem cells, opened the door to the use of
patient-derived cells as a model for neurodegenerative diseases. Nowadays, it is possible
to differentiate human induced pluripotent stem cells (iPSC) into dopaminergic neurons
through a 35 days protocol that yields cultures that are both tyrosine hydroxylase (TH)
and G protein-activated inward rectifier potassium channel 2 positive and show a syn-
aptic activity characteristic of mature SNpc dopaminergic neurons [71]. Through these
types of studies it has been possible to determine that iPSC-derived dopaminergic neur-
ons carrying a triplication of α-synuclein or the A53T mutation present an increment
in intracellular α-synuclein accumulation, perturbed mitochondrial function, increased
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endoplasmic reticulum stress and impaired lipid homeostasis. Moreover, in iPSC-derived
dopaminergic neurons carrying a triplication of α-synuclein it was possible to detect an
increment in oligomeric species and α-synuclein secretion to the extracellular space [72].
This model has also been used to prove the prion-like propagation and amplification of
α-synuclein fibrils in human iPSC-derived cortical neurons [52].
1.4.2 In vivo models of PD
Although in vitro models of PD allow us to study the biochemistry aspects of the dis-
ease in detail, they lack the complexity necessary to fully understand how PD affects
the interaction between different types of cells, like neurons and glia, and how it spreads
through the brain. It is also not possible to asses if addressing any of the particular
problems that arise in the cells like elevated ROS, α-synuclein aggregation or mitochon-
drial dysfunction, will result in a change in phenotype. In order to solve these issues it
is necessary to develop in vivo models of PD that give a phenotypical readout directly
related to PD pathology. In the case of PD an ideal model would reproduce both, the
behavioural and pathological characteristics of the disease, and it would be predictive for
drug testing. Although multiple models exist, none of them has been entirely successful
in the generation of this “ideal” model [73, 74].
Caenorhabditis elegans
This nematode, of just 1-2 mm length, is a extensively characterised organism. Its
genome was sequenced 1998 [75], and the position and synaptic connections of each its
302 neurons have been precisely mapped [76]. Moreover, this organism is fully transparent
making the direct visualisation of fluorescent reporter proteins in vivo easily achievable
[77]. The expression of WT and A53T α-synuclein variants under a dopaminergic neurons
specific promoter leads to motor deficits and loss of dopaminergic neurons and dendrites
[78]. Furthermore, the expression of WT α-synuclein fused to YFP in the muscle cells of
C. elegans also leads to α-synuclein aggregation and motor deficiencies [79]. Moreover the
α-synuclein aggregation and the associated motor phenotype in this model are sensitive
to drugs, like trodusquemine, which is able to affect the α-synuclein aggregation kinetics
in vitro and hence, can be use in the screening of drugs anti-PD [80].
Drosophila melanogaster
As a model, Drosophila melanogaster present several advantages: it requires little space
and equipment, its genome is easy to edit and has been fully sequenced and possess a rel-
ative complex nervous system with dopaminergic clusters involved in the control of motor
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behaviours, such as walking, climbing or flying [77]. The expression of WT α-synuclein
or the A53T and A30P mutant recapitulates the adult-onset loss of dopaminergic neur-
ons, the formation of filamentous electron-dense intraneuronal α-synuclein inclusions re-
sembling Lewy bodies and neurites and locomotor dysfunction [81, 82]. Moreover, the
administration of dopamine agonists rescued this phenotype, proving that this model can
be used as a first step in the testing of anti-PD drugs [82, 83].
Mus musculus
Over the years, multiple mouse models of PD have been developed with varying degrees
of success.
One of the oldest methods to generate mice models of PD relies on the use of neurotox-
ins, like 6-hydroxydopamine or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),
that are able to specifically damage the mitochondria of the dopaminergic neurons of the
SNpc and induce the death of these neurons. Although these models are able to repro-
duce the loss of motor functions associated with PD through the induction of the death
of the dopaminergic neurons, they do not induce the aggregation of α-synuclein or the
formation of Lewy bodies and neurites. Moreover, due to the fact that the neuronal dam-
age does not extend to other areas of the brain, these models are not able to reproduce
other hallmarks of PD like olfactory loss, sleep and affective disorders, and autonomic
and digestive dysfunction [74, 73]. Further more, many compounds that showed neuro-
protection in these models failed later on in clinical trials [77].
Another popular model is the use of transgenic mice carrying mutations in some
of the genes associated with the genetic forms of the disease. For example, models that
overexpress the G2019S variation of LRRK2 or the G309D one of PINK1 have been found
to induce the aggregation of α-synuclein [77]. Knock-out models simulating the loss of
function of Parkin or PINK1, involved in mitophagy and associated with genetic forms of
PD, do not show any sign of Lewy bodies related pathology, while the knock-out of DJ-1
induces motor defects without the degradation of dopaminergic neurons [84]. However all
these models failed to recapitulated all the main hallmarks of PD. Even more important
is the fact that, as they are based in low prevalent hereditary forms of PD they may not
be suitable to test drugs aimed to stop the progression of the sporadic form of PD.
The facts that 1) both mutations in the α-synuclein gene and protein overexpression
can trigger the development of PD and 2) that the Lewy bodies and neurites are clear
hallmarks of sporadic and hereditary forms of the disease, provide a link between this
two forms of the disease and make α-synuclein an excellent focus for developing a mouse
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model of PD. Over a number of years, several mouse models for PD based on this idea
have been developed and include, the transgenic model, the recombinant adeno-associated
virus (rAAv) α-synuclein model, and the pre-formed fibrils (PFF) model [85, 73].
Several transgenic models of PD expressing human wild type (WT) α-synuclein, A53T
α-synuclein and A30P α-synuclein under the control of different promoters have been
developed. Between these promoters the most used ones are: the tyrosine hydrolase
promoter, the prion protein promoter, and the Thy promoter. Under the control of
the tyrosine hydrolase promoter α-synuclein is only expressed in the catecholaminergic
neurons and although the accumulation of α-synuclein within the dopaminergic neurons
of the SNpc is a common finding, these mice only present some pathogenic phenotypes
when they express α-synuclein carrying both, the A30P and the A53T mutations or
C-terminal truncated forms of the protein [85]. The expression of α-synuclein under
the prion protein promoter causes its aggregation in the spinal cord, the brainstem and
parts of the midbrain but not in the SNpc, and upon age, these mice display a motor
impairment [82, 85]. The use Thy1 promoter allows the expression of α-synuclein mainly
in the neurons of the central nervous system which causes the apparition of granular
and insoluble somatodendritic accumulations of α-synuclein across several regions of the
brain, but again, not in the SNpc; the phenotypes in the mice are really variable, from
a fast death due to the degeneration of neuromuscular junctions to an age-related loco-
motor pathology [82, 85]. Behind the lack of success of these models in reproducing the
characteristic of PD lies two factors: first, due to the expression of α-synuclein from an
exogenous promoter, all of them fail to reproduce the spatiotemporal expression patterns
which are clinically observed; and second, the unpredictability of the transgene insert
site, which directly influences the strength of the phenotype [86, 74, 87, 85]. In order to
address this issues transgenic mice using bacterial artificial chromosomes (BAC) carrying
the entire human α-synuclein gene and its gene expression regulatory regions have been
generated. The introduction of WT α-synuclein in this manner does not lead to the form-
ation of α-synuclein inclusions or cellular death, although these mice manifest a decrease
in anxiety-like behaviours, which could correspond with non-motor symptoms typical of
early PD [88]. This approach has also been used to express the E46K α-synuclein mutant,
these mice present a degeneration of the dorsal striatum, innervated by the SNpc, but
not of the dopaminergic neurons of the SNpc themselves. Transcriptomic analysis of
the striatum revealed alterations in synaptic plasticity, neurotransmission, mitochondrial
function and lipid metabolisms consistent markers of cellular dysfunction prevalent in
PD [89].
Another strategy that has been widely used in model development is based on the
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rAAv model in which the α-synuclein is delivered specifically into the SNpc using a viral
vector inducing its constitutive expression. This model successfully reproduces the loss
of dopaminergic neurons and this translates to motor defects when the neuronal loss
becomes greater than 40 %. Neuroinflammation, another disease hallmark of PD, is also
caused by an early activation of the microglia in this model. However, the observed
α-synuclein aggregates do not entirely recapitulate the morphological features of Lewy
bodies and Lewy neurites and due to its overexpression, α-synuclein is localised within
the entire cytosol instead of just in the pre-synaptic terminals. In addition, the viral titer
and serotype, the promoter, and the site(s) of integration influence the expression levels
of α-synuclein and contribute to the high variability that can be observed in this model
[73].
The third most common model system is the PFF model, in which fibrillar α-synuclein
species (obtained by sonication of mature fibrils) are injected into the striatum of WT
mice and act as seeds to recruit endogenous α-synuclein. This model recapitulates the
loss of dopaminergic neurons and displays α-synuclein inclusions that strongly resemble
the Lewy bodies and neurites: they have a fibrillar morphology observed by microscopy,
are phosphorylated at serine 129, ubiquitinated and are detergent-insoluble (Figure 1.7).
Furthermore, this model is able to faithfully reproduce the spreading of α-synuclein inclu-
sion through the brain allowing the study of this process and assessment of PD therapies
aimed to contain the spreading of the disease through the brain instead of its onset [73].
However, this model generally fails to show a strong motor disruption [73] and its res-
ults are not always reproducible. This may be related to several factors like the use of
human instead of mouse α-synuclein seeds, the presence of lipopolysaccharide (LPS) in
α-synuclein preparations that have been recombinationally expressed [90], the prepar-
ation method of the seeds or the nature of the species injected. Even though, mouse
α-synuclein only differs by 7 aa compared to the human isoform (Figure 1.5), it has been
shown to have faster aggregation kinetics and a shorter lag time [91]. Moreover, it has
been reported that the elongation of the PFF is more efficient when both, the seeds and
the monomer belong to the same species and that this has a direct influence on the num-
ber of inclusions detected in the neurons, with the amount of aggregates detected in mice
injected with mouse PFF being statistically higher than the number detected in mice
injected with human PFF [92, 49]. Another factor to take into account is the presence
of the LPS, a component of the Gram-negative bacteria able to trigger an inflammatory
cascade through the activation of some of the components of the immune system, like
monocytes, macrophages and microglia [93]. Furthermore, it is known that the injec-
tion of small amounts of LPS into the SNpc or via intraperitoneal in the α-synuclein
transgenic mice is able to trigger the aggregation of α-synuclein and the degeneration
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of dopaminergic neurons in response to microglia activation [94, 95]. In addition, the
injection of short fragments of α-synuclein fibrils have been proven to be more effective
than the injection of longer ones inducing a PD-related phenotype [67, 51].
Figure 1.7: Lewy bodies and neurites in the PFF model. Example of the pS129 positives
Lewy neurites-like and Lewy bodies-like in a mouse sacrifice 4 months after PFF injection.
The scale bar in a is set at 30 µm. The image has been taken from [73].
1.5 Aims and objectives of this thesis
It is the aim of this thesis to investigate the possible relationship between the structural
and biophysical properties of different α-synuclein species (monomer, oligomers and dif-
ferent strains of fibrils) and its ability to induce toxicity at a cellular and organism level.
In order to evaluate this in a systematic and thorough manner several approaches were
explored.
First, in collaboration with Dr. Laura Volpicelli-Daley we explored how the prepar-
ation and storage of different α-synuclein conformers (monomer, oligomers, short fibrils,
medium fibrils and long fibrils) can influence the induction of a PD phenotype after its
injection into the brains of mice. This study allowed us to concluded that not only the
length of the fibrils could influence the phenotypical response, with the short fibrils the
more successful α-synuclein species at inducing behavioural changes, but that the storage
of this fibrils could influence its final length and hence the final output of the experiment.
Next, the ability of kinetically trapped oligomers derived from different α-synuclein
variants to induce cellular toxicity was assessed. From these experiments it was possible
to conclude that oligomers generated from WT and G51D α-synuclein variants are able
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to induce a stronger cellular toxicity than oligomers generated from other α-synuclein
mutational variants. Furthermore, G51D oligomers seem to have both a highly conform-
ational variability with different degrees of α-helix present in their structure and highly
variable toxic effects. Through the assessment of the toxicity of G51D oligomeric prepar-
ations with different degrees of α-helix it was possible to establish a correlation between
both features, with a higher content of α-helical structure correlating with higher toxicity
levels.
The study of the toxic properties of different oligomeric species was followed by the
study of the efficiency with which different α-synuclein fibrillar species are able to recruit
endogenous α-synuclein. With this objective fibrils with different secondary structures
and dimensions were generated, and their respective seeding abilities were evaluated
in mouse primary neurons. These experiments revealed that although all the different
fibrillar species were able to be internalised by cells, they induce the recruitment of
endogenous α-synuclein at different rates.
Finally, with the aim of exploring if the different fibrillar species were also able
to induce different signatures of cellular toxicity, the viability of SH-SY5Y cells after
the exposure to α-synuclein fibrils was assessed through the widely used MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. While performing these
experiments it was observed that α-synuclein fibrils and other unrelated amyloid aggreg-
ates were able to induce the formation of formazan crystals that resulted in a false-positive
result. After thoroughly evaluating the nature of this phenomena, the time scale in which
it happens, and which species were able to induce it, it was possible to conclude that
amyloid fibrils, but not monomers or kinetically trapped oligomers, are able to induce





All chemicals and reagents were purchased from Sigma Aldrich (UK) Ltd. (Gillingham,
Dorset, UK) unless otherwise stated.
2.1 α-Synuclein variants purification
All centrifugation steps were performed in a Beckman Avanti J centrifuge (HighWycombe,
UK) unless otherwise stated. E. Coli BL 21 cells were transformed, using standard heat
shock treatment, with the pRK172 plasmid containing the gene for the mouse WT or
E110C α-synuclein variants or the human WT, A30P, G51D, A53T, E46K, H50Q or
N122C α-synuclein variants. A single colony containing each of the plasmids was selected
according to its resistance from LB-Agar plates with 100 µg/ml ampicillin. The selected
E. Coli cells were grown overnight as starter cultures (10 ml of LB medium, 100 µg/ml
ampicillin, 37 °C, 180 rpm) and the next day 1 L 2xYT media with 100 µg/ml ampicillin
was inoculated with this culture (1:1000 dilution). The larger cultures were grown in an
orbital incubator to an OD600nm of 0.6-0.8 (37 °C, 180 rpm). Once the desired OD was
reached, expression of the protein was induced with the addition of IPTG (isopropyl-
β-D-1- thiogalactopyranoside) (1 mM) and the cells were left to incubate (overnight,
28 °C). The cells were then harvested by centrifugation in a Beckman Coulter JLA-
8.1000 rotor (5,000 rpm, 20 min, 4 °C). The bacterial pellet from 1 L cell culture was
resuspended in 20 ml of 10 mM Tris-HCl, pH 7.7, 1 mM EDTA and 1 mM proteinase
inhibitor (cOmplete(TM), EDTA-free Protease Inhibitor) and then lysed by sonication
(40 % amplitude, 5 min, 15 sec on pulse, 45 sec off pulse) on a sonicator ultrasonic
processor xl model XL2020 sonicator (Misonix Fisher Scientific). The cell lysate was
centrifuged in a Beckman Coulter JA-25.5 rotor (15,000 rpm, 30 min, 4 °C) and the
supernatant was collected. The supernatant was boiled (20 min) and further centrifuged
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(15,000 rpm, 30 min, 4 °C) to remove the precipitated, heat-sensitive proteins, leaving
α-synuclein in the supernatant. Streptomycin sulphate was added to the supernatant to
a final concentration of 10 mg/ml for DNA precipitation and incubated with stirring (15
min, 4 °C) followed by centrifugation (15,000 rpm, 30 min, 4 °C). Finally, α-synuclein
was precipitated by the addition of ammonium sulphate to a final concentration of 361
mg/ml. The solution was stirred (30 min, 4 °C) and centrifuged (15,000 rpm, 30 min, 4
°C).
The protein pellet was resuspended in 25 mM Tris-HCl, pH 7.7 (40 ml for each 1
L cell culture) and dialysed overnight in natural cellulose membrane (cut-off 3500 Da)
against the same buffer to remove the excess of salts. After dialysis, the sample was
purified on an anion exchange column (Hi Load 26/10 Q sepharose High Performance, GE
Healthcare Lifescience, Little Chalfort UK) equilibrated with using 25 mM Tris-HCl, pH
7.7 on an AktaPrime chromatography workstation (GE Healthcare Ltd.). The protein was
eluted using a NaCl gradient (0-1.5M) and the fractions containing protein (determined
spectroscopically and by SDS-PAGE analysis [Figure 2.1]) pooled and further purified by
size exclusion chromatography (SEC) on a HiLoad 26/60 Superdex 75 pg column (GE
Healthcare Ltd) previously equilibrated with phosphate buffered saline (PBS; pH 7.4).
The fractions containing only the monomeric protein (as identified by SDS-PAGE, purity
above 90 % [Figure 2.1]) were collected and aliquoted, then flash frozen in liquid N2
and stored at -80 °C. The protein concentration was determined from the absorbance at
275 nm, using a molar extinction coefficient ε = 5600 M−1 cm−1 in case of the human
α-synuclein variants and using a molar extinction coefficient ε = 7000 M−1 cm−1 in the
case of the mouse ones. For the E110C mouse and N122C human α-synuclein, all buffers
used during lysis and purification contained 3 mM DTT to prevent the formation of
intermolecular disulphide bonds.
2.2 Aβ40 purification
All centrifugation steps were performed in a Beckman Avanti J centrifuge (HighWycombe,
UK) unless otherwise stated. BL21 (DE23) PlysS containing the Aβ40 plasmid were grown
in a starter culture of 50 mL LB broth (10 g/l Bacto-tryptone, 5 g/l yeast extract, 10 g/l
NaCl) containing 100 µg/ml ampicillin at 37 °C overnight, under shaking. In order the
amplify the starter culture, 1 mL of the starter culture was added to 1 l of auto-induction
TB medium (60 g/l) containing 10 mL/l glycerol and 100 µg/ml ampicillin and left to
grow overnight, under shaking, at 37 °C. The cells were then harvested by centrifugation
at 5000 rpm, at 4 °C, for 35 min (Beckman Coulter, JLA 8.1000).
The harvested cells were resuspended in 250 mL of working buffer (10 mM Tris, pH
40
Figure 2.1: Purification of the different α-synuclein variants. SDS-PAGE analysis after
the ion exchange (IEX) and size exclusion (SEC) steps of the different α-synuclein variants
used in this thesis. After SEC, only pure fraction were collected.
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8, 1 mM EDTA, sonicated for 3 minutes (amplitude 52, pulse on/off 1 minute) and then
centrifuged (Beckman Coulter, JA-25.5, 18000 rpm, 10 min, 4 °C). This procedure was
repeated for a total of three times. After the third round, the pellets were resuspended
in 40 ml of 8 M urea and incubated at room temperature for 45 minutes. The solution
was then sonicated again, and incubated with the DEAE Sepharose Fast flow resin (GE
Healthcare) previously washed (500 mL ultrapure H2O and three funnel volumes of work-
ing buffer) under shaking for 30 minutes at 4 °C. After the incubation time, the solution
was placed into a Buchner funnel equipped with filter paper in order to remove the beads
of the resin and collect the flow through. Next, one funnel volume of working buffer was
run through, followed by 100 ml of 25 mM NaCl and 100 ml 125 mM NaCl. The latter
two solutions were collected into pierced falcon tubes, flashed frozen in liquid nitrogen
and lyophilised.
After lyophilisation Aβ40 was resuspended in 6 M guanidinium hydrochloride and
injected in an AKTA system (GE Healthcare, Chicago, IL) connected to a Superdex
26/600 column (GE Healthcare, Buckinghamshire, U.K), previously equilibrated in 20
mM sodium phosphate buffer, pH 8. The protein containing fractions (at elution volume
180-190 ml) were then flashed frozen in liquid nitrogen and lyophilised. Finally, the
lyophilized protein was resuspended again in 6 M guanidium hydrochloride and subjected
to a further process of SEC using a Superdex 75 HR 26/60 column (GE Healthcare,
Buckinghamshire, U.K) equilibrated in ammonium acetate buffer, 50 mM, pH 8.5. The
desired protein fraction eluted at approximately 12 mL was (SDS-PAGE is performed to
confirm, purity above 90 % [Figure 2.2]) flash frozen stored at -80 °C.
Figure 2.2: SDS-PAGE analysis of the purity of Aβ40 after purification. SDS-PAGE
analysis of the purity of Aβ40 after purification. This figure was prepared by Katarina
Pisani, who purified the SDS-PAGE analysis Aβ40 used in this study.
2.3 Removal and quantification of lipopolysaccharide levels
The protein samples (mouse WT α-synuclein and mouse E100C α-synuclein) were di-
luted to around 130 µM and any remaining lipopolysaccharide (LPS) was removed using
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the Pierce High-Capacity Endotoxin Removal Resin (Thermo Scientific, Waltham, MA,
USA) following the protocol for batch purification with spin columns (as provided by
the manufacturer). The amount of LPS present in the subsequent samples was meas-
ured using the Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Scientific,
Waltham, MA, USA), following manufacturer’s instructions. After this point all the buf-
fers were prepared with water containing less than 1 EU LPS (Water (double-processed
cell culture), Sigma).
2.4 Preparation of Alexa-488 labelled α-synuclein
In order to remove the DTT, mouse E110C or human N122C α-synuclein in PBS contain-
ing 3mM DTT (1 ml) was added to a P10 desalting column (GE Healthcare Lifescience)
pre-filled with Sephadex G25 resin (sigma) and equilibrated in PBS. The sample was
collected in 12 aliquots (0.5 mL) and the protein concentration was determined on a
nandrop UV spectrometer (Labtech International Ltd, Heathfield, East Sussex, UK). To
this protein solution, Alexa Fluor 488 C5 Malemide (Life technologies, Waltham, MA,
USA) was added (1.5:1 molar ratio of dye-to-protein) and the reaction was left on a rolling
incubator (overnight, 4 °C) protected from light. The labelled protein was separated from
the excess unreacted dye using a P10 desalting column filled with Sephadex G25 equi-
librated in PBS pH 7.4. The protein was aliquoted, flash frozen in liquid nitrogen and
stored at -20 °C. The labelling efficiency (> 95 %) was confirmed by mass spectrometry,
and the presence of dimeric protein was ruled out by SDS PAGE analysis (first batch
98 % monomer, second batch 97 %). The protein concentration was estimated from the
absorbance of the Alexa flour 488 dye (ε495 = 72,000 M−1cm−1).
2.5 Preparation of purified α-synuclein oligomeric samples
The mouse and human α-synuclein oligomeric species were prepared as described previ-
ously [34]. Briefly, monomeric α-synuclein (6 mg) was dialysed against water overnight
and placed in a 15 ml falcon tube (the volume must not exceed 4 ml). The sample was
flash frozen in liquid nitrogen and lyophilised for at least 48 h (RT). The lyophilised pro-
tein was resuspended in PBS (pH 7.4, 0.5 mL), filtered through a 0.22 µm filter (Millipore
[Watford, Hertfordshire, U.K.]) and incubated (24 h, 37 °C). In order to remove potential
fibrillar species that can appear during the incubation time, the sample was placed in a
1 ml polycarbonate centrifuge tube (11 x 34 mm ) and ultracentrifugated (90,000 rpm, 1
hr) in an Optima TLC Ultracentrifuge using a TLA-120.2 rotor 288,000 x g) (Beckman).
After ultracentrifugation, the supernatant was recovered and passed through a 100 KDa
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cut-off centrifuge filter ((Millipore (Watford, Hertfordshire, U.K.)) (4 times) to remove
excess monomer. The oligomeric concentration was determined from the absorbance at
275 nm (ε = 7000 M−1cm−1 for human WT, A53T, H50Q, E46K; ε = 12444 M−1cm−1
for human G51D and A30P; and ε = 8750 M−1cm−1 for mouse species). The oligomeric
concentration of the Alexa-488 labelled species was determined from the absorbance at
495 nm (ε = 72,000 M−1cm−1).
2.6 Preparation of α-synuclein fibrils
F0 anf F1 generation fibrils: 70 µM of α-synuclein (PBS pH 7.4 or 50 mM Tris-HCl
pH 7.5 with 150 mM KCl) and containing 0.02 % (w/v) of sodium azide (NaN3) in a
final volume of 300 µL was incubated in an orbital incubator (37°C, 180 rpm, 5 days).
Subsequently, the sample was centrifuged (10 min, 13,200 rpm, RT), and the supernatant
was discarded. The pellet was washed twice with PBS and after the last centrifugation
cycle, was resuspended in PBS to the final required volume. To determine the concentra-
tion, an aliquot of fibrils (40 µL) was mixed with 40 µL of 8M guanidinium chloride (in
order to provoke the disaggregation of the fibrils) and the monomer concentration was
determined using the absorbance at 275 nm (ε = 5,600 M−1cm−1). These fibrils were
denoted as F(0). To generate F(1) fibrils, an aliquot of F(0) fibrils (100 µM, 300 µL)
was sonicated with a Bandelin, Sonopuls HD 2070 (1 min, 3 0% cycles, 20 % maximum
power) to obtain seed fibrils. These seeds (10 µM) were added to α-synuclein monomer
(100 µM) in PBS, pH 7.4 to a final volume of 150 µL and this was incubated in a standard
laboratory incubator (37 °C , 24 hr). After this the same procedures used for the F(0)
were followed. Fibrils injected into the mice: The fibrils used for the mouse model
project and the first stability studies were prepared as previously describe [67]. Briefly,
mouse α-synuclein (5 mg/ml, final volume of 500 µL) was incubated in a Thermomixer
set inside a standard laboratory incubator (37 °C, 700 rpm, 7 days). Fibrils prepared
in the presence of PEG, Dextran or 10 % methanol: 100 µM of human monomeric
α-synuclein in PBS was incubated in the presence of 300 mg/ml dextran (MW 70000),
300 mg/ml polyethylene glycol (PEG) (MW 8000) or 10 % methanol at 37 °C in a 96
well plate for seven days inside a BMG Clariostar (BMG LABTECH, Aylesbury, Bucks,
UK) reading every 10 minutes. After this, the sample was ultracentrifugated at 20 °C,
120000 rpm for 1.5 h before resuspending it in PBS. In order to assure the complete
removal of the crowding agent or the methanol this process was repeated three times. Fi-
nal fibrillar concentration was measured as described for the F0 and f1 generation fibrils.
Fibrils prepare in the presence of 35 % methanol: 100 µM of human monomeric
α-synuclein in PBS was incubated in the presence 35 % methanol at 37 °C in an static
44
incubator for 24h. Protofibrils:Protofibrils were produced as described in [27]. Briefly,
dimyristoyl phosphatidylserine (DMPS) vesicles were prepared by subjecting a dilution
of 2mM DMPS in 20 mM sodium phosphate buffer, pH 6.5 to 5 freeze-thawing cycles
and 2 sonication cycles of 5 min 10 % power, 50 % cycles ( 0.5 sec on 0.5 sec off) in a
Bandelin, Sonopuls HD 2070. After centrifugation the resulting vesicles for 30 min at
15000 rpm at room temperature, 100 µM of this vesicles were incubated with 100 µM
monomeric human α-synuclein in 20 mM sodium phosphate buffer, pH 6.5 at 30 °C in 96
well plate for 5 days. After collecting the samples in an eppendorf tube, this mixture was
incubated for 1.5 h at 37 °C with 1 % sarkosyl in 20 mM sodium phosphate buffer, pH
6.5. Afterwards, the sample was ultracentrifugated at 20 °C, 120000 rpm for 1.5 h before
resuspending it in PBS. In order to remove the lipids and detergent mixture completely
this process was repeated three times. Final protofibrillar concentration was measure as
described for the F0 and f1 generation fibrils.
2.7 Cross-linking of antiparallel α-synuclein fibrils
100 µl at 100 µM of 35 % methanol fibrils (antiparallel fibrils) or F1 fibrils were incubated
with 0.25 % glutaraldehyde for 2 minutes at 37 °C. After this, the reaction was stopped
by the addition of 10 µl of 1 M Tris-HCl, pH 8.0 The excess of glutaraldehyde was washed
away by centrifugation the samples at maximum speed for 10 minutes at room temper-
ature, discarding the supernatant and resuspending the sample in PBS. This process was
repeated 3 times.
2.8 Preparation of Aβ40 oligomeric samples
The Aβ40 stabilised oligomers were prepared according to the protocol described in [96].
Briefly, the lyophilized protein was resuspended in 300 µL HFIP (Sigma, 105228), and
sonicated in ultrasonic cleaner for approximately 10 seconds and incubated overnight at
4 °C. The following day, the HFIP was dried under a gentle flow of nitrogen, and the
resulting film was resuspended in DMSO to a final concentration of 10 mg/ml. The sample
was sonicated two times for 10 minutes and centrifuged at 13000 rpm for 5 minutes. The
pellet was discarded and the supernatant was diluted in 20 mM sodium phosphate buffer,
at pH 6.9, with 200 µM ZnCl2 to a final concentration of 100 µM and then incubated at
20 °C for at 20 hours. Finally, the solution was centrifuged at 15000 g for 15 min at 20
°C and the pellet containing the oligomers was resuspended in 20 mM sodium phosphate
buffer, at pH 6.9, with 200 µM ZnCl2.
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2.9 Preparation of Aβ40 monomers and fibrils
Aβ40 monomers and fibrils were prepared as decribed in [96]. Briefly, solutions of the
monomeric peptide were prepared by dissolving the lyophilized Aβ40 peptide in 6 M
guanidinium hydrocholoride. The monomers were then further purified using a Superdex
75 10/300 GL column (GE Healthcare, Chicago, IL) attached to an AKTA system (GE
Healthcare, Chicago, IL) at a flow rate 0.5 mL/min and equilibrated in 20 mM sodium
phosphate buffer, pH 8. The monomeric peak was collected, and the peptide concentra-
tion determined from the absorbance of the integrated peak area using ε280 = 1490 M−1
cm−1. For the preparation of Aβ40 fibrils, Aβ40 was incubated for 10 h at the concen-
tration of 50 µM in 20 mM sodium phosphate buffer, pH 8, at 37 °C in a 96 well plate
(3880, Corning B.V. Life Sciences, Tewksbury MA, USA). Part of these samples was
supplemented with a solution of 20 µM ThT to monitor the aggregation of the samples
with ThT kinetic. Samples not treated with ThT were then collected from the wells into
low-binding eppendorf tubes.
2.10 Preparation of lysozyme fibrils
Lysozyme fibrils were generated as described in [97]. 6.8 µM monomer was incubated
in 0.1 M sodium citrate buffer, pH 5.0 with stirring at 60 °C in a Cary Eclipse spectro-
fluorimeter (Varian Ltd) overnight. Light scattering was monitored at 500 nm in order
to asses the aggregation precess. Thu buffer was exchanged to PBS by centrifugating the
sample (10 min, 13,200 rpm, RT), Discarding the supernatant and resuspending in the
same volume of PBS. This process was repeated twice. Finally, fibrils were sonicated (10
sec, 30 % cycles, 10 % maximum power) in a Bandelin, Sonopuls HD 2070.
2.11 Circular dichroism spectroscopy
Far-UV circular dichroism (CD) spectra (10 accumulations) of the different mouse and hu-
man α-synuclein species were acquired in PBS at 20 °C at a final protein concentration of
ca. 10 µM using a 1 mm path length quartz cuvette and a J-810 Jasco spectropolarimeter
(Tokyo, Japan), equipped with a thermostated cell holder. The Far-UV CD spectrum
of the buffer was recorded separately and subtracted manually. For the different human
α-synuclein variants 15-30 accumulations were taken using concentration ranges between
1 and 10 µM. Spectra were deconvoluted using the BestSel web server. In order to make
the CD signal intensity independent of sample concentrations before comparing them the
units of the CD spectra were converted from measured ellipticity (mdeg) to molar residue
ellipticity (deg cm2 dmol−1).
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2.12 Fourier transform infrared spectroscopy
The fourier transform infrared (FT-IR) spectra of monomeric and oligomeric mouse α-
synuclein were acquired with sample concentrations of ca. 800 µM, while the fibrillar
spectra were acquired with a sample concentration between 150 and 300 µM. All spectra
were acquire using a Bruker VERTEX 70 FT-IR spectrophotometer (Bruker, Coventry,
UK). The spectra corresponding to the characterisation of the mouse α-synuclein con-
formers experiments as well as the ones used to characterise the fibrils produce in the
presence of 35 % methanol were acquired using a Bruker BioATRCell II. However, the
spectra for the fibril fragmentation experiments and the ones pertaining the characterisa-
tion of the kinetically trapped oligomers of the different human α-synuclein variants were
measure in a PLATINUM ATR accessory. For each spectrum recorded, 256 interfero-
grams were co-added at 2 cm−1 resolution, the buffer background (for the BioATRCell)
or air background (for the PLATINUM ATR) was subtracted and the amide I region
(1720-1580 cm−1) of the spectra was selected. In both cases the data were corrected by
atmospheric compensation and the baseline was subtracted. All absorbance spectra were
normalized for comparison. The FT-IR spectra were deconvoluted using a 6 Gaussian
curves and the percentage of the different secondary structures were determined using
the following ranges as a guide: α-helix/random coil (1640-1660 nm), β-sheet (1610-1639
nm, 1685-1700nm) and β-turn (1661-1684 nm).
2.13 Determining protein concentration in the soluble versus
fibrillar fractions
Fibrillar samples (12 µL) were diluted in 108 µL of buffer and placed in Beckman polycar-
bonate centrifuge tubes (230 µL, 7 x 21 mm) and centrifuged in an Optima TLX Ultra-
centrifuge (90,000 rpm, 20 °C, 1 hr) using a TLA-100 Beckman rotor (436,000 x g).
Following centrifugation, the supernatant was transferred to a clean 1.5 mL eppendorf
tube and the fibril pellet was dissolved in 8M guanidinium chloride (120 µL). The protein
concentration of both the pellet and the supernatant was then determined using the Pierce
BCA Protein Assay Kit (Thermo Scientific), following the manufacturers instructions.
2.14 Transmission electron microscopy
Samples for transmission electron microscopy (TEM) analysis were diluted to a final con-
centration of 10 µM and applied (10 µL) to carbon coated copper grids (400 mesh) (EM
resolutions, Saffron Walden UK). After incubation for 1 min, the grids were washed twice
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with Milli-Q water followed by staining with a 2 % (w/v) uranyl acetate solution (10
µL). The grids were washed twice with Milli-Q water and allowed to dry for 5 min prior
to storage in a grid box. The samples were imaged on a Tecnai G2 80-200 kV transmis-
sion electron microscope (Cambridge Advanced Imaging Centre (CAIC), University of
Cambridge UK).
2.15 Atomic force microscopy
Samples for AFM analysis were diluted to a final concentration of 5 µM and deposited (10
µL) onto a layer of freshly cleaved mica and allowed to dry overnight. The next day, the
mica was washed with Milli-Q water 5 times and left to dry. The micas for the fibrils frag-
mentation experiments were imaged on a Nanowizard II atomic force microscope (JPK
instruments, Berlin, Germany) while the ones used in the biophysical characterisation of
mouse α-synuclein conformers were imaged using a multimode 8 atomic force microscope
(Bruker, Massachusetts, USA). The images were analysed with Gwyddion open source
software (http://www.gwyddion.net).
2.16 Analytical ultracentrifugation
Sedimentation velocity measurements of the oligomeric samples (40 µM, 400 µM) were
performed at 20 °C, 43,000 rpm using a Beckman-Coulter Optima XL-I analytical ul-
tracentrifuge equipped with UV-visible absorbance optics and an An50Ti rotor (De-
partment of Biochemistry, University of Cambridge, UK). The sedimentation coeffi-
cient distributions, corrected to standard conditions by using the SEDNTERP pro-
gram, were calculated via least-squares boundary modelling of sedimentation velocity
data using the c(s) and ls-g*(s) methods, as implemented in the SEDFIT program
(www.analyticalultracentrifugation.com/default.htm).
2.17 Dot blot analysis
Dot blot assays were performed by applying drops of purified monomeric, oligomeric or
fibrillar human α-synuclein (1 µg) to a 0.2 µm nitrocellulose membrane (Millipore.) The
membrane was blocked with 5% (w/v) bovin serum albumin (BSA) in PBS (1 hr, RT)
and then incubated (4°C, overnight) with primary antibodies for total α-synuclein (Anti-
α-synuclein, Transduction Laboratories, Lexington, Kentucky, USA), oligomeric species
(A11, Sigma) or fibrillar amyloids (OC, Sigma) at 1:500 v/v dilutions in PBS containing
5% (w/v) BSA. Afterwards, the membranes were washed with 0.01% (v/v) Tween-20 in
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PBS (3 times, 10 min each), and subsequently incubated with Alexa Fluor-488 goat anti-
mouse (in the case of the membrane incubated with anti-α-synuclein) or Alexa Fluor-488
goat ani-rabbit (in the case the membranes incubated with of A11 nd OC) secondary
antibody (Invitrogen) (1 hr, RT) using a 1:5000 dilution in PBS containing 5% BSA
and 0.01% Tween-20. Finally, the excess of secondary antibody was removed by washing
the membranes 0.01% Tween-20 in PBS (3 times, 10 min each). Immunofluorescence
quantification was performed on a Typhoon Trio scanner (Amersham Bioscience, place)
and the images were analysed with ImageJ.
2.18 Assessing monomer integrity after aggregation
10 µM of α-synuclein oligomers, short fibrils, medium fibrils and long fibrils were incub-
ated in 7M urea at overnight at RT and subsequently 10 µl of each species were loaded in
a track of two SDS-PAGE gels. After gel electrophoresis one of these gels was developed
with Instant Blue (Thermo Fisher Scientific, Waltham, MA, USA) while the other was
developed with a silver saining kit (Thermo Fisher Scientific, Waltham, MA, USA).
2.19 Seeding aggregation experiments
Sonicated fibrils prepared with a Bandelin, Sonopuls HD 2070 (20 sec, 30 % cycles, 10
% maximum power) (10 µM, 100 µL or 5 µM, 100 µL in the case of the cross-seeding
experiments) were added to monomeric α-synuclein (100 µM) in a solution containing
50 µM Thioflavin-T (ThT) and 0.02 % (w/v) sodium azide. The samples were placed
in a Corning assay plate 96 wells half area (3881, CORNING B.V LIFE SCIENCES,
Tewksbury MA, USA), in triplicate. The ThT fluorescence was recorded in a BMG
Fluostar Optima (BMG LABTECH, Aylesbury, Bucks, UK) using an excitation filter of
440 nm and an emission filter of 480 nm, taking readings every 10 min over the course of
10 hr at a constant temperature of 37 °C.
2.20 Cellular culture
Human SH-SY5Y neuroblastoma cells (A.T.C.C., Manassas, VA) were differentiated by
the addition of 10 µM all-trans-retinoid acid to the cellular media for 7 days. Cells were
cultured in Dulbecco’s Modified Eagles Medium (DMEM)-F12+GlutaMax supplement
(Thermo Fisher Scientific, Waltham, MA, USA) with 10 % inactivated fetal bovine serum.
The cell cultures were maintained in a 5.0 % CO2 humidified atmosphere at 37 °C and
grown until 80 % confluence in T75 flasks. Once cells reached confluence, they were split
using a 1:10 dilution.
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2.21 Primary neurons
Pregnant CD1 mice (E18) were sacrificed by cervical dislocation, after which the em-
bryos were placed on ice and beheaded. Once the two hemispheres of the brain were
extracted, the meninges were removed and the hippocampi collected in a 15 ml falcon
tube containing 10 ml of Hibernate E (Thermo Fisher Scientific, Waltham, MA, USA).
After this there were washed twice with Hank’s balanced salt solution (HBSS) (Thermo
Fisher Scientific, Waltham, MA, USA) and treated with 0.05 % trypsin (Thermo Fisher
Scientific, Waltham, MA, USA) for 20 min. This reaction was stopped by the wash-
ing of the hippocampi with 10 ml of plating media (Neurobasal media [Thermo Fisher
Scientific, Waltham, MA, USA], Glutamax 1/100 [Thermo Fisher Scientific, Waltham,
MA, USA], FBS [5 %], B27 1/50 [Thermo Fisher Scientific, Waltham, MA, USA] and
Penicillin/streptomycin 1/200 [Thermo Fisher Scientific, Waltham, MA, USA]) contain-
ing 10 U/ml of DNase, followed by other 10 ml of plating media and two washes with 10
ml of HBSS. Hippocampi were dissociated in 1 ml of HBSS using a 1000 micropipette,
resuspended in 5 ml of plating media and further dissociated into a single cell state with
the help of a cell strainer (Thermo Fisher Scientific, Waltham, MA, USA). Neurons were
counted using a haemocytometer and plated at density of 100,000 neurons per well in
a 24 well fitted with poly-d-lysine coated coverslips. After 2 h the plating media was
exchanged by maintenance one (Neurobasal media [Thermo Fisher Scientific, Waltham,
MA, USA], Glutamax 1/100 [Thermo Fisher Scientific, Waltham, MA, USA] and B27
supplement 1/50 [Thermo Fisher Scientific, Waltham, MA], USA).
2.22 Measurement of cell viability by MTT assay
SH-SY5Y cells were plated at a concentration of 10000 cells/well, in a flat bottom 96 well
plate and placed in the incubator (37 °C , 5.0 % CO2). After 24 hours of incubation,
the medium was removed and the cells were treated with different concentration of the
different samples diluted in cell culture medium. A minimum of six wells per condition
were used and the volume of sample added was kept constant through the plate to guar-
antee that possible differences are not due to differences in the volume of PBS added.
The plate was then incubated again for 24 hours or 2 hours, after which the treatment
was removed and substituted with 100 µL of a 0.5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) solution (MTT powder in RPMI for 4 hours. In
the case of the 0 hours timepoint α-synuclein fibrils were added directly to this MTT
solution. Pictures, at least 5 from three different wells, were taken using a 20x objective
in a EVOS5000 (Thermo Fisher Scientific, Waltham, MA, USA) 2 and 4 hours after the
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addition of the MTT. The percentage of cells presenting formazan crystals was quantified
using ImageJ. After 4 hours incubation, 100 µL of stop solution (20 % SDS, 50 % N,N-
dimethylformamide, pH 4.7) was added and the plate incubated for one hour at 37 °C
under shaking. Absorbance values were acquired in the range of 500 nm and 700 nm using
a plate reader (BMG Labtech, Aylesbury, UK). The difference 570-690 nm absorbance
values were used to determine the cell viability, which was expressed as the percentage
of MTT reduction in treated cells as compared to untreated cells (taken as 100 %). For
the membrane integrity experiments, after 24 h incubation in the presence of α-synuclein
fibrils, the cell media was remove and replaced by 2 µM Calcenin-AM (Thermo Fisher
Scientific, Waltham, MA) dissolved in Live Cell Imaging media (Thermo Fisher Scientific,
Waltham, MA, USA) for 30 minutes. After this the cells were washed twice with PBS
and the MTT solution was added. Plates were imaged after 30 min and 2.5 hours using
a 20x objective in a EVOS5000.
2.23 Measurement of cell viability by CellTiter-Glo assay
SH-SY5Y cells were plated at a concentration of 10000 cells/well, in a flat bottom 96
well plate and placed in the incubator (37 °C, 5.0 % CO2). After 24 hours of incubation,
the medium was removed and the cells were treated with different concentration of the
different samples diluted in cell culture medium. A minimum of six wells per condition
were used and the volume of sample added was kept constant through the plate to guar-
antee that possible differences are not due to differences in the volume of PBS added.
The plate was then incubated again for 24 hours at 37 °C and further 30 minutes at
romm temperature. After this 100 µL of CellTiter-Glo (Promega, Madison, WI) reagent
was added and after a 10 minutes incubation the ATP (adenosine triphosphate) levels
were determined by measuring the fluorescence in plate reader (BMG Labtech, Aylesbury,
UK).
2.24 Measurement of cellular cholesterol levels by Flipin III
assay
SH-SY5Y cells were plated at a concentration of 10000 cells/well, in a flat bottom 96 well
plate and placed in the incubator (37 °C, 5.0 % CO2). After 24 hours of incubation, the
medium was removed and the cells were treated with 0.3 µM of α-synuclein fibrils diluted
in cell culture medium. After this cell were treated as indicated in the Cholesterol Assay
Kit (Cell-Based) (Abcam, Cambrigde, UK) protocol. Briefly, after removal of cellular
media cells were fix with "fixative solution" for 10 min and subsequently washed 3 times
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for 5 minutes with "wash buffer". After the last wash cells were incubated with Flipin III
solution for 50 minutes, washed twice for 5 minutes and imaged using a 20x objective in
a EVOS5000.
2.25 Measurement of reactive oxygen species assay
SH-SY5Y cells were plated at a concentration of 10000 cells/well, in a flat bottom 96 well
plate and placed in the incubator (37 °C, 5.0 % CO2). After 24 hours of incubation, the
medium was removed and the cells were treated with 0.6 µM of α-synuclein oligomers
and 5 µM CellROX-Orange (Thermo Fisher Scientific, Waltham, MA, USA) diluted in
Live Cell Imaging media (Thermo Fisher Scientific, Waltham, MA, USA). After 2 h at 37
°C, images were acquire in a Cytation5 (Swindon, UK) and analysed using the Cytation5
software.
2.26 Seeding of endogenous α-synuclein
The different conformers of mouse α-synuclein (prepared as indicated in sections 2.5 and
2.6) were added at a final concentration of 70 nM to seven days old mouse hippocampal
primary neuronal cultures (produced as described in section 2.21). Neurons were fixed
7 days later and immunofluorescence detection of p-α-synuclein (Abcam, Cambrigde,
UK) and tau (Agilent Dako, Santa Clara, CA, USA) was performed as described in
the immunocytochemistry section. The different conformers of human α-synuclein fibrils
(prepared as described in section 2.6) were added to neurons at seven days in vitro at a
final concentration of 0.3 µM. Neurons were fixed 5 days later and immunofluorescence to
p-α-synuclein and neurofilament (Abcam, Cambrigde, UK) or Wheat Germ agglutinin-
594 (Thermo Fisher Scientific, Waltham, MA, USA) was performed as described in the
immunocytochemistry section.
2.27 Internalisation assay
In the case of the different mouse α-synuclein species, the internalisation assay was per-
formed as described [98] with some modifications. Primary neurons were incubated for
30 minutes in cold PBS containing α-synuclein-Alexa488 fibrils or oligomers (final con-
centration 70 nM) allowing the species to bind the plasma membrane. The neurons were
then transferred to 37 °C to allow internalisation. Extracellular α-syn-Alexa488 fibrils
were quenched with freshly made trypan blue, final concentration 1 mM in PBS. Images
were captured using a Zeiss Axio Observer Z1 with Colibri LED illumination. The ex-
citation/emission was 470/550 nm for the fibrils and 560/630 nm for trypan blue. The
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average intensity of each frame captured was quantified using Fiji and normalized to the
fluorescence signal from trypan blue bound to the neuronal membrane. In the case of
the different human α-synuclein fibrillar conformers, primary neurons were incubated for
1 h at 37 °C with media containing 0.3 µM of the different α-synuclein-Alexa488 fibrils.
Images were captured using a Leica DMI 6000B and a 63x objective.
2.28 Immunocytochemistry
Primary neurons were cultured in 35 mm glass cover slips and fixed with a 4 % solution of
paraformaldehydefor 20 min. If the cell membrane was going to be labelled, cells were in-
cubated with 0.5 µg/µl Wheat Germ agglutinin-594 (Thermo Fisher Scientific, Waltham,
MA, USA) for 10 min at this point. After this cells were permeabilised with a solution of
0.1 % Triton-X for 15 minutes. After washing 3 times with PBS, cells were blocked for 1
hour in 3 % BSA in PBS before incubation overnight in the presence of primary antibody
(p-α-synuclein [1:5000] and neurofilament [1:1000] diluted in 3 % BSA in PBS). The next
day, cell were washed 3 times with PBS before incubating for 1 hour in the presence of
secondary antibody ([(AlexaFluor-488 and AlexaFluor-647], 1:1000 in 3 % BSA in PBS).
Cell were mounted using ProLong-Glod (Thermo Fisher Scientific, Waltham, MA, USA)
and imaged using a 63x objective in a Leica DMI 6000B microscope.
SH-SY5Y cells were cultured in 35 mm glass cover slips and fixed with a 4 % solution
of paraformaldehydefor 20 min after which they were permeabilised with a solution of
0.1 % Triton-X for 15 minutes. After washing 3 times with PBS, cells were blocked for
1 hour in 3 % BSA in PBS before incubation overnight in the presence of primary anti-
body (0C [1:500] or A11 [1:500] diluted in 3 % BSA in PBS)). The next day, cells were
washed 3 times with PBS before incubating for 1 hour in the presence of secondary anti-
body ([(AlexaFluor-647], 1:1000 in 3 % BSA in PBS). Following 3 washes with PBS, cell
were incubated in the presence of 300 nM Nile red (Thermo Fisher Scientific, Waltham,
MA, USA) for 10 min followed by 5 min incubation in the presence of hoechst. Cell
were mounted using ProLong-Glod (Thermo Fisher Scientific, Waltham, MA, USA) and
imaged using a 63x objective in a Leica SP8 confocal microscope.
2.29 Animals
All animal protocols were performed at AAALAC accredited sites and approved by the
University of Alabama at Birmingham Institutional Animal Care and Use Committee.
C57BL/6 J male mice were obtained from Jackson laboratories and housed in groups
of no more than five animals per cage. Food and water were accessible 24 hours a day,
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and animals were kept on a 12 hour light/dark cycle. Experiments were conducted when
animals were two to four months old.
2.30 Surgeries
For duration of surgery, mice were deeply anesthetized with vaporized isoflurane on a gas
mask fitted to a digital stereotaxic frame. Mouse respiration was monitored throughout
the procedure. Solutions for injection were drawn to a gas-tight syringe with a 26s gauge
needle (Hamilton) and controlled by a digital pump. The injection of 2 µL and subsequent
withdrawal of needle occurred over the course of 12 min to prevent solution running back
up the needle track. Solutions were injected into the right dorsal striatum using the
following coordinates: 0.2 mm anterior and 2.0 mm lateral to the Bregma, and 2.6 mm
ventral relative to the skull. Scalp incisions were closed with EZ-Clips (FisherSci).
2.31 Immunohistochemistry of brain sections
Mice injected with various α-synuclein conformations (monomers, oligomers and fibrils
prepared as describes in sections 2.1, 2.5 and 2.6 respectively) were anaesthetised three
months post injection with isofluorane and transcardially perfused with a saline solution
(0.9 % NaCl, 0.005 % sodium nitroprusside, and 10 units/mL heparin sodium) followed
by freshly prepared 4 % PFA buffered in PBS. Brains were removed, postfixed for 24 h in
4 % PFA and PBS solution, floated into 30 % sucrose PBS solution for up to three days,
frozen in methylbutane solution (-50 °C), and stored at -80 °C. Brain tissue was sectioned
at 40 µM with a freezing microtome. All tissues were sectioned coronally. Immunohis-
tochemistry was performed using an antibody to p-α-synuclein EP1536Y (Abcam), at
1:5000 dilution. A biotinylated secondary antibody (goat anti Rabbit IgG), avidin-biotin
complex and 3,3’diaminobenzidine (DAB) were used to develop the sections. Immuno-
histochemistry for Tyrosine Hydroxylase (EMD Millipore) and dopamine transporter (a
generous gift from Dr.Allan Levey, Emory University) was also performed as indicated
above and developed using AlexaFluor-555 goat anti-chicken and AlexaFluor-488 goat
anti-rat secondary antibodies. Images were taken using a Leica TCS-SP5 Laser scanning
confocal microscope.
2.32 Behaviour assays
All behavioural tests were performed with the help of the UAB (University of Alabama
in Birmingham) Neuroscience Behavioural Core. At one and three months or at six
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months post injection, mice were subjected to a series of different behavioural tests of
gross and fine motor function. Animals were acclimated to the test environment for at
least 30 minutes prior to testing and were given at least a 1 day rest between each test.
Open Field Test: each mouse was placed at the side of a 100 × 100 × 50 cm white
Plexiglass open field. A computerized tracking system (Ethovision) recorded movement
for 5 minutes from which the following was derived: latency to first enter the centre of the
open field, the amount of time spent in the centre and periphery of the test apparatus,
velocity of movement, and the total distance travelled. Adjusting Steps Test: mice
were placed in a covered plexiglass cylinder (dimensions) with activity recorded for five
minutes by Ethovision software on a camera positioned underneath the cylinder. An
experimenter blinded to the treatment conditions scored each video, which could be
slowed and rewound as needed. The following behaviours were scored: number of rears,
front limb steps, hind limb steps, and total steps. Pole Test: mice were placed on top of
a wooden pole (diameter 1 cm; height) wrapped in chicken wire. Each subject completed
5 trials with a 1 minute rest between each trial. Time to turn with nose facing down
and time to reach the bottom of the pole were recorded and combined to derive the total
time to descend. If a mouse did not climb down the pole after 2 minutes, the trial time
was not included in that animal’s average total time to descend. Cage Hang: mice were
placed on a cage top elevated 50 cm above a cage filled with bedding. The cage lid was
shaken slightly and flipped over to measure latency to fall over the course of 3 trials ( >
1 minute rest between each trial). A trial less than 10 seconds was redone and trials were
concluded at 3 minutes if a mouse was still hanging.
2.33 Stereology
Stereology was completed using a Olympus BX51 microscope and StereoInvestigator soft-
ware (MBF Biosciences) using the UAB Neuroscience Molecular Detection and Stereology
Core. In each injected brain stained with TH using the methods described above, contours
were drawn around 6-7 serial sections containing SNc. Unbiased stereological estimation
of total TH-positive neurons in the SNc contralateral and ipsilateral to injection was per-
formed using the Optical Fractionator probe by an investigator blinded to experimental
conditions.
2.34 α-Synuclein spread mapping
Serial sections (40 µm) from the entire mice brains were stained with p α-synuclein as
described above. Mapping of the location and abundance of pathology was performed
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using representative brains from each type of α-synuclein conformation (oligomers and
fibrils) with α-synuclein monomer as a control.
2.35 Statistical analyses
In vivo data from the mouse studies (presented in section 3.2.2) were analysed using
GraphPad Prism. One-way or two-way ANOVA were performed. Outliers were identified
using the ROUT method in Graphpad Prism. The only data in which 2 outliers were
identified were in the cage hang motor test. The data from the remaining sections of this




Improving the preformed fibrillar model
of Parkinson’s disease
This work has been done in collaboration with the lab of Dr. Nunilo Cremades (Zaragoza,
Spain) and Dr. Laura Volpicelly-Daley (Birmingham, Alabama,USA). Jessica Froula,
from Dr. Laura Volpicelli-Daley lab injected generated the different α-synuclein species
into the mice brains and performed the in vivo experiments. I spent three weeks in the lab
of Dr. Laura Volpicelli Daley in May 2017 learning primary neuronal culture and helping
with immunocytochemistry and with the immunohistochemistry analysis. José Camino,
from Dr. Nunilo Cremades lab took the AFM images of the different conformers injected
into the mice brains. The results presented in this chapter have been partially published
in the next manuscript:
Jessica M. Froula*, Marta Castellana-Cruz*, Nadia M. Anabtawi, José D. Camino, Se-
rene W. Chen, Drake R. Thrasher, Jennifer Freire, Allen A. Yazdi, Sheila Fleming,
Christopher M. Dobson, Janet R. Kumita, Nunilo Cremades, and Laura A. Volpicelli-
Daley. Defining α-synuclein species responsible for Parkinson disease phenotypes in mice.
Journal of Biological Chemistry, 294(27):10392-10406, 2019
3.1 Introduction
As it has been mentioned before, none of the mouse models of Parkinson’s disease (PD)
is able to faithfully reproduce the disease in a reliable manner. However, the preformed
fibrillar (PFF) model is specially interesting as it is able to reproduce the spreading of
α-synuclein inclusions through the brain and in consequence, can potentially be used to
test therapies targeting the advanced states of the disease and its spreading. As nowadays
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it is not possible to diagnose PD at early stages, this model becomes specially relevant.
However, in order to be able to explore all of its potential, it is necessary to improve
the frequency with which mice inoculated with α-synuclein fibrils develop a locomotor
phenotype. Typically fibrillar species are injected in the striatum of the mice brains, as
this regions present a larger and more accessible target than the substantia nigra pars
compacta (SNcp), inducing a neuronal death between 40 and 50 % in this region [73].
However, this only translates into a 30 % of neuronal loss in average in the SNcp, as
the threshold to develop a motor phenotype is approximately 40 % of neuronal loss in
the SNcp region, locomotor phenotype in this models tends to be variable (with defects
reported mainly in the rotarod and wired hang tests) [53, 73].
One of the main possible sources of variability is the type of α-synuclein (mouse or
human) used to produce the seeds that are subsequently injected into the mice’s brains
has been extensively studied before [92, 49]. As it has been mentioned in the introduct-
ory chapter (section 1.4.1), these studies demonstrated that mice injected with human
α-synuclein fibrils accumulated fewer aggregates compared to mice injected with mouse
α-synuclein fibrils. This is in agreement with what can be found in vitro, both by mon-
itoring the elongation of mouse α-synuclein fibrils with human or mouse α-synuclein
monomer or by feeding human or mouse α-synuclein fibrils to primary neurons [92, 49].
In both cases, the cross-seeding of α-synuclein fibrillar fragments with monomer from a
different specie resulted in a slower elongation rate and fewer aggregates in the neurons.
However, other potential sources of variability have remained largely unexplored. Here
we hypothesised that the heterogeneity of the methods used to prepare the seeds and
the lack of characterisation of the fibrillar mixtures which are injected into the mice are
likely contributing to the differences in phenotypes displayed by PFF model. To try to
overcome some of these technical challenges, and with the collaboration of Dr. Nunilo
Cremades (Department of Biochemistry and Molecular Biology, University of Zaragoza)
and Dr. Laura Volpicelli-Daley (Center for Neurodegeneration and Experimental Thera-
peutics, Department of Neurology, The University of Alabama at Birmingham), we have
biophysically characterised and isolated five mouse α-synuclein species (monomer, oli-
gomers, short fibrils, medium fibrils and long fibrils) that may be present in the fibrillar
mixtures typically used in this model. By evaluating the capacity of these α-synuclein
conformers to induce the aggregation of endogenous α-synuclein in vitro and in vivo we
aimed to determine which α-synuclein species are able to produce neuropathological and
neurodegenerative phenotypes in mice. Moreover, another potential source of variability
between the different batches of fibrils used to inject the mice cohorts is the storage of the
fibrillar samples. It is common in the field to produce large batches of α-synuclein seeds
and store them at -80 °C or in liquid nitrogen for long periods of time before being used
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[26, 33, 67]. However, the maintenance of the structural integrity of the fibrils after these
processes has not been studied before. In order to address this issue, here we performed
a study comparing different structural characteristics (length and secondary structure)
of fibrillar samples before and after storing them at - 80 °C.
3.2 Results
3.2.1 Study of mouse α-synuclein fibril stability
As it has been previously discussed, some researchers in the field tend to prepare large
batches of fibrils and store them in liquid nitrogen or at -80 °C for long periods of time [67].
Therefore, an important question in terms of developing reproducible PFF mouse models
was to determine how this process affects α-synuclein fibril stability and morphology. In
order to address this question, some preliminary analysis were conducted on mouse α-
synuclein fibrillar samples that our collaborator, Dr. Volpicelli-Daley had stored in either
liquid nitrogen, -80 °C or room temperature for different periods of time (Table 3.1).
At the time of the analysis, the 27-june-16 LN and 21-june-16 -80 samples had been
stored for around five months, the 23-sept-16 LN for 3 months and the 11-oct-16 RT and
27-oct-16 short RT for one month.
In order to determine if the α-synuclein fibrils were stable under these conditions,
the amount of the protein in monomeric and fibrillar forms present in the sample was
analysed. With the aim of reducing the effect of cold-denaturation on the samples [99],
they were thawed at room temperature and a 1/10 dilution of each sample was ultra-
centrifuged for 1 hour. After this, the amount of protein present in the supernatant and
in the pellet was determined using a BCA assay (Table 3.2) using known concentrations
of mouse α-synuclein monomer as a standard curve. The amount of protein present in
the supernatant seems to vary greatly between the samples: in the liquid nitrogen stor-
age conditions 74.5 % (sample 27-june-16 LN) and 7.9 % (sample 23-sept-16 LN) of the
protein was detected in the soluble fraction, in the -80 °C freezer storage conditions, 30
% (sample 21-june-16 -80) of the protein was present in the supernatant, finally in the
samples stored at room temperature (sample 11-oct-16 RT and sample 27-oct-16 short
RT) a 9 % and 23 % of the protein was detected in the soluble fraction respectively.
The amount of protein present in the supernatant seems to correlate with the age of the
samples themselves, suggesting that the longer the fibrils stay frozen the more disaggreg-
ation occurs. However, these fibrils were generated by shacking 350 µM at 700 rpm for 7
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Sample name Sample description
27-june-16 LN 100 µL of mouse α-synuclein fibrils at 5
mg/ml in 10mM Tris pH 7.5, 50mM NaCl
made on 27/Jun/16 and stored in liquid ni-
trogen
21-june-16 -80 20 µL of mouse α-synuclein fibrils at 5 mg/ml
in 10mM Tris pH 7.5, 50mM NaCl made on
21/Jun/16 and stored at -80 °C
23-sept-16 LN 100 µL of mouse α-synuclein fibrils at 5
mg/ml in 10mM Tris pH 7.5, 50mM NaCl
made on 23/Sept/16 and stored in liquid ni-
trogen
11-oct-16 RT 50 µL of mouse α-synuclein fibrils at 5 mg/ml
in PBS made on 11/Oct/16 and stored at
room temperature
27-oct-16 short RT 100 µL of mouse α-synuclein fibrils at 5
mg/ml in PBS made on 9/Sept/16 and
stored in LN until the 27/Oct/16, when it
was thawed, sonicated and passed through a
0.22 µm cut-off filter. After this, the sample
was stored at room temperature
Table 3.1: Samples of mouse α-synuclein used to compare the effect of storage conditions
on fibril stability.
days and the conversion rate of monomer into fibrils was not determined by our collab-
orators. Because of this, it is also possible that the differences between the percentage
of protein found in the supernatant corresponded just to a variation in the conversion
rate of different batches of fibrils. In order to asses this, the aggregation efficiencies of
different α-synuclein samples generated by shacking 70 µM α-synuclein at 200 rpm for
5 days was measured. It was found that the amount of protein present in the pellet
oscillated between 50.7 % and 91 % (Table 3.3) supporting, in part, the hypothesis that
the differences between the amount of protein present in the supernatant of the different
samples are due to the intrinsic diversity of the aggregation process.
Theoretically, the sum of the protein concentrations measured in the supernatant and
the pellet should equal ca. 350 µM in all the cases; however, this value is clearly lower in
most cases. Our collaborator, Dr. Laura Volpicelli-Daley, has observed that after storage
in the -80 °C freezer, the concentration of the monomeric samples of α-synuclein decreases
significantly [100]. A similar process may be occurring in the fibrillar samples and could
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Sample











27-june-16 LN 99.4 34 133.4 74.5 25.5
21-june-16 -80 70.7 163.1 233.8 30.2 69.8
23-sept-16 LN 20.6 240.5 261.1 7.9 92.1
11-oct-16 RT 44.7 418.4 463.1 9.6 90.4
27-oct-16 short RT 43.5 145.5 189 23 77
Table 3.2: Total and relative amounts of protein present in the soluble fraction and in
the pellet of the analysed samples.
be responsible, at least in part, for the difference between the theoretical and measured
protein concentrations. The 11-oct-16 RT sample is the only one that does not follow
this trend, as its concentration was above the expected amount. As we only received ca.
50 µL instead of the expected volume of 100 µL, we believe that the evaporation of the
buffer may have contributed to this change in concentration.
Sample 1 2 3 4 5 6 7 8 9 10 11 12
Pellet (%) 52.05 75.2 50.7 81.4 68.5 80.5 79.1 75.8 91 86 76.9 83
Table 3.3: Conversion efficiency of monomer into fibrils of different α-synuclein samples.
After this initial characterisation we proceeded to analyse the structural characterist-
ics of the same samples. Fourier transform infrared (FT-IR) analysis (Figure 3.1) shows
that the characteristic β-sheet secondary structure present in mature fibrils is only main-
tained in the sample stored at room temperature (11-oct-16 RT), with a dominant peak
about 1620–1630 cm−1. In the other samples, although an overall β-sheet structure is
observed, there is an increase in the random coil content which may indicate the presence
of monomeric protein. Unfortunately, it was not possible to take the FT-IR spectra of
the 21-june-16 -80 sample dues to a lack of sample volume.
To determine if any further changes occurred after thawing the samples, they were kept
at room temperature for another week and re-analysed by FT-IR spectroscopy (Figure 3.1
b, c and d). It was observed that whilst the structure of the 27-june-16 LN and 23-sept-16
LN samples did not change over time, a decrease in the absorption in the random-coil
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Figure 3.1: FT-IR spectra of the different samples (a) only the 11-oct-16 RT retain a
fully characteristic fibrillar structure. The result from the FT-IR spectra performed after
keeping the samples at room temperature show that while the structure of 27-june-16
LN (b) and 23-sept-16 LN (c) samples do not change overtime, the structure of 27-oct-16
short RT (d) sample presents decrease in the absorption in the random-coil region.
region of the 27-oct-16 short RT sample occurred. This change in the spectrum indicates
that the structure of the sample has changed over time, potentially due to the elongation
and re-formation of the fibrillar structure.
To confirm structural differences within the samples, microscopy techniques which
could report on the fibril morphology and physical dimensions were performed. Trans-
mission electron microscopy (TEM) and atomic force microscopy (AFM) images of all the
samples were taken (Figure 3.2). In agreement with the FT-IR results, only the 11-oct-16
RT contained long mature fibrils forming networks. The TEM images showed that the
27-june-16 LN sample consisted of fibrillar fragments of different sizes and some clumps
of longer fibrils, while in the AFM images only short fibrils of different sizes could eb
appreciated, but as it is impossible to scan the entire mica surface, it is not possible to
rule out the presence of fibrillar clumps in this analysis. Something similar happened
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in the case of the 23-sept-16 LN sample where by TEM the presence of fibrillar clumps
and some fragments was observed while by AFM it was only possible to appreciate a
collection of fibrillar fragments of different sizes. Both the TEM and AFM images of the
21-june-16 -80 sample showed the presence of small fibrils and some very small fragments
that could be oligomers. As expected, both techniques confirmed that the 27-oct-16 short
RT sample was composed by short fibrillar fragments, matching the description of the
sample provided for us by Dr. Laura Volpicelli-Daley (Table 3.1).
Overall, the fibrils from the 11-oct-16 RT were the only ones that maintained a typical
parallel β-sheet secondary structure with a morphology characteristic of mature fibrils.
Although the storage in the -80 °C freezer or liquid nitrogen did not seem to trigger the
fibril disaggregation, TEM and AFM imaging indicated that the freezing of the samples
triggers the fragmentation of the fibrils.
With the objective of exploring this phenomena more extensively it was hypothesised
that the buffer chosen to aggregate α-synuclein may affect the fragmentation process.
Accordingly, this hypothesis was tested in the experiments reported in this section of the
thesis by the use of the three most commonly used buffers identified in the literature
for the generation of α-synuclein. These buffers were the following: phosphate buffered
saline (PBS) pH 7.3, 50 mM Tris-HCl 150 mM KCl pH 7.5 and 50 mM Tris-HCl 150 mM
NaCl pH 7.5. Two different batches of α-synuclein fibrils were produced, the first one,
denominated F0, was created by shaking 70 µM monomer at 200 rpm for 5 days and the
second one, denominated F1, was produced by the reseeding of F0 with fresh monomer
for 24 h. This process of reseeding existing fibrils with monomer has been proven to
produce more homogenous fibrils that are less prone to clump [101]. Both types of fibrils
were centrifuged for 10 min at 13000rpm, the soluble fraction containing unaggregated
monomer was discarded and the pellet was resuspended at 350 µM, aliquoted in 125 µL
aliquots and store at -80 °C for 2 months.
Upon thawing changes in fibrillar content, secondary structure and grade of fragment-
ation were monitored.
The analysis of the fibrillar content indicated that the amount of monomer present in
the supernatant fraction after 2 month storage was increased in all the samples (Figure
3.3), although in all the cases it represented less than the 3 % of the total protein. This
small increment can be explained by the process of cold denaturation that the fibrils
undergo while thawing, the differences between samples seemed to indicated that fibrils
produced under different conditions are not equally affected by this process. The fibrils
produced in Tris KCl proved to be the least susceptible to this phenomena with the
monomer content only increasing 1.24 ± 0.66 times for the F0 and 1.36 ± 0.45 for the
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Figure 3.2: Microscopy imaging of the fibrillar samples. (a) TEM and AFM images of
27-june-16 LN show that the sample is composed by fibrillar fragments of different size
and some clumps of longer fibrils. (b) TEM and AFM images of 23-sept-16 LN show
that the sample is composed by fibrillar fragments of different size and some clumps of
longer fibrils. (c) TEM and AFM images of 21-june-16 -80 sample show the presence of
small fibrils and some very small fragments that could be oligomers (d) TEM and AFM
images of 11-oct-16 RT show that the sample is composed by long mature fibrils forming
networks. (e) TEM and AFM images of 27-oct-16 short RT show that the sample is
composed by small fibrillar fragments.
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F1. For the samples made in Tris NaCl, the amount of protein in the supernatant was
incremented by a factor of 3.24 ± 0.66 in the F0 samples and 3.6 ± 0.55 in the F1. Finally
the PBS samples showed the highest variability between fibril generations and a higher
amount of protein in the supernatant than the samples produced in either of the Tris
based buffers, with the monomer concentration elevated 9.58 ± 3.75 times in the case of
the F0 and 3.59 ± 1.02 of the F1.
Figure 3.3: Structural characterisation of the fibrillar samples. (a) difference between the
protein present in the supernatant at time 0 and after 2 months at -80 °C. (b) represent-
ative FT-IR spectra of the F0 generation samples at the two mentioned timepoints. (c)
representative FT-IR spectra of the F1 generation samples at time 0 and after 2 month
of storage.
Since the different susceptibilities to cold denaturation may be caused by small dif-
ferences in the structure of the fibrillar samples the secondary structure of the fibrils by
FT-IR (Figure 3.3) was examined. The deconvolution of the FT-IR spectra (Figure 3.4)
showed that all the fibrils have similar secondary structure content. F0 fibrils made in
Tris-NaCl were 62.04 % ± 5.8 β-sheet and 17.22 % ± 13.59 α-helix/random-coil and F1
61.62 % ± 0.73 and 9.66 % ± 3.21 respectively. In the case of the samples produced in
Tris-KCl the percentage of β-sheet was slightly lower, 57.7 % ± 1.83 for F0 and 57.34 %
± 0.48 for F1, while the α-helix/random coil one was higher, 20.45 % ± 6.25 for F0 and
21.91 % ± 0.39 for F1. The fibrillar species formed in PBS had a similar β-sheet (57.88 %
± 2.68 for the F0 and 57.2 % ± 0.34 for the F1) and α-helix/random-coil (21.28 % ± 2.68
for F0 and 22.18 % ± 0.89 for F1) content. Although there was not significant difference
between the β-sheet and α-helical/random-coil content of the different fibrillar samples,
the raw spectra of the fibrils produced in Tris-based buffers were slightly different to
the PBS ones. Specifically, the shape around the α-helical/random-coil region seemed to
differ, with Tris-based fibrils presenting a higher signal than the PBS ones. The fact that
these changes are consistent across different samples seems to indicate that although both
sets of fibrils have largely the same structure there are some small differences between
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them, specially in the the α-helical or random coil regions.
In agreement with the data gathered during the measuring of the protein present in
the supernatant fraction of the samples, the FT-IR spectra of the different fibrillar species
did not show significant changes after two months of storage at -80 °C (Figure 3.3).
As it had been previously noticed in our collaborator’s samples, the storage of the
samples for two month at -80 °C triggered the fragmentation of the fibrils in all the
cases (Figure 3.5). With the exception of the Tris-NaCl sample, all the F0 fibrils were on
average longer than the F1 ones when freshly made (Table 3.4), this fact can be attributed
to the fact that the grade of clumpling in the Tris-NaCl samples hindered the proper
determination of their length. Moreover, as it has been previously reported [101], the F1
fibrils were more homogeneous in length and less clumped than their counterparts. Upon
thawing, all sets of fibrils experienced a significantly (p<0.001) decrease of length and
interestingly, all the fibrils had a similar average length and display a similar distribution
of sizes (Figure 3.6).This seems to indicate that the storage of fibrillar samples at -
80 °C promotes the fragmentation of the fibrils to a determinate length (400-500 nm)
independent of the buffer in which they were originally produced.
Tris NaCl Tris KCl PBS
Fresh 2 moth -80 °C Fresh 2 moth -80 °C Fresh 2 moth -80 °C
F0 1152.42 ± 641.99 456.5 ± 320.13 966.99 ± 584.39 798.3 ± 449.4 1468.09 ± 1407.47 533.96 ± 463.24
F1 894.74 ± 439.62 451.06 ± 292.75 1192.95 ± 638.1 468.5 ± 328.12 604.55 ± 367.64 427.42 ± 281.15
Table 3.4: Average length and standard deviation of the different fibrillar samples.
Samples were prepared in duplicates (n=2) and at least 5 TEM images were taken of
each grid.
In conclusion, here we have demonstrated that although the freezing of the samples
does not significantly alter the fibrillar structure it does promote the fragmentation of
the fibrils. Because this type of samples is usually frozen with the objective of using them
in different experiment separated across time, and it has been previously proven that the
length of the fibrils affects the degree of cellular internalisation, this fact is of special
relevance. For example, if an experimentalist were to use long fibrils freshly prepared,
that have a low internalisation rate and produce a mild phenotype, in one experiment and
frozen fibrils in another one, the variation in size could result in different internalisation
rates and thus, a different phenotype, contributing to the great variability that we see
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Figure 3.4: Deconvolution of the FT-IR spectra. Example of the deconvolution and
second derivative of each one of the α-synuclein fibrillar species studied here. In all the
cases a total of 6 Gaussian curves were used to fully reproduce the original spectra. The
peaks identified by this curves were in good agreement with the ones highlighted in the
second derivative functions.
67
Figure 3.5: TEM images of the fibrillar samples. Here it is possible to appreciate the
fragmentation that the fibrils undergo upon their freezing at -80 °C as well as the longer
size and the higher degree of clumping characteristic of the F0 generation fibrils.
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Figure 3.6: Size distribution of the different samples imaged by TEM. Samples were
prepare in duplicates (n=2) and at least 5 TEM images were taken of each grid. Size
distribution of (a) PBS, (b) Tris KCl, (c) Tris NaCl F0 generation fibrils at two different
time points, time 0 and 2 months at -80 °C. (d) comparison between the sizes of the
different α-synuclein conformers after 2 months at -80 °C, PBS and Tris KCl fibrils share
the same distribution while the Tris NaCl one is slightly displaced. Size distribution of (e)
PBS, (f) Tris KCl, (g) Tris NaCl F1 generation fibrils at two different time points, time
0 and 2 months at -80 °C. (e) comparison between the sizes of the different α-synuclein
conformers after 2 months at -80 °C; all the fibrillar species share a similar distribution.
across this model. Due to this we believe that it is best to prepare fresh fibrils in the
preferred buffer.
3.2.2 Defining α-synuclein conformers responsible for Parkin-
son’s disease phenotypes in mice
Another main source of the phenotypical variability observed in the PFF model could
be the amount of each different α-synuclein species injected into the brains of mice. The
creation of α-synuclein fibrils from monomer by shacking results in a complex mixture
of fibrils, monomer, oligomer and protofibrils that is often use unprocessed before being
injected into the brains of mice. Moreover, the concentration of the sample is calculated
assuming a 100 % conversion efficiency but, as it can be derived from (Table 3.3) the
efficiency of monomer conversion into fibrils is not constant. Hence, different fibrillar
batches generated this way could contain different amounts of α-synuclein fibrils, which
in turn could lead to the injection of variable amounts of fibrils into the brains of mice.
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This could influence the number of α-synuclein aggregates that develop in the brains
of these mice and in consequence, contribute to the phenotypical variability observed
across this model. As it has been explained in the introductory chapter (section 1.3)
both, oligomers and fibrils, have been proposed as the toxic species responsible for PD,
moreover both types of α-synuclein species are generated during the production of α-
synuclein fibrils and are still present in the samples traditionally injected in this model.
Here we seek to determine the seeding capacity and toxicity of these different α-synuclein
species in the mouse brain through the study of five different α-synuclein conformers:
monomer, kinetically trapped oligomers, long fibrils, medium size fibrils (obtained by
sonication) and short fibrils (obtained after filtering the medium size fibrils through a
0.22 µm membrane). Because the cross-seeding between human α-synuclein seeds and
mouse monomer is not as efficient as the seeding of mouse α-synuclein monomer with
mouse α-synuclein fibrils ([49], Figure 3.10 a), we decided to use mouse recombinant
α-synuclein for these experiments. It is a well known fact that the lipopolysaccharide
(LPS) present in the membrane of E. Coli binds to recombinantly expressed proteins,
contaminating the sample. As LPS is a potent activator of microglia, with the injection
of 5 µg of LPS into the mouse brain have been proven to trigger this process [95], our
first step was to clean the purified mouse α-synuclein with the Pierce High Capacity
Endotoxin Removal Spin Column, which brought the LPS levels down from 0.77 EU per
milligram of protein to less than 0.035 EU/mg.
Since mouse α-synuclein aggregated species have not been extensively characterised
before, our first step was to biophysically characterise the different conformers and to
compare them to their human counterparts [34]. After preparation, the secondary struc-
ture of the mouse α-synuclein monomer and oligomers, long, medium and short fibrils
were determined using far-UV CD and FT-IR spectroscopies. CD spectroscopy in the
far-UV region is able to define secondary structure elements such as random coil, α-helix
and β-sheet structures whereas FT-IR analysis of the amide I region can, in addition,
provide information of the arrangement of the β-sheet structures (i.e. parallel versus
anti-parallel) which are present. The spectra of the mouse α-synuclein species revealed
that the overall secondary structure is similar to their human homologues (Figure 3.7 a
and b). As expected, the far UV-CD spectra of the monomer showed a typical random
coil shape with a strong negative peak at 200 nm and the FT-IR presented a peak around
1650 -1640 cm−1 that can be attributed to a random coil conformation. All the fibrillar
species produced similar spectra in both FT-IR and far-UV CD, showing an absorption
band at the 1620-1630 cm−1 region in the FT-IR and a clear minimum at 220 nm in the
far-UV CD. Deconvolution of the FT-IR spectra showed that long fibrils were 72.0 % ±
4.9 β-sheet, the medium ones were 70.0 % ± 3.2 and the short ones were 73.0 % ± 6.2,
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which is in line with the values previously reported for human α-synuclein fibrils (65 %
± 10 [34]). In the case of the oligomers, both the FT-IR and far-UV CD indicated that
in a similar manner to the human α-synuclein oligomers, the mouse species possessed an
intermediate structure between a fibril and a monomer. The FT-IR spectrum displays
an absorption peak at 1650 -1640 cm−1 that could be attributed to random coil content,
and another one at 1620–1630 that, together with the shoulder present at 1695 cm−1,
indicates the presence of antiparallel β-sheet structure. In this spectrum, we can also
observe that the percentage of β-sheet content seems to be higher in the case of the
mouse α-synuclein oligomers (56.23 % ± 3 instead of the 35 % ± 5 reported for the hu-
man α-synuclein oligomers [34]). Finally, Thioflavin T (ThT) binding data showed that
only the fibrils have a mature amyloid structure, in contrast to oligomers which showed
a marginal ability to bind ThT molecules (Figure 3.7 d). Long, medium and short fibrils
show similar ThT binding and thus had equivalent amyloid conformation.
In order to determine the morphology and size of the different mouse α-synuclein
conformers TEM and AFM images of the different species (Figure 3.8) were taken. Due
to the time constraints of the projects, the injection of the different α-synuclein species
into the mouse brains was performed by our collaborator Dr. Laura Volpicelli-Daley
before the characterisation of fibrillar stability upon different storage conditions could
be performed, and fibrils stored in liquid nitrogen for several months were used for this
purpose. As it has been shown before, fibrils made in PBS by shacking α-synuclein
monomer should have had an approximated length of 1400 nm, but our long fibrillar
sample shown an average height of 7 nm and an average length of 266 nm, which is
indicative of the fragmentation process that has taken place upon the freezing of the
samples. As expected, sonication of the samples to create medium sized fibrils created an
heterogeneous population with a length rage between 40-225 nm and an average length of
120 nm. The filtration of this medium size population through an 0.22 µm filter resulted
in an enriched population of the smaller fibrillar fragments with an average length of 70
nm and a more homogenous distribution of 40-125 nm. In agreement with what has been
previously shown for human α-synuclein oligomers [34], mouse α-synuclein oligomers had
a spherical-like morphology, an average length of 54 nm and an average height of 5.5 nm.
Finally, the analysis of the sedimentation velocity measurements of the mouse α-synuclein
oligomeric sample obtained by analytical ultracentrifugation (Figure 3.7 c) also reflects a
similar size distribution to human α-synuclein oligomers [34]. In both cases, it is possible
to observe two oligomeric populations, the first with a maximum peak at 10 S, and the
second maximum peak at 15 S. This second peak is slightly higher in the case of the mouse
α-synuclein oligomers, as this population has been previously shown to be increased likely
due to the enrichment of β-sheet structure in this the oligomeric population [34]; therefore,
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Figure 3.7: Structural characterisation of α-synuclein species used in the in vivo mouse
studies. (a) representative far-UV CD spectra of an n=3. Oligomers (mouse and human)
have a β-sheet content intermediate between monomer and fibrils. (b) representative FT-
IR of an n=3. FT-IR spectra shows that long ( M F-L), medium (M F-M), and short (M
F-S) fibrils species are primarily composed of parallel β-sheet (band at 1620-1630 cm−1)
and similar to their human (H F-M) counterparts, and that the oligomeric (mouse (M
O) and human (H O)) species are primarily antiparallel (band at 1620-1630 cm−1 and
shoulder at 1695cm−1). (c) analytical ultracentifuge sedimentation velocity measurement
of human (grey dashed line) and mouse oligomers (grey continuous line) (n=3) shows 10S
and 15S species. (d) ThT binding assay shows that all fibrillar adopt a similar amyloid
conformation, the oligomers show limited ThT binding and monomer shows no ThT
binding (n=3). [102]
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this result is in line with our previous observation of an increased β-sheet content in the
mouse oligomeric samples with respect to its human counterpart. In order to further
confirm the nature of these α-synuclein conformers a dot bolt against total synuclein,
oligomeric speceies and fibirllar species was performed. As expected OC, an antibody
raised against amyloids, preferentially recognised the fibrillar form of α-synuclein, while
A11, an antibody designed to recognise oligomers, preferentially recognised the oligomeric
species (Figure 3.9 b and c). Because the antibody A11 has been previously shown to
be able to recognise other conformers of α-synuclein [103], the partial recognition of
monomeric and fibrillar samples by A11 observed in the dot blot does not necessarily
imply a contamination of oligomeric species in these samples. As the rest of the tests
performed to characterise these samples (FT-IR, CD, TEM, AUC, AFM) supported a
correct isolation of the different α-synuclein conformers, it can be concluded that the
different α-synuclein species were generated and purified successfully.
With the objective of assessing the integrity of the α-synuclein monomer after the ag-
gregation process 5 µM of monomer, oligomer, short fibrils, medium fibrils and long fibrils
were disaggregated by incubating overnight in 7M urea and the degree of fragmentation
was assessed by SDS-PAGE. After developing the gel with silver stain, a band below the
monomeric molecular weight was detected in the oligomeric sample (Figure 3.9 a), the
fact that this could not be appreciated after staining with Instant Blue means that the
this band contains less than 0.25 ng of protein (0.8 µM of each species were loaded into
the gels). Based on this, the integrity of the α-synuclein monomer after aggregation into
the different conformers was judged to be conserved.
In conclusion, the biophysical characterisation of the different mouse α-synuclein con-
formers reveals that they share similar structures and properties with their human homo-
logues and hence, they can be used in this project as a model to reliable study the seeding
capacity and toxicity of this different α-synuclein species in vivo.
Our next step was to assess the seeding efficiency of the different α-synuclein con-
formers in vitro. This was first investigated by following the time-dependent incremental
change in ThT fluorescence at 37 °C of a mixture of 100 µM mouse α-synuclein and
10 µM of the different species (Figure 3.10 b). Neither the monomer nor the oligomers
were able to seed the formation of amyloid fibrils, this is consistent with the fact that
oligomers produced following this protocol are kinetically trapped and hence off-pathway
[34]. The kinetics of seeded fibril formation was similar when medium or short fibrils
were used as seeds and slightly slower for the long fibrils, this can mainly be explain by
the fact that sonication of the long fibrils results in a more fragmented population and
as a consequence produces more fibrillar ends capable of inducing elongation [51]. To
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Figure 3.8: Morphological characterisation of the mouse α-synuclein species used in the
in vivo mouse studies. TEM and AFM images of long fibrils (F-L) (a, b), medium fibrils
(F-M) (e, f), sonicated fibrils enriched in short fragments (F-S) (i, j), and oligomers (O)
(m, n). (c-p) AFM was used to quantify the length and height of each species shown in
the histograms. [102]
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Figure 3.9: Structural integrity of mouse α-synuclein species and characterisation by
structural antibodies. (a) The structural integrity of the mouse α-synuclein monomer
after its aggregation into oligomer and fibrils was assessed by SDS-PAGE after incubation
of 10 µM of each species with 7 M urea overnight. (b) Dot blot of the monomer, oligomer,
short fibrils, medium fibrils and long fibrils against a total anti-α-synuclein antibody
(syn1), oligomeric species (A11) and fibrillar species (OC). (c) Quantification of the
signal from the dot blot displayed in (b). The relative intensity derived from each mouse
α-synuclein species was normalised to the signal of the monomer and corrected by the
total amoun of mouse α-synuclein
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examine the ability of different α-synuclein fibrils to seed inclusion formation in neurons,
our collaborator Dr. Laura Volpicelli-Daley added 50 nM of monomeric, oligomers, long,
medium or short fibrils to wild type primary hippocampal neurons and quantified the
abundance of phosphorylated α-synuclein, a marker of inclusion formation [104], seven
days later (Figure 3.10 c and d). Consistent with the in vitro ThT binding assays, neither
monomeric nor oligomeric α-synuclein produced p-α-synuclein inclusions while both short
and medium fibrils produced significantly more inclusions that the long fibrils. The ma-
jority of inclusions appeared as bright, and thread-like similar to Lewy-neurites found in
synucleinopathy brains. To determine if these differences in inclusion formation were a
consequence of the different seeding efficiencies and if it is related to the internalisation
rate of each species, an internalisation assay using α-synuclein labelled with Alexa488 was
performed [98]. For this experiment a cysteine variant of mouse α-synuclein, E110C, was
labelled with Alexa-488 through a malemide bond and the different mouse α-synuclein
conformers were produced. The mouse E110C α-synuclein monomer was purified, LPS-
cleaned, labelled with Alexa-488 and aggregated into the different conforms in Cam-
bridge before shipping to our collaborator in Alabama. Previous studies [36, 105] have
demonstrated that the labelling of α-synuclein through this method does not alter the
monomer conformation nor the structure of kinetically trapped oligomers or fibrils. With
the objective of assessing the internalisation of the different conformers, the 70 nM of
Alexa-488 labelled α-synuclein species was added to primary hippocampal neurons for
one hour, after which the extracellular fluorescence was quenched with trypan blue and
the samples were imaged. Both Alexa-488 labelled short α-synuclein fibrils and oligomers
were readily internalised, while long fibrils remained mainly in the extracellular region
(Figure 3.10 e). As it has been previously demonstrated [106], this correlates with a low
number of inclusion formations, however the addition of kinetically trapped oligomers,
that are both efficiently internalised and toxic by themselves [34], was not able to induce
the aggregation of endogenous α-synuclein. Taken together these results indicate that
both the size and the seeding competency of the aggregates are factors that affect the
formation of α-synuclein inclusions.
To determine the extent to which monomer, oligomers and different length fibrils seed
formation of α-synuclein inclusions in the brain, our collaborator performed unilateral
striatal injections of each conformer in 15 male C57BL/6 L male mice. In order to
generate each of the conformers three different batches of monomeric protein were used
to generate three independent batches of each conformer. The exact concentration of the
samples was determined later during the biophysical characterisation and was 300 µM
for the oligomers and monomer and 150 µM for all the fibrillar samples. This last data
was surprising since the fibrils have been prepared using 300 µM monomer. Although
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Figure 3.10: Seeding ability of the different assembled forms of α-synuclein species in
vitro and in primary neurons. (a, b) monomer (100 µM) was incubated with 5 µM fibril-
lar or oligomeric seeds in the presence of ThT and the ThT fluorescence was monitored
over time. The figure represent the average of n=3. (c, d) for the primary hippocampal
neurons, 70 nM of long (F-L), medium (F-M), short (F-S) fibrils or oligomers (O) were
added to the neurons and after seven days, the neurons were fixed and inclusion form-
ation was visualized using an antibody to p-α-synuclein (green). Immunofluorescence
for tau (magenta) shows the distribution of axons (scale bar = 50 µM). Image J was
used to quantify the percent area occupied by p-α-synuclein. The data are presented as
the mean ± SEM. (e) Primary hippocampal neurons were pre-incubated with Alexa-488
tagged long (F-L), short (F-S) fibrils or oligomers (O) 1 h at 37 °C to allow internalisa-
tion. Fluorescence of external α-synuclein-Alexa 488 was quenched using trypan blue.
Images show representative α-synuclein-Alexa 488 fibrils or oligomers (scale bar = 50
µM). The fluorescence intensity of Alexa 488 from 10 fields per condition was quanti-
fied and normalized to trypan blue immunofluorescence. The internalisation experiments
were repeated two times. [102]
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the oligomers were prepared in Cambridge and shipped to Alabama, the fibrillar samples
were prepared by our collaborator to avoid the clumping of the sonicated fragment during
the transport [101, 100] and the concentration of the monomer used to produce the fibrils
was determined by a BCA assay instead of the absorbance at 280 nm, which is known
to significantly overestimate the concentration on mouse α-synuclein [107]. This could
explain the differences between the expected fibrillar concentration and the observed one.
Thus, the concentration of oligomers injected was two times more than fibrils in terms of
mass concentration.
Mice were perfused 3 months later and the exact localisation of the injection site was
evaluated via immunohistochemistry. Signs of a successful injection into the striatum
were found in 12 mice injected with monomer, 15 injected with oligomers, 11 injected
with long fibrils, 12 injected with medium fibrils and 11 injected with short fibrils. The
remaining mice were excluded from further analysis. Immunohistochemistry was per-
formed using an antibody specific for α-synuclein phosphorylated at serine-129 that has
been characterised and validated using α-synuclein knockout mice [108, 109]. Mice injec-
ted with long medium and short fibrils presented p-α-synuclein positive inclusions while
mice injected with oligomers and monomers presented a more diffuse and less intense
signal in the cytosol, indicating that none inclusions had been formed (Figure 3.11). The
inclusions appeared as Lewy-neurite like threads in the neuropil and skein-like inclusions
in the soma. The abundance of inclusions in different areas of the brain was quantified
using a semi-quantitative rating scale (Table 3.5) and the average score from the animals
in each group was calculated (Table 3.5). The areas of the brain that presented more
inclusions included the cortex, amygdala and striatum. In all the cases, the inclusions
had a higher prevalence in the ipsilateral side to the injection, but with the exception of
the SNc, the aggregates were also present in the contralateral side (Figure 3.11 c). As
it had been observed in vitro, medium and short fibrils produced a similar number of
inclusions while long fibrils produced significantly less aggregates (Figure 3.11 c).
The fact that the most abundant inclusions appear in region that project to the
striatum (cortex, amygdala, and SNc)[110], suggested that the fibrils are internalised into
the axon terminals and then transported to the soma. This is consistent with findings
that after addition of fibrils to WT mice, inclusions appear first in axons and later in
the the soma [48] and with the preferential localisation of α-synuclein at the presynaptic
terminal [111]. To test this theory, we co-injected short fibrils with retrotracer beads
into the right dorsal-lateral striatum. These beads are internalised and travel via axons
to the neuronal soma allowing the tracing of connections in the brain. Two weeks after
injections, p-α-synuclein positive inclusions were visible in the SNc, cortex and amygdala
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Figure 3.11: Inclusion formation in the mouse brain after injection of different forms of
α-synuclein. C57BL/6J mice received unilateral striatal injections of two µL of soluble
monomer (300 µM), long (F-L) (150 µM), medium (F-M) (150 µM), short (F-S) fibrils
(150 µM) and oligomers (O) (300 µM). After three months, mice were perfused and im-
munohistochemistry was performed using an antibody to p-α-synuclein. Representative
images from the SNc (a) and amygdala (b) are shown. Arrowheads indicate inclusions
in the soma and arrows indicate Lewy neurite-like inclusions. (c) Quantification of the
abundance of inclusions by an investigator blinded to experimental conditions. Numbers
of mice: monomer (12), long (F-L) (11), medium (F-M) (12), short (F-S) fibrils (11),
oligomers (O) (15). Data are shown as the mean score ± SEM and were analysed using a
two-way ANOVA, α-synuclein species/cingulate F(2,30) = 37.85, p < 0.0001; α-synuclein
species/motor cortex F(2,30) = 7.9, p < 0.002; α-synuclein species/insular cortex F(2,30)
= 22.3, p < 0.0001; α-synuclein species/striatum F(2,30) = 8.5, p < 0.001; α-synuclein
species/amygdala F(2,30) = 6.6, p = 0.004; α-synuclein species/SNc F(2,30) = 6.2, p <
0.005. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Scale bar = 100 µm (top panels);
20 µm (bottom panels). [102]
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Brain area Ipsilateral score Contralateral score
Motor Cortex 1.6 1.1
Somatosensory Cortex 1.6 1
Insular Cortex 1.6 1
SNc 1.6 0
Auditory Cortex 1.4 0.9
Lateral Orbital Cortex 1.3 0.9
Amygdala 1.3 0.6
Ectorhinal Cortex 1.3 0.9
Striatum 1.1 0.5
Cingulate Cortex 1.0 1.0
Visual Cortex 1.0 0.4
Piriform Cortex 1.0 0.5
Nucleus Accumbens 0.4 0.4
Retrosplenal Cortex 0.7 0.3
Subiculum 0.6 0
Hippocampus 0.4 0
Mammillary nucleus 0.5 0.1
Olfactory Tubercle 0.2 0
Fimbria 0 0
Cerebellar Flocculus 0 0
Colliculus 0 0
Table 3.5: Quantification of inclusions present in different brain areas after the injection
of short fibrils. The abundance of inclusion was rated on a scale from 0 to 3 (0:no inclusion
in soma or neurites. 1: less than 10 aggregates in the soma and none in the neurites. 2:
between 10 and 50 inclusion in the soma and less than 10 in the neurites. 3: more than 50
aggregates in the soma and more than 10 in the neurites). Brains from nine independent
mice were scored to obtain the average score.
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in the same area as the retrotracer beads and four weeks after injections, p-α-synuclein
positive inclusions were abundant in all three brain regions (Figure 3.12). These data
suggest that as we had hypothesized, the α-synuclein seeds are internalised in the striatum
by axons projecting into this region and subsequently transported to the soma of neurons,
efficiently spreading the aggregates through different areas of the brain.
Figure 3.12: Appearance of p-α-synuclein inclusions in brain areas that project to the
striatum. Fibrils and retrotracer beads were co-injected unilaterally into the striatum.
After, one (N=3), two (N=3) or 4 weeks (N=3), mice were perfused and immunofluores-
cence to p-α-synuclein (green) was performed. The retrotracer beads are shown in red.
Representative images from the SNc, motor cortex and amygdala are shown. [102]
In order to quantify dopaminergic neuronal loss in the ipsilateral and contralateral
injection side of the SNc unbiased stereology the numbers against tyrosine hydroxylase
(TH), a marker of dopaminergic neurons was performed. Three months after injection,
only short fibrils produced a significant, approximately 30 % loss of dopaminergic neurons
in the ipsilateral SNc compared to monomer injected mice (Figure 3.13). This reduction
was also significant with respect to the contralateral injection side (Figure 3.13 b). In-
terestingly, the oligomers produced a significant reduction in the number of neurons on
the side ipsilateral to the injection site relative to the non-injected side, which correlates
with previous findings of kinetically trapped oligomers being toxic to neurons ([34, 38].
Although a reduction of TH positive neurons is generally accepted as an indicator of
neuronal loss, another possible explanation is that the TH levels are simply being down-
regulated. To address this possibility, we performed immunofluorescence measurements
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against NeuN, a marker of neuronal nuclei, (Figure 3.14) in the SNc. Compared to mice
injected with monomeric α-synuclein, there was a slight, but not statistically significant,
reduction in the number of NeuN positive neurons in the mice that received injections of
short fibrils. However, the TH-immunofluorescence in the short fibrils and oligomers injec-
ted mice appeared beaded compared to monomer injected mice, suggesting the presence
of dying neurons. The loss of dopamine terminals was determined by immunofluorescence
detection of the dopamine transporter (DAT) in the striatum (Figure 3.13 c, d). Mice
injected with either medium and short fibrils showed an approximately 30 % reduction in
DAT-positive dopamine terminals relative to the control. In addition, unlike the unilat-
eral loss of dopamine neurons in the SNc, the loss of dopamine terminals in the striatum
was bilateral. This correlates with the fact that no p-α-synuclein positive inclusions were
detected in the contralateral side of the injection in the case of the SNc while α-synuclein
aggregates were detected bilaterally in the case of the striatum. Although unilateral
injection of unpurified sonicated fibrils into the striatum has been previously shown to
produce a 35 % loss of dopaminergic neurons in the SNc [112] 6 months post injection, no
statistically significant differences in the numbers of TH-positive dopamine neurons were
detected 3 months after injection. As we have been able to shown a comparable reduc-
tion in the TH levels at only 3 months post-injection, this supports our theory that the
generation of pure homogeneous well characterised fibrils is important to work towards
the improvement of the PFF model.
Finally, we investigated if the formation of α-synuclein inclusions and the loss of
dopamine neurons and terminals was translated in defects in motor behaviours. After
3 months only the mice injected with short fibrils showed changes in motor behaviour
(Figure 3.15). Specifically, this mice showed an increment of the amount of time needed to
descend a pole, a well establish test for “bradykinesia” [113], and reduction in the amount
of time that the mice could hang from the lid of a cage, a test for motor strength [112].
However, no significant differences among any groups were found in the open field test for
time spent in centre (a measure of “anxiety) or velocities of movement. A cylinder test
modified specifically for mice [106] also showed no differences between mice injected with
different α-synuclein conformers in the average number of hind limb steps or the average
number of rears. Therefore, and in line with our previous results, only the injections
of short fibrils is able to cause defects in motor strength and induce bradykinesia. This
further highlights the fact that the best method to produce a strong robust phenotype in
this model is to inject small seeding competent α-synuclein species.
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Figure 3.13: Quantification of TH-positive neurons in the SNc, and DAT terminals in stri-
atum following unilateral striatal injections of different α-synuclein species. C57BL/6J
mice received unilateral striatal injections of two µL of soluble monomer (300 µM), long
(F-L) (150 µM), medium (F-M) (150 µM), short (F-S) fibrils (150 µM) and oligomers
(O) (300 µM). After three months, the mice were perfused and immunostaining was per-
formed. Numbers of mice: monomer (12), long (F-L) (11), medium (F-M) (12), short
(F-S) fibrils (11), oligomers (O) (15) (a) representative images of tyrosine hydroxylase im-
munohistochemistry in the SNc of monomer and short fibrils injected mice. (b) unbiased
stereology of tyrosine hydroxylase positive neurons performed by an investigator blinded
to experimental conditions. Data are shown as the mean counts ± SEM and analysed
using a two-way ANOVA, α-synuclein species F(5,67) = 2.7, p = 0.03. (c) representative
images of immunofluorescence for DAT in the striatum from monomer and short fibrils
injected mice are shown. (d) Image J was used to quantify the integrated fluorescence
intensity of DAT in the striatum. Data are shown as the mean counts ± SEM and ana-
lysed using a two-way ANOVA, α-synuclein species F(3,43) = 5.7 , p = 0.002. *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001. Scale bar = 100 µm. [102]
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Figure 3.14: Double labeling immunofluorescence for TH and NeuN was performed using
sections of SNc from mice that received unilateral injections of monomer (M), short fibrils
(F-S), or oligomer (O). Images were captured using confocal microscopy. In image J, the
colours were separated and thresholded using MaxEntropy autothreshold. The TH images
was used to outline the SNc and the outline was transferred to the NeuN image. NeuN
was converted to a binary image and “Analyze Particles” was used to count neurons.
Data is presented as the mean NeuN count ± SEM (N, monomer = 8, N, short fibrils
= 8, N, oligomer = 6. ANOVA revealed no significant differences between groups. Scale
bar = 100 µM [102]
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Figure 3.15: Motor behavior of mice following unilateral striatal injections of different
α-synuclein species. C57BL/6J mice received unilateral striatal injections of two µL of
soluble monomer (300 µM), long (F-L) (150 µM), medium (F-M) (150 µM), short (F-S)
fibrils (150 µM) and oligomers (O) (300 µM). Three months later, mice were subjected to
the following behavioural tests: open field, pole test, cage hang, cylinder test (modified
for mice). Numbers of mice for pole test, cage hang, open field: monomer (12), long fibrils
(11), medium fibrils (12), short fibrils (11), oligomers (15). Numbers of mice for cylinder
test: monomer (10), long fibrils (10), medium fibrils (10), short fibrils (10), oligomers
(10). The data were analysed by one-way ANOVA: pole test F(4,69) = 4.7, p = 0.002;
cage hang F(4,66) = 2.86, p = 0.03; open field/% time center F(4,69) = 1,1, p = NS;
open field/velocity F(4,69) = 0.6, p = NS; hind limb steps F(4,45) = 1.1, p = NS; rearing
F(4,45) = 0.5, p = NS. [102]
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3.3 Discussion
The development of good models of Parkinson’s disease is key in the designing and testing
of therapeutic strategies to halt the progression and spread of the disease. Although the
PFF model does not reproduce the onset of the disease, it does reliably mimic its spreading
state. Since there is not currently any test to detect the early stages of PD, this makes
this model especially useful to test therapies focused on later stages of the disease that can
currently be diagnosed. The successful targeting of the spreading state of PD requires
the characterisation of the α-synuclein conformations responsible for PD phenotypes,
including inclusion formation in multiple brain areas, dopamine terminal loss, neuronal
death in the SNc and motor behaviours. Here, we used a combination of techniques
from biophysics to immunohistochemistry to behaviour to demonstrate that small, 70 nm
fragments of α-synuclein fibrils are the most efficient molecular species capable of inducing
PD-like pathology features when injected into the brain of healthy mice. These aggregates
are able to grow and recruit endogenous monomeric α-synuclein, suggesting that these
species are important agents for the spreading of toxicity and disease. Stabilised α-
synuclein oligomers are, in agreement with previous reports, able to induce a significant
14 % loss of dopamine neurons in the SNc on the side ipsilateral to the injection compared
to the contralateral side [34, 36, 38, 114], but due to fact that their are kinetically trapped
they were unable to seed the formation of endogenous α-synuclein inclusions, cause loss
of dopamine terminals in the striatum or cause motor behaviour phenotypes. Thus our
results suggest that the ability of aggregated species to recruit endogenous monomeric
protein and to generate new toxic aggregates has a higher impact than the inherent
toxicity of the injected species in the probability of inducing the development of PD-
related phenotypes. In addition, our results suggest that the major disease spreading
agents consist of small, seeding-competent α-synuclein fibrillar aggregates.
Whether fibrils or oligomers are the most toxic species of aggregated protein has been
extensively studied in multiple neurodegenerative diseases including Alzheimer’s disease,
Huntingtin’s disease and PD. As the oligomers used in this study are kinetically trapped
and hence are unable to seed the formation of inclusions and spread the disease, it is not
possible to discard that on-pathway oligomers play a role in the induction of PD-related
phenotypes in the mice injected with short fibrils. In fact, the loss of dopaminergic
neurons induced by oligomeric species has been shown in vivo by using lentivirus to
express human α-synuclein variants prone to oligomerize [115]. Moreover, the release
of on-pathway oligomers upon the interaction of small α-synuclein fibrillar samples with
the cellular membrane has been recently observed [116]. As the aggregation cascade of
α-synuclein is complex and the fibrils do not necessarily represent its end-point, there are
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other mechanisms by which on-pathway oligomers can be formed in mice injected with
short fibrils. These mechanisms include the possibility that the sonication of the fibrils
pre-injection could produce some oligomers as a by-product, and that oligomeric species
could be generated by the fragmentation of longer α-synuclein fibrils or by the induction
of secondary nucleation processes. Although these on-pathway oligomers are expected
to be toxic [30], due to their low concentration and lack of a defined amyloid structure
[34], they are probably not the main species responsible of the spreading of the disease
through the brain. In contrast with these oligomers, small fibrils are more stable and
are composed by several α-synuclein protofilaments arranged in a specific conformation,
which constitutes a fibrillar polymorph. This could potentially allow small fibrils to
spread through the brain seeding the formation of new α-synuclein fibrils from a specific
polymorph, which would be in line with the recent findings of specific α-synuclein fibrillar
polymorphs being present in different synucleinopathies [57, 58, 59].
Our results suggest that targetting the small fibrillar α-synuclein fragments generated
by the aggregation of monomeric protein or by the fragmentation or disaggregation of
longer fibrils, have the potential to be a therapeutic strategy in the treatment of PD.
However, antibodies that are not selective for fibrillar α-synuclein also reduce its total
concentration inside the cell, and may result in the impairment of the synaptical function
[117, 118]. However, antibodies that selectively target α-synuclein fibrils can potentially
hinder their ability to spread from cell-to-cell and therefore reduce the rate of disease
propagation. Antibodies that target the N-terminal region of α-synuclein have been
proven more efficient in impairing the interaction of the fibrillar aggregates with the
cellular membrane and abrogating the downstream toxic affects [37]. One example is
BIIB054 which selectively binds the N-terminal region of fibrillar α-synuclein [119], and
using the PFF mouse models of PD was able to inhibit inclusion formation, dopaminergic
neuronal loss, and defects in motor behaviour.
Overall, our data highlights the importance of biophysically characterising in a meth-
odological way, the species of α-synuclein responsible for the major events of dysfunction
related to PD. In this study, injection of short fibrillar fragments of approximately 70
nm in length induced the formation of p-α-synuclein inclusions, neuron loss and motor
dysfunction 3 months after the injection, while previous studies were not able to detect
neuronal loss until 6 months post injection [112]. Interestingly, the injection of fibrillar
fragments with a similar length (40-225 nm) as used in this previous studies [112, 53] was
able to induce the formation of inclusions but not to trigger neuronal loss or behavioural
phenotypes. This suggests that differences in the fibrillar length of the α-synuclein frag-
ments might be the origin of some of the phenotypical variability reported within this
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model. Since we have previously established the freezing of the fibrils will induce their
fragmentation and therefore affect their size, this highlights the importance of preparing
fresh fibrils before each round of injections.
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Chapter 4
Exploring the correlation between struc-
tural polymorphism of α-synuclein oli-
gomers and cellular toxicity
These experiments have been developed in collaboration with Catherine Xu, who performed
the biophysical characterisation of the different oligomeric species.
4.1 Introduction
The misfolding of proteins and their aggregation into amyloid fibrils has been implicated
in numerous neurodegenerative disorders, including Parkinson’s and Alzheimer’s diseases.
As it has been previously discussed, α-synuclein is an intrinsically disordered protein
that upon binding with lipid membranes is able to adopt an α-helical structure in the
N-terminal region [120]. This association with lipid membranes is likely to have biological
relevance [121] and it has been found to be a key trigger of aggregation [27, 122]. Once
aggregated, α-synuclein adopts a cross-beta structure characteristic of amyloid aggregates
[1]. During this aggregation process a heterogeneous mixture of species, including differ-
ent populations of oligomeric species with varying percentage of β-sheet structure, can be
detected [30]. It is believed that these oligomers are one of the main α-synuclein species
responsible for cellular toxicity in vivo [36], recently using solution and solid NMR-state
experiments, it has been proposed that this toxicity its mediated by both, the interaction
of the N-terminal region with the cell membrane and the insertion of the β-sheet hydro-
phobic core into the lipid bilayer [36] which disrupts membrane integrity (Figure 1.6 g).
Experiments with oligomeric species from other proteins suggest the presence of a key
link between hydrophobicity, size and toxicity [36, 115, 34, 123], were more toxicity is
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linked to those oligomers that are small and have a higher degree of exposed hydrophobic
regions.
Since the oligomers are especially relevant to explaining the α-synuclein aggregation
toxicity in vivo, an effort has been made to study the oligomeric populations formed
during the aggregation of the α-synuclein mutants related with the genetic form of Par-
kinson’s disease (PD) (Figure 4.1). As it has been mentioned before, some of these
mutations (A53T and A30P) are able to accelerate the aggregation of α-synuclein while
others (E46K, H50Q and G51D) slow it. However, this does not necessarily reflex changes
in the oligomeric populations. Due to the lowly populated nature of oligomers they are
difficult to characterise, one possible approach to solve this is the use of single-molecule
techniques like measuring of intermolecular FRET efficiency. This technique has allow the
detection of two different oligomeric species, "Type A" and "Type B", present during the
aggregation of α-synuclein [30] (Figure 1.6). As it has been explained before, "Type A"
oligomers form fist during the aggregation process and present a reduced toxicity, while
"Type B" oligomers are able to induce higher levels of cellular toxicity. Single molecule
FRET studies of the oligomerisation of the A53T, A30P and E46K variants of α-synuclein
revealed significant differences between the A53T and A30P oligomeric population respect
to the wild-type [124]. In addition, the concentration of oligomers during the lag-phase
of the aggregation of wild-type and mutated alpha-synuclein is similar, suggesting that
the properties of the oligomers generated during the aggregation process might be more
relevant than their absolute concentration for triggering neurodegeneration. Due to the
transient and rapidly changing nature of the on-pathway oligomers, it is extremely chal-
lenging to study their structure in a detailed manner. In order to address this problem,
stabilised oligomers, similar to "Type B" oligomers, of the different α-synuclein variant
related to PD, A53T, E46K, H50Q, A30P and G51D were produced. Moreover, the form-
ation of oligomers that are not able to progress into fibrils have been detected during the
aggregation of WT, A5T, E43K and A30P α-synuclein variants [125, 126]. This high-
lights the importance of understanding the role that kinetically-trapped oligomers in cell
toxicity, not just as a model of on-pathway oligomers, but also as part of the aggrega-
tion process. Since these α-synuclein mutations (A53T, E46K, H50Q, A30P and G51D)
are pathogenic and oligomers have been identified as one of the toxic species of the ag-
gregation pathway, this work seeks to study the possible relationship between oligomeric
structure and cellular toxicity using kinetically trapped oligomers as a model.
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Figure 4.1: Human α-synuclein sequence showing in red mutation associated with genetic
forms of PD. In order: A30P, E46K, H50Q, G51D and A53T
4.2 Results
Oligomers from the familial PD associated α-synuclein variants, A30P, E46K, H50Q,
G51D and A53T were successfully generated using our previously described protocols
[34]. Briefly 6 mg of lyophilised monomeric α-synuclein were resuspended in 500 µL
of PBS, incubated overnight at 37 °C, ultracentrifugated to eliminate possible fibrils
and concentrated using a 100 kDa filter in order to eliminate excess monomer. First,
we compared the size of this variants oligomers with the WT. Transmission electron
microscopy (TEM) images showed that they had a similar size and morphology to the
WT oligomers, being all of them approximately spherical with a diameter of around 5-15
nm (Figure 4.2). This measures were confirmed using dynamic light scattering (DLS),
which showed a major peak for the oligomers around 20 nm diameter, in contrast to 4
nm peak of the monomers (Figure 4.2). This difference in the estimate size obtained
from the DLS measures and the TEM is probably due to the effects of solvation and bias
towards larger species of the DLS. [127]
Figure 4.2: All α-synuclein variants form oligomers with similar size and morphology.
TEM images of variant oligomers, confirming that relatively homogeneous oligomer pop-
ulations are produced in all cases, with roughly spherical shape and 5-15 nm diameter
(scale bar = 100 nm). DLS profiles of all variant oligomers (solid), are shown alongside
the profiles for their corresponding monomeric species (dotted).
As all the oligomeric variants had a similar size we next investigated if they also shared
a similar secondary structure. Using fourier transform infrared (FT-IR) spectroscopy, we
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were able to determined that, as the WT oligomers, all the oligomers variants possessed
an antiparallel β-sheet core (Figure 4.3), intermediate between the one of a fibril and a
monomer. This was further confirm by far-UV circular dichroism (CD) spectroscopy (Fig-
ure 4.4). Interestingly, the analysis of far-UV CD revealed that, the structure of the G51D
oligomers shifted greatly within different batches, with some of them showing standard
β-sheet oligomeric properties and others showing different degrees of α-helical structure
(Figure 4.4). Although the origin of this structural variability could not be experimentally
determined, it was possible to establish a link between the lyophilisation process and the
acquisitions of a particular secondary structure, with batches of monomeric α-synuclein
lyophilised at the same time consistently showing the same secondary structure. As the
FT-IR spectra remains largely unchanged between different G51D batches, indication the
β-sheet structural element is largely conserved, the α-helical structure was likely to arise
from regions that remain disordered in the WT and other variant oligomers.
Figure 4.3: FT-IR spectra of the different variants and conformers of α-synuclein. Rep-
resentative (n > 5) FT-IR spectra of all α-synuclein variants. Oligomers display β-sheet
content intermediate between that of the respective monomers and fibrils and display
a clear anti-parallel peak at 1695 cm−1. (Solid line: oligomer; Dotted line: monomer;
Dashed line: fibril).
Since the WT oligomers had been proven to cause oxidative stress, membrane dis-
ruption and cell death [34, 38, 39, 36], the next step was to explore the cellular tox-
icity of these oligomeric variants. It was first decided to study their effect in cell vi-
ability, with this purposed we performed the MTT assay, which monitors the MTT (
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction to formazan by
92
Figure 4.4: Far-UV CD spectra of the different variants and conformers of α-synuclein.
All variant oligomers display β-sheet content intermediate between that of the respective
monomers and fibrils. Representative (n > 5) CD spectra of variant α-synuclein species,
with several different preparations of G51D oligomers shown. (Solid line: oligomer; Dot-
ted line: monomer; Dashed line: fibril).
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the NAD(P)H-dependent oxidoreductases present in the cytosol. A lower reduction of
MTT can be attributed to a decrease in metabolic activity and hence to a reduction of
cell viability [128]. Here SH-SY5Y were incubated cells with 0.3 µM of oligomers for 24h,
after this the media was removed and replaced with a solution of 0.5 mg/mL of MTT
that was allowed to be reduced for 4 hours. In agreement with previous reports the WT
oligomers reduced the cell viability by 17 % ± 9 compared to the control. Surprisingly
A30P, E46K, H50Q, and A53T oligomeric variants, that have apparently identical struc-
tural properties to the WT oligomers, did not show decreased levels of MTT reduction
with respect to the control (Figure 4.5 a). Interestingly, although in average the G51D
samples did not induce a significant reduction in cell viability, a great variability between
batches of oligomers could be appreciated, with values ranging from 5 % reduction of cell
viability to a 50 % reduction. In order to reduce this variability and to better determine
the true toxicity of the G51D variants, more replicas of the MTT test (initaly only three
different batches of each oligomeric variant were tested) were performed. For each one of
these replicas a different oligomeric batch was used and 6 wells of a 96 well plate were
used in each case as technical replicates. In general, at least 5 batches of every oligomeric
species were tested, and this number was increased to 11 in the case of G51D. Although
G51D samples continued to show the greatest variability within the oligomers variants,
this strategy allowed us to determine that the G51D oligomers are in fact, able to induce
a significant reduction in cell viability compared to its PBS control (Figure 4.5 b). It
is important to take note here of a few considerations regarding the technical set-up of
the experiments: first, due to the low concentration at which the oligomeric α-synuclein
mutants are purified (form 70 µM - 1 µM), the volume of PBS added to the wells var-
ies between experiments, secondly in order to be able to compare between samples the
MTT results were normalised to untreated values and compared via an ANOVA statist-
ical analysis to their own PBS controls. In general, it was possible to dilute all variants
to the lowest concentration within the plate in order to avoid variability, but the low
yield of G51D oligomers made it necessary to treat them differently and add a specific
PBS controls (Figure 4.5 a and b). This change in the volume of PBS added per well
can explain the higher toxicity found in the cells treated with PBS volumes equivalent to
the G51D samples. Another element that could potentially influence the toxicity readout
is the amount of lipopolysaccharide (LPS) present in the samples, in order to explore
this possibility a solution of 1 µM of each of the variants monomeric stocks was tested.
Although the levels of LPS change between stocks, the samples that register the higher
levels, A30P (1.8 EU/ml) and A53T (3 EU/mL), do not correspond with the species
that showed a decrease in cellular viability in the MTT test. This suggest that the MTT
results are indeed independent from the LPS present in the samples (Figure 4.5 c). The
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contamination of monomeric α-synuclein with LPS occurs during the purification process,
hence the different levels of LPS observed in the different stocks of the α-synuclein vari-
ants could be due to the presence of higher levels of LPS during the purification process
(which could be caused by differences in the number of bacteria harvested) or to different
mutants of α-synuclein presenting different affinities for LPS.
In view of the differences in toxicity showed by the different oligomeric variants and
since WT oligomers have been shown to be able to increase the intracellular reactive
oxygen species (ROS) production levels in a consistent way [34, 38, 36], we next assessed
if other oligomeric variants also shared this ability. As G51D had shown the greatest
variability in the MTT test, 3 different preparations of it were included in each set of
experiments. SH-SY5Y cells were treated with 0.6 µM oligomers in the presence of
CellRox-Orange, a probe that becomes fluorescence in the present of ROS, after 2 hours
incubation the fluorescence levels of each sample were determined. Interestingly, the ROS
levels in the G51D treated cells were higher and more variable that the ones induced by
any of the other α-synuclein oligomeric variants (Figure 4.6). Generally, the ROS levels
are increased in the cells exposed to any of the oligomeric variants, this is especially
obvious in the case of the WT (Figure 4.6), however this increment is only statistically
significant in the case of G51D. This can be explained by the fact that, in order to acquire
the G51D data without saturating the image, the laser setting of the microscope had to be
kept at a relative low intensity, which can potentially place the ROS signal derived by cell
exposure to the other oligomeric variants of α-synuclein bellow the detection threshold
(Figure 4.6 b).
Since high surface hydrophobicity has been reported to be a predictor for oligomer
toxicity [64, 129, 130] (an elevated number of hydrophobic residues exposed to the solvent
could increase oligomers’ affinity for lipid membranes facilitating membrane disruption
[123, 64, 131, 132]) we investigated if changes in the hydrophobicity of the kinetically
trapped α-synuclein oligomeric variants could explain the differences observed in cellular
toxicity. Using 8-anilino-naphthalene sulphate (ANS), a dye whose fluorescence emission
is enhanced upon binding to hydrophobic regions, we determined that A30P, E46K, H50Q
and A53T oligomers showed similar amounts of solvent-accessible hydrophobic residues as
the WT oligomers (Figure 4.7 a). However, the oligomers generated by the G51D variant,
independently of their secondary structure content, exhibited a significantly lower ANS
fluorescence, which is indicative of a reduced hydrophobic surface with respect to the WT
oligomers (Figure 4.7 b). Thus, according to this model, and in line with previous reports
showing that G51D oligomers induced less membrane disruption than other PD variants
[133], G51D kinetically trapped oligomers should induce less cellular toxicity than other
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Figure 4.5: Cellular toxicity of the different oligomeric α-synuclein variants. (a) toxicity
tested with MTT assay on SH-SY5Y cells of 3 preparations of each oligomer variant,
with error bars shown for standard error and data for all individual replicates overlaid as
points. (b) toxicity tested with MTT assay on SH-SY5Y cells of (n ≥ 5) preparations of
each oligomer variants, with error bars shown for standard error and data for all individual
replicates overlaid as points. (c) Quantification of LPS content in 1 µM monomer stocks
of each variant, with PBS shown for comparison. Statistical analysis was run using one-
way ANOVA (all variants except for G51D) or Student’s t-test (G51D only) *(p < 0.05)
**(p < 0.001).
variants. However, our MTT and ROS results point out towards another conclusion,
being that the G51D oligomers are the most toxic within the variants, therefore, it is
clear that other variables, apart of size and hydrophobicity, need to be considered in
order to explain the toxic properties of the α-synuclein variants [123].
As the variability of the G51D readouts in both tests was significantly higher than
for any of the other variants and the G51D preparations are the ones that show more
structural diversity between them, the possibility that structural changes between G51D
batches could be affecting its ability to induce cellular toxicity was next investigated. In
order to explores this hypothesis we deconvoluted the far-UV CD spectra of the different
variants and estimated the relative secondary structures of the different preparations
of all the oligomers variants [134, 135]. Even though the fits obtained reproduced our
experimental data with extremely low residuals, indicating that this is a robust method for
comparatively analysing our spectra (Figure 4.8 a), the deconvolution analysis identified
an 11 % of α-helical content in the WT oligomers, which was not observed in the solid
state NMR structural data reported previously [36]. This suggest that the α-helical
percentage reported here should only be used as a relative quantification between oligomer
samples, but not as an absolute one. Since, as previously confirmed by FT-IR, G51D
batches only differ structurally between them in α-helical content, the possibility of the
relative amount of α-helical content present in each sample correlating with its cellular
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Figure 4.6: Intracellular ROS levels induce by different oligomeric α-synuclein variants.
Example of two different experimental replicas (a) and (b) performed with different pre-
parations of α-synuclein oligomers. SH-SH5Y were exposed to 0.6 µM oligomers variant
and ROS levels were measure after 2 h using CellRox-Orange. Statistical analysis was run
using one-way ANOVA (all variants except for G51D) or Student’s t-test (G51D only)
*(p < 0.05) **(p < 0.001).
toxicity was explored. In order to avoid the variability in toxicity associated with the
differences in sample volumes, the relative value of MTT reduction was normalised here
to its corresponding PBS controls instead of to untreated. Indeed, a clear correlation
between increased α-helical content and decreased MTT values (Figure 4.8 b) was found.
However, no correlation was observed between cell toxicity and β-sheet or random coil
structures, suggesting that the effect on cellular dysfunction can be solely attributed to
the α-helical content (Figure 4.8 c). This in agreement with previous reports that showed,
using stabilised oligomers from several proteins, that the amount β-sheet content present
in the sample did not correlate with cellular toxicity [136].
4.3 Discussion
In conclusion, our results suggest that together with size and hydrophobicity, the amount
of α-helical content can be a determinant of the toxicity of diverse oligomeric struc-
tures. Indeed, α-synuclein acquires an α-helical structure upon binding lipids, which it
is believed to be the first step towards triggering cell toxicity mediated by membrane
disruption [36, 133]. Detailed work on the WT oligomers generated through this protocol
has identified the mechanistic features by which α-synuclein oligomers induced membrane
disruption: first the disordered N-terminal regions of the oligomers binds to the cellular
membrane adopting an α-helical structure and acting as an anchor and allowing the β-
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Figure 4.7: Hydrophobicity of the different oligomeric α-synuclein variants. (a) Repres-
entative ANS emission spectra of variant oligomers (n ≥ 3) (b) The surface hydrophobicity
of G51D oligomers is markedly decreased compared to that of the WT oligomers, despite
differences in α-helical content of the G51D oligomers.
sheet hydrophobic core to get closer to the membrane and insert itself into the interior
of the lipid bilayer [36]. Furthermore, the impairment of the N-terminal binding to the
membrane has been reported to abolish the oligomers associated toxicity [37, 36]. In
our study, despite the lower hydrophobic nature of the G51D oligomers, we observe an
enhanced cellular toxicity correlating with an increase in the content of α-helical struc-
tural. This may suggest that the existence of pre-formed α-helical structure in the G51D
oligomers facilitates the anchoring to the plasma membrane, allowing a more efficient
insertion of the hydrophobic core into the lipid bilayer, which in turn would induce mem-
brane disruption and cellular dysfunction. One possible hypothesis to explain the higher
propensity of G51D to form an α-helical structure is the introduction of a negative charge
near the fourth imperfect KTKEGV repeat which could extend its length and, in turn,
shortened the hydrophobic region between the fourth and fifth KTKEGV repeats. This
increases the homogeneity in length of the hydrophobic motives and the periodicity of
the KTKEGV repeats which could facilitate the acquisition of an α-helical configuration.
Although the intermediate content of β-sheet between a monomer and a fibril is one of
the main structural characteristics of amyloid oligomers, it has recently been shown that
the percentage of β-sheet structure present in the oligomers does not correlate with their
toxicity; therefore, investigations of other factors that can dictate toxicity are necessary
[136]. Interestingly, α-helical structure has previously been detected in the aggregation
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Figure 4.8: Relationship between the secondary structure of α-synuclein oligomeric vari-
ants and cellular toxicity. (a) Far-UV CD spectra of G51D oligomers displaying different
degrees of α-helical structure (black solid), shown alongside the fitted spectra (blue dot-
ted) (b) MTT reduction as a function of α-helical content of oligomers as estimated by
far-UV CD spectra deconvolution. The data correlation (linear relationship visualized as
a grey dashed line) obtained was: (fraction viability) = -0.016 * (percentage α-helical
content) + 1.06, with an R2 value of 0.29 and p value of 0.0026. (c) Liner fitting of the
toxicity data versus the β-sheet and random coil content. However, the only fit with
a statistically significant deviation from null correlation was α-helical content (0.0026),
with values of 0.14 and 0.77 for β-sheet and random coil content, respectively.
cascade of several α-synuclein variants [137, 138]. Moreover, α-helical intermediates have
been observed in multiple systems such as IAPP (islet amyloid precursor protein), the Aβ
amyloid peptide associated with Alzheimer’s disease, and the PSM3α peptide; together
this suggests that the presence of α-helix configuration within amyloid structures may
have broader implications [139, 140, 141, 142, 143, 144, 145]. In addiction an α-helical
conformation of the PrP monomer have been shown to induce higher toxicity in vitro
and in vivo than other configurations of PrP [146]. Furthermore, structural polymorphs
of amyloid fibrils derived from the PSM3α peptide, implicated in Staphylococcus aureus
pathogenicity, have previously been found to induce several degrees of cellular toxicity,
with the α-helical form showing a higher toxicity towards eukaryotic cells [140, 127].
Moreover, studies on the PSM3α peptide showed that this increase toxicity shown by the
α-helical variant may be mediated by interactions with lipid membranes, supporting our
suggestion that the α-helical content within α-synuclein oligomers promotes toxicity by
facilitating membrane insertion [141]. The observation of such effects in two unrelated
systems implies that α-helical content may be a key determinant in a range of systems
that exert their toxicity via interactions of oligomeric protein species with membranes.
Together with our results, this suggest that along with the size and hydrophobicity,
the α-helical content may be a determinant of the oligomeric toxicity. In order to confirm
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this hypothesis, more studies with amyloid conformers from different proteins containing
varying degrees of α-helical content are needed. Such studies will allow the determination
of the threshold of helical content that can modulate the toxicity predicted by models
that take into account size and hydrophobicity [123] and further our knowledge about
amyloid toxicity. One of the key factors that would determine the success of these studies
is the ability to accurately deconvolute the CD spectra of different amyloid aggregates.
In the present study the deconvolution software BESTSEL was used for this purpose,
this software allowed the fitting of the different spectra (that range form β-sheet in shape
to α-helical) with low residuals (Figure 4.8) and the estimation of the percentage of α-
helical, β-sheet and random coil content of the different oligomeric variants. However,
the deconvolution of the spectra cannot precisely determine the secondary structure of
these aggregates [135, 134]. Because of this, it would be beneficial to incorporate the
use of other markers of α-helical content, like the absorbance value at 208 nm or the
ratio between the absorbance at 220 nm and at 208 nm [135], to further support this
correlation between the degree of α-helical content and cellular toxicity in future studies.
Even though all the α-synuclein variants used in this chapter are related to early
onset forms of PD, only the oligomers produced from the WT and G51D variants were
able to significantly reduce cellular viability as shown in Figure (4.5). However this
does not necessarily imply a lack of toxicity of on-pathway oligomeric species derived
from A53T, E46K, H50Q and A30P α-synuclein variants. Although the WT α-synuclein
kinetically trapped oligomers used in this study are considered to be structurally close
to WT α-synuclein on-pathway form [34], this has yet to be proven for the rest of the
α-synuclein variants. Moreover, the increased toxicity of the pathological mutations of
α-synuclein may not be related to the structure of the oligomeric intermediaries. An
increment in the number of these species during the aggregation process or a higher
propensity to generate off-pathway oligomers during this process may also explain the
higher toxicity attributed to these α-synuclein variants [124]. Furthermore, a recent study
has detected the release of oligomers from WT α-synuclein fibrils upon its interaction
with the cellular membrane [116]. A different propensity of different fibrillar variants of
α-synuclein to realease oligomers could also affect the capability of this PD-associated
forms of α-synuclein to induce cellular toxicity. In conclusion, the origin of oligomeric
toxicity is sill poorly understood and more studies with both off-pathway and on-pathway
species are necessary in order to fully elucidate its source.
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Chapter 5
Assessing the seeding capabilities of
different α-synuclein fibrillar conform-
ers
This work was developed during a visit (September 2019 - December 2019) to the lab of
Dr. Nunilo Cremades in Zaragoza, Spain. Although this study was based in previous
results of José Camino, the protein and the different conformers of α-synuclein used in
this project were produced by Marta Castellana Cruz.
5.1 Introduction
The secondary structure polymorphism within fibrils, at the end point of the aggregation
process, has extensively been studied in the context of fibrillar polymorphs, or strains,
and toxicity [56, 147, 148, 42, 55]. Different neurodegenerative diseases caused by the
aggregation of α-synuclein have been shown to be related to slightly different fibrillar
polymorphs [58] (Figure 5.1). Moreover the injection of different α-synuclein strains
into mouse brains have been shown to produce different phenotypes [56]. In light of
this, it is important to study the effects that different α-synuclein polymorphs may have
upon cellular toxicity. Moreover fibrils encounter in the brain of Parkinson’s disease (PD)
patients have been proven to be different to the ones generated in vitro [59], since fibrillar
polymorphism modulates cellular toxicity [42, 58] it is specially relevant to develop the
ability of generating new α-synuclein polymorphs that could potentially be structurally
closer to those generated in vivo.
José Camino, a PhD student in the Cremades lab has been working on characterising
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Figure 5.1: AFM images of the different polymorphs of α-synuclein fibrils used in this
study. Scale bar corresponds to 200 nm. Figure adapted from [19]
a number of different α-synuclein polymorphs [19]. These different polymorphs (Table
5.1) have been produced in the presence of crowding agents such as dextran and poly-
ethylene glycol (PEG) or in the presence of alcohols, such as methanol, under minimal
shaking conditions. Most of the aggregates display a parallel β-sheet core, characteristic
of amyloid fibrils but morphologically, they are more globular species closer in size to kin-
etically trapped oligomers. Through the incubation of α-synuclein in highly dehydrating
conditions (i.e. the addition of 35 % methanol) it was possible to obtain antiparallel fibrils
of α-synuclein, however these structures are not stable in more physiologically relevant
buffers like PBS. Antiparallel intermolecular β-sheet structure is normally found in the
kinetically trapped toxic oligomers but amyloid fibrils are always parallel in nature. This
raises the question of if on-pathway oligomers will be parallel or anti-parallel in nature,
as all the amyloid fibrils characterised have a parallel β-sheet structure the existence of
anti-parallel on-pathway oligomers will imply a significant reorganisation of the β-sheet
core before being able to progress into mature fibrils. Because of this, on-pathway anti-
parallel oligomers are improbable to exist in nature. As the kinetically trapped oligomers
used to model and study the structural and toxic properties of on-pathway oligomers are
antiparallel in nature, it is necessary to determine if possessing an anti-parallel β-sheet
core influences the cellular toxicity of these species. Since the isolation of on-pathway
oligomers is extremely difficult, the possibility of producing antiparallel fibrils would al-
low us to further study the relationship between secondary structure and toxicity and to
determine if intermolecular β-sheet arrangement plays a role in it.
Given that toxicity has generally been linked with antiparallel oligomeric species and
to a lesser extent, parallel β-sheet fibrils, the array of polymorphs that can be generated
allows us to compare different structural attributes in relationship with cellular toxicity,
internalisation rate and seeding ability.
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Aggregation conditions β-sheet core Morphology
Size (nm)
Heigh Width Length
300 mg/ml PEG 8000 Parallel Globular 36 ± 0.4 70 ± 7 70 ± 7
300 mg/ml Dextran 70000 Parallel
Fibrillar 4.4 ± 0.7 59 ± 9 280 ± 5
Globular 10 ± 2 80 ± 6 80 ± 6
10% Methanol Parallel Globular 8 ± 2 82 ± 3 82 ± 3
35% Methanol Anti-parallel Globular 4.8 ± 0.7 29 ± 5 29 ± 5
Stabilised oligomers Anti-parallel Globular 5.5 ± 0.5 54 ± 10 54 ± 10
F1 fibrils Parallel Fibrillar 13 ± 1 50 ± 10 1200 ± 600
Table 5.1: Structural and morphological characteristics of the different fibrillar α-
synuclein aggregates.
5.2 Results
The alternative parallel fibrillar synculein polymorphs were generated by incubating 100
µM of human monomeric α-synuclein in PBS in the presence of the 300 mg/ml dextran
or PEG or 10 % methanol at 37 °C in a 96 well plate for seven days. Initially, since the
aggregation kinetics were acquired in a plate reader without shacking, this process was
performed in a static 37 °C incubator. However this strategy proved unsuccessful as the
aggregation yield after seven days was between 0 and 2 %, it was hypothesised that some
minimal shaking (as the one produced by the plate reading process itself) was indeed
necessary. Subsequent tries in which the plate was incubating inside the plate reader
with or without it performing a read every 10 minutes confirmed this hypothesis. From
this point onwards these aggregates were produced inside a plate reader programmed to
read a single well every 10 minutes. Antiparallel fibrils were generated by incubating 100
µM of human monomeric α-synuclein in PBS in the presence 35 % methanol at 37 °C
in an static incubator. Protofibrils were produced by the aggregation of 100 µM human
α-synuclein in the presence of DMPS vesicles as describe in [27]. Finally F1 generation
fibrils were generated as described in chapter 1.
Since protofibrils have been shown to be formed in the presence of lipid vesicles, to
which they remain attached, it was necessary to isolate them before testing their effect
on cells. With this objective in mind, protofibrils were incubated for 1.5 h at 37 °C
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with 1 % sarkosyl in 20 mM sodium phosphate buffer, pH 6.5, afterwards the sample
was ultracentrifugated at 20 °C, 120000 rpm for 1.5 h before resuspending it in PBS. In
order to remove the lipids and detergent mixture completely this process was repeated
three times. The parallel conformers produced in the presence of dextran, PEG or 10 %
methanol were subjected to the same process in order to wash away any residual monomer
from solution. As the antiparallel conformers are not stable in PBS (Figure 5.2), the 35
% methanol fibrils and a sample of F1 fibrils, as a control, were cross-linked by incubating
with 0.25 % glutaraldehyde for two minutes at 37 °C. The excess of glutaraldehyde was
washed away by centrifuging the samples at maximum speed for 10 minutes at room
temperature. The concentration of all the conformers was determined by an aliquot with
4M GmdCl to solubilise the aggregates and measuring the absorbance at 275 nm.
Figure 5.2: Fibrils made in the presence of 35% methanol (a) revert to a mostly monomeric
conformation after incubation in PBS for 2 h (b). Representative FT-IR spectra are
shown.
Since different polymorphs of fibrils have been shown to be related with different
synucleinopathies the different fibrillar generated here were tested for their ability to
seed α-synuclein inclusions. As the SH-SY5Y do not express endogenous α-synuclein,
we used mouse hippocampal primary neurons, a more advanced model for PD, in this
study. Since the objective of this study was to compare the toxicity of conformers of
different size and morphology, only the F1 fibrils and the protofibrils were sonicated
before applying them to the cells according to established protocols [101, 100] in order
to allow their internalisation. As the rest of the α-synuclein conformers generated here
(Table 5.1) are similar in size to sonicated fibrils (120nm, as established in chapter 3) no
sonication step was applied to these conformers. Primary neurons were incubated with
0.3 µM of each conformer, and after 5 days the amount of aggregated α-synuclein was
determined by the presence of S129-phosphorylated α-synuclein (Figure 5.3). α-Synuclein
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inclusions have been reported to be widely phosphorylated at serine 129 [104], because
of that S129-phosphorylation of α-synuclein has been extensively used as a maker for
α-synuclein aggregation both in vivo and in vitro. Surprisingly, the protofibrils were able
induce the aggregation of endogenous α-synuclein in a more efficient way than the F1
fibrils (Figure 5.3). Neither the fibrils produced in the presence of dextran nor PEG were
able to induce the formation of α-synuclein inclusions, while the ones produced in the
presence of 10 % methanol induced only low levels of aggregation (Figure 5.3). Neither
set of cross-linked fibrils were able to seed endogenous α-synuclein, but as the standard
F1 fibrils were seeding competent (Figure 5.4), this is possibly caused by the cross-linking
itself. As most of the amines available to react with glutaraldehyde in α-synuclein are
in the N-terminal region, which has been shown to mediate the anchoring of oligomers
and monomers to the lipid membrane [36, 149], it is possible that the cross-linking with
glutaraldehyde inhibits the internalisation of the conformers by impeding the N-terminal
region from forming an α-helical structure.
As the ability to seed endogenous α-synuclein is directly related to the internalisation
rate of these conformers, the ability of mouse hippocampal neurons were indeed to in-
ternalised these α-synuclein species at similar rates was assessed. In order to do this, we
labelled a cysteine mutant of human α-synuclein N122C, chosen because the C-terminal
localisation of the cysteine makes it less probable to the dye to interfere with the aggreg-
ation process, with alexa-488 and produced the different parallel aggregates as previously
described. After 1 h incubation with 0.3 µM of each of the conformers the neurons were
fixed and the membrane labelled with wheat germ agglutinin (WGA)-Alexa 647. Al-
though, in agreement with previous reports [30, 102], a partial internalisation could be
detected in the case of the F1 fibrils, protofibrils and monomer (Figure 5.5), the imaging
of the aggregates produced with 10 % methanol, dextran and PEG revealed the presence
of large clumps of protein (Figure 5.5). These clumps of protein are most likely formed
during the ultracentrifugation process and since the majority of the sample protein is
sequestered in them, they may be responsible for the poor seeding of these aggregates
(Figure 5.3).
In order to address this issue the clumped samples were subjected to a gentle sonic-
ation before applying them to the neurons. After this, the internalisation and seeding
experiments were repeated. No clumps of protein could be detected during the internal-
isation experiments and indeed, a partial internalisation of the aggregates was detected
in all the cases (Figure 5.6). In agreement with the internalisation results, the aggreg-
ates formed in the presence of PEG were able to seed the aggregation of endogenous
α-synuclein. Interestingly, the aggregates formed in the presence of 10 % methanol were
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Figure 5.3: Seeding of α-synuclein aggregation in mouse primary neurons (I). Mouse
hippocampal neurons were incubated with 0.3 µM α-synuclein aggregates. They were
stained with p-129-α-syn (green) and neurofilament (magenta). Representative images
of one set of experiments are shown, at least 5 images of 3 different coversilps treated
with the same preparation of α-synuclein fibrillar variants were taken). Due to clumping
issues (Figure 5.5), only the experiments using protofibrils and F1 fibrils were repeated
twice using different neuronal cultures and fibrillar preparations.
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Figure 5.4: Seeding of α-synuclein aggregation in mouse primary neurons (II). Mouse
hippocampal neurons were incubated with 0.3 µM cross-linked α-synuclein aggregates.
They were stained with p-129-α-syn (green) and neurofilament (magenta). Representative
images of 1 out of 2 sets of experiments (at least 5 images of 3 different coversilps were
taken) are shown. Different preparations α-synuclein fibrillar aggregates were used in
each experiment.
still able to induce just a fraction of the aggregation induced by F1 fibrils (Figure 5.7,
Figure 5.3), this may indicated that these aggregated are seeding deficient or that they
are only able to grow up to certain length (this is generally true for all amyloid fibrils,
although usually mature amyloid fibrils can reach a length of microns). Due to a lack
of protein, the seeding experiments with the aggregates produced in the presence of dex-
tran could not be repeated. Although these results are very promising, further follow
up is needed to obtain repeats of these experiments, as well as the experiments with the
dextran produced aggregates, to confirm our findings.
5.3 Discussion
In conclusion, these preliminary results suggest that the different conformers of α-synuclein,
previously characterised by José Camino, are able to seed the aggregation of endogenous
α-synuclein in mouse primary neurons with different efficiencies. These results further
support the theory that different α-synuclein polymorphs, or strains, are able to induce
different synucleinopathies. While conformers produced in the presence of 10 % meth-
anol, a type of globular fibrils with a similar size to stabilised oligomers, were barely
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Figure 5.5: Internalisation of different α-synuclein aggregates (I). Mouse hippocampal
neurons were incubated with 0.3 µM Alexa-488 labelled α-synuclein conformers for 1
hour. The cellular membrane was stained with WGA-647 (magenta). All the species
were produced using Alexa-488 labelled α-synuclein. Representative images of an n=1
preparation of α-synuclein fibrillar aggregates (at least 5 images of 3 different coversilps
were taken) are shown. This experiment was not repeated.
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Figure 5.6: Internalisation of different α-synuclein aggregates (II). Mouse hippocampal
neurons were incubated with 0.3 µM Alexa-488 labelled sonicated α-synuclein conformers
for 1 hour. The cellular membrane was stained with WGA-647 (magenta). Representative
images of an n=1 preparation of α-synuclein fibrillar aggregates (at least 5 images of 3
different coversilps were taken) are shown. Due to time constrains this experiment could
only be performed once.
able to induce the formation of inclusions, protofibrils were able to trigger this process in
a more efficient way than mature F1 fibrils. It is possible that longer incubation times
would significantly increase the aggregation seeded by the 10 % methanol fibrils. As any
residual clumping of the samples or fragmentation of the original α-synuclein aggregates
could potentially affect the seeding properties of these conformers the sonication precess
needs to be further optimised. As the objective of this project was to compare the toxicity
profiles of α-synuclein aggregates with different morphologies, it is important to evaluate,
by atomic force microscopy (AFM) or transmitted electron microscopy (TEM), how the
sonication process affects their original conformation and selects those settings that allow
for minimal clumping of the sample and minimal disruption of the original morphology.
In addition to the ability to seed, other toxicity readouts must be explored. α-
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Figure 5.7: Seeding of α-synuclein aggregation in mouse primary neurons after sonication.
Mouse hippocampal neurons were incubated with 0.3 µM of sonicated fibrils made with
10% methanol (a) or sonicated fibrils made in the presence of PEG (b) for 5 days. They
were stained with p-129-α-syn (green) and WGA-647 (magenta). Representative images
of an n=1 preparation of α-synuclein fibrillar aggregates (at least 5 images of 3 different
coverslips were taken) are shown.Due to time constrains this experiment could only be
performed once.
Synuclein fibrils have shown to mildly elevate the intracellular reactive oxygen species
(ROS) production [34], to induce the disruption of the cellular membrane [36, 38] allow-
ing an influx of calcium into the cytoplasm and to induce neuronal death dependent of
parthanatos [150]. Since the smaller size of these aggregates may facilitate their binding
to the membrane and consequently the internalisation as well as the binding to other
membrane receptors like the sodium-potassium ATPase special attention to these altern-
ative toxicity readouts must be paid. Moreover, a recent study [116] identified oligomers
released from α-synuclein fibrils upon binding with the membrane as the species respons-
ible from cellular toxicity induced by fibrils. If these polymorphs of fibrillar α-synuclein
were to present different rates of oligomeric release or were not be affected by this phe-
nomena, their ability to induce cellular toxicity could be affected, and in consequence a
differential pattern of cellular toxicity could emerge.
Hopefully the study of the process by which these α-synuclein fibrillar aggregates
interact with the neurons, are internalised, recruit endogenous α-synuclein monomers and
induce cellular toxicity will advance the current understanding of how small differences
in the fibrils structure, which create different fibrillar strains, modulates the origin and
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spreading of different synucleinopathies.
Furthermore, the assessment of the ability of antiparallel fibrils to disrupt the cellular
membrane will advance our knowledge of the possible differences between the toxicity
triggered by the kinetically trapped oligomers used in chapter 3 and on-pathway oli-
gomers. The determination of which percentage, if any, of the toxicity associated with
kinetically trapped oligomers comes from the fact that they possess an antiparallel core,
will help to further validate the use of the kinetically trapped oligomers to model the
effects of the on-pathway ones, which are probably parallel in nature. As on-pathway
oligomers are transient species present in the aggregation reaction at low concentrations,
and hence difficult to isolate and study by traditionally techniques, the study of these
anti parallel fibrils in comparison between the parallel fibrils may help to highlight any
possible relevant difference between off-pathway and on-pathway oligomers. However, the
instability of the antiparallel fibrils makes it necessary to cross-link these samples in order
to study their effects in a physiological context. Most probably due to its mechanism of ac-
tion, the cross-linking with glutaraldehyde, that suppressed ability of α-synuclein fibrillar
aggregates to recruit monomeric α-synuclein, has proven to be unsuitable for this purpose.
Alternative methods that could be explored are cross-linking via PICUP (Photo-Induced
Cross-Linking of Unmodified Proteins) [151] or the introduction of cysteine residues in





Effects of amyloid fibrils on the MTT
test
This work has been done in collaboration with Katarina Pisani and Dr. Janet Kumita.
Katarina Pisani purified the Aβ40 monomer and generated the different conformers used
in this chapter. Dr Janet Kumita prepared the fibrillar species of lysozyme.
6.1 Introduction
The 2-(4,5-dimethyl-2-thiazolyl)-3,5-diphenyl-2H-tetrazolium bromide (MTT) (Figure 6.1)
assay is a wildly used test to measure the cellular metabolic rate and cellular viability.
In its oxidised state MTT is positively charged which it has been hypothesised to fa-
cilitate its cellular uptake via the membrane potential [128]. Once inside the cytosol,
MTT is reduced mainly by NAD(P)H-dependent oxidoreductases and dehydrogenases
and partially (∼10 %) by succinate dehydrogenase in the mitochondria [128] (Figure
6.1). Once reduced MTT becomes insoluble forming a formazan salt, and accumulates
in intracellular granules that with time are transported to the plasma membrane where
they get extruded via exocytosis. The formazan salt is then exposed to the extracellu-
lar media where it crystallises [152]. Although these intracellular granules were initially
thought to be endosomes and lysosomes [152], recent experiments have shown that they
are lipid droplets [153, 154] which provide an intracellular hydrophobic environment for
the water-insoluble formazan product. As the MTT reduction depends mainly of the
available amount of NAD(P)H, it is a measure of the cellular metabolic rate, and hence
indirectly of cell viability [128].
Early studies on the toxicity of Aβ revealed that the addition of Aβ25−35 and Aβ42
to the cytosol of cells was able to induce an enhancement of the formazan crystallisa-
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Figure 6.1: 2-(4,5-dimethyl-2-thiazolyl)-3,5-diphenyl-2H-tetrazolium bromide (MTT) and
formazan salt structures. Figure taken from ([155])
tion rate in PC12, B12, rat cortical neurons and rat astrocytes cultures (Figure 6.2)
[156, 157, 158, 159]. This effect was accompanied by a reduction in the total formazan
levels [157]. The comparison with other viability test, like MTS ((3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)) and LDH (lactate
dehydrogenase)) release, showed that these latter assays were not in agreement with the
MTT test, pointing out that the result of the MTT reduction levels could be an artefact
and not reflect any real change in cellular viability [156]. Although it could not be ex-
perimentally proven, it was hypothesised that this reduction in the formazan levels was
a result of the blockage of the MTT endocytosis by the formazan crystals present at the
plasma membrane [159]. Moreover, it was also hypothesised that the increased rate of
formazan crystallisation was a consequence of an enhancement of exocytotic processes
induced by the presence of Aβ species [157]. Additional experiments with human amylin
allowed the authors to suggest that the responsible species behind this effect were prob-
ably amyloid fibrils, but they were not able to prove the existence of fibrils within the
Aβ monomeric solution [159].
Figure 6.2: Aβ induce the formation of formazan crystals. B12 cells were treated with
DMSO (a) or 10 µM Aβ25−35 (b) for 16 hours followed by 30 min of MTT reduction.
Figure reproduced from [159]
Additional experiments revealed the that the presence of free cholesterol is crucial to
the formation of formazan crystals in both, untreated and Aβ treated cells [160]. The
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addition of cholesterol was able to induce the crystallisation of the formazan in untreated
cells while the depletion of it abrogated this effect in both untreated and treated cells. In
addition other compounds, like β-estradiol [161], genistecin or monesine [159], without
apparent relation among each other were found to completely inhibit the crystallisation
of the formazan.
Here, the effect of different amyloid species from three different proteins, α-synuclein,
lysozyme and Aβ40 on the MTT test is explored. Pure monomeric, oligomeric and fibril-
lar species of different lengths were used in order to determined the conformers behind
the alterations in the formazan salt crystallisation patterns. Furthermore, using an broad
range of concentrations the specificity of this effect and the response time were defined.
Moreover the possible mechanisms by which amyloid fibrils induce formation of formazan
crystals were further investigated, exploring the possibility of an alteration in the exo-
cytosis rate, the involvement of extracellular receptors, and the ability of amyloid fibrils
to induce changes in the cholesterol cellular levels.
6.2 Results
6.2.1 Amyloids fibrils induce the formation of formazan crystals
After having studied how structural features are able to influence the toxic effect of α-
synuclein oligomers and how the structural characteristics of different fibrillar aggregates
are able to affect their seeding properties, our next aim was to compare the toxicity of
these different fibrillar α-synuclein aggregates. With this objective in mind the MTT
test, which have been extensively used in the field to study the toxicity associated to
amyloid species [58, 162, 96, 42, 80, 136], was selected. Previous studies showed that
in comparison to α-synuclein oligomers, α-synuclein fibrils present a milder toxicity in
both reactive oxygen species (ROS) and membrane permeability tests [34, 30, 114, 38],
and because of this reason, similar results in the MTT test were expected. Surprisingly,
after 24h incubation α-fibrils consistently induce a higher reduction of cell viability (55
%) than the kinetically trapped oligomers (83 %) at the same concentration (Figure 6.4).
Due to previous reports of Aβ species being able to induce artefacts in the MTT test, the
possibility that α-synuclein species were able to produce the same effect was explored.
Indeed, SH-SY5Y cells treated with α-synuclein fibrils for 24 hours and then incubated
with MTT solution for 2 h displayed formazan crystals on their surface while in the un-
treated ones the formazan remained trapped inside the cytosol (Figure 6.3). Moreover,
when performing the CellTiter-Glo test, which measures the amount of intracellular ad-
enosine triphosphate (ATP), no indication of reduced cell viability was found using the
115
same experimental setup (Figure 6.4 f).
Due to the methodology available when previous studies were performed, the data
generated were able to suggest but not to prove that this effect is caused specifically by
the fibrillar form of Aβ [159]. Hence, it was decided to explore and characterise this
phenomena in a greater detail. Different α-synuclein conformers (fibrils, sonicated fibrils
[or short firbils], kinetically trapped oligomers and monomer) were prepared. SH-SY5Y
cells were exposed for 24 h to different concentrations of these conformers (ranging from
0.03 nM to 3 µM), the cells were imaged 2 and 4 hours after the addition of MTT and the
final levels of MTT reduction were determine using a plate reader measuring absorbance.
The quantification of the amount of crystals present in the cells at a different timepoints
revealed that only the fibrillar species were able to induce the formation of formazan
crystals at earlier timepoints than the control cells (Figure 6.3 a-g). Interestingly, con-
centration as low as 0.3 nM of short fibrils were enough to induce a statistically significant
difference respect to controls in both number cells presenting formazan crystals and final
MTT reduction absorbance levels (Figure 6.4). Moreover, long fibrils were only able to
induce similar effects at higher concentrations (3 nM) (Figure 6.3 f-n) indicating that
this effect is dependent not only on the concentration of the fibrillar species but also on
their size. Both types of fibrils reached saturation, meaning the point where all the cells
showed the presence of crystals, at 0.03 µM (Figure 6.4 a and b). In the case of the long
fibrils it is possible to detect the presence of the protein itself in the microscope pictures
at the higher concentration (3 µM) in the form of clumps (Figure 6.3 i and o), which
could easily be confused with cellular debris. The results after 4 h closely resembled the
2h ones, with the untreated cells and the ones treated with unsaturating concentrations
of fibrils presenting a higher number of crystals as a result of the natural exocytosis of
the formazan salt (Figure 6.4 a and b). In addition, the same trend observed at the
microscope can be identified in the final absorbance readout of the MTT test, with the
cells presenting a higher number of crystals having reduced a lower amount of MTT (Fig-
ure 6.4 c, d). Since long fibrils have been reported to be internalise more slowly that
shorter ones [102], this may indicate that this effect is dependent on fibrils internalisa-
tion. Alternatively, it is also possible that differences in the number of fibrillar fragments
binding to the membrane could explain this effect: at the same concentration, there will
be a major number of fibrillar fragments present in the short fibrillar samples than in the
long ones, as the concentration is calculated as monomer equivalent resulting in higher
number of fibrillar conformers binding to the cellular membrane. Moreover, experiments
using the N-terminal acetylated form of α-synuclein, a more physiological variant since
α-synuclein have been reported to be 100 % N-acetylated in vivo [163], confirmed the
ability of α-synuclein fibrils to trigger the formazan crystallisation (Figure 6.5).
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Furthermore, neither monomeric nor oligomeric species af α-synuclein were able to
induce early formation of formazan crystals (Figure 6.6) at any of the concentrations
tested. Moreover, in agreement with previous results [80], the addition of 0.3 µM kin-
etically trapped oligomer did produce a decreased of around 17 % in MTT reduction at
the endpoint of the reaction, indicating that the toxicity observed in previous studies
for the different α-synuclein oligomeric variants (including those described in chapter 4),
is not the result of an artefact of the MTT test. The fact that higher concentration of
stabilised oligomers are unable to trigger a reduction of cell viability may be explained
by the crowding and clumping of the aggregates induced by the presence of high amounts
of protein [164, 162].
Since the previous results indicated that this effect on the MTT test seems to be
related to the presence of amyloid fibrils we then decided to explore if amyloid aggregates
of different proteins were able to induce the same phenomenon as the α-synuclein ones.
Indeed, it was found that lysozyme amyloid fibrils but not lysozyme monomer, were able
to induce the early crystallisation of the formazan inducing a false readout of reduced cell
viability (figure 6.7). The fact that lysozyme fibrils were not able to induce cellular death
in SH-SY5Y cells was further confirmed by the CellTiterGlo, which showed no decreased
in the ATP levels of treated respect to the untreated ones (Figure 6.4 g). However, the
lysozyme fibrils seemed to induce the formation of formazan crystals less efficiently than
its α-synuclein counterparts as illustrated by the fact that at 0.003 µM and after 2h of
MTT incubation only 25.6 % of the cells presented crystals in contrast with the 65.9 % in
the case of the long α-synuclein fibrils and the 78.5 % for the short ones (Figure 6.4 a and
b). Following this experiments with lysozyme fibrils, the ability of Zn+2 stabilised Aβ40
oligomers [96] to induce the crystallisation of the formazan was tested. These oligomers
have been reported to induce cellular death by several tests (MTT test; resazurin assay,
which also measures the metabolic activity of the cells; and trypan blue, which is only able
to stain cells whose membrane has been disrupted), an increment of ROS and membrane
disruption [96]. As previously observed in the case of α-synuclein, after 24h incubation
there was not appreciable induction of the early formation of formazan crystals respect to
control cells in the concentration range previously tested (Figure 6.8). However, at high
oligomeric concentration, 10 µM, a small percentage of cells (25.7 %) presented formazan
crystals after 2h of MTT incubation (Figure 6.4 a and b). This may be indicative of a
residual amount of amyloid fibrils present within the oligomeric population or of these
oligomers, which have a β-sheet core, being able to trigger this phenomenon at high
concentrations. Preliminary data showed that, in agreement with our previous results,
Aβ40 amyloid fibrils but not monomers were able to induce the crystallisation of the
formazan salt after 24 h incubation and 2 h of MTT reduction (Figure 6.8). These
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Figure 6.3: α-Synuclein fibrillar species induce formazan crystallisation. (a-g) SH-SY5Y
cells were incubated for 24 h with increasing concentrations of short α-synuclein fibrils
following by incubation in the MTT solution for 2 h. It is possible to observe the presence
of formazan crystals with concentrations as low as 0.3 nM. (h-n) SH-SY5Y cells were
incubated for 24 h with increasing concentrations of long α-synuclein fibrils following by
incubation in the MTT solution for 2 h. It is possible to observe the presence of formazan
crystals with concentrations as low as 3 nM. (o) 3 µM long α-synuclein fibrils were
incubated in cellular media for 24 h and then imaged. Representative images taken from
1 experiment out of 3 (at least 5 pictures per condition in each of these experiments were
taken) are shown. Each of these three experiments were performed using independent 96
well plates and different batches of α-synuclein fibrils. The results of these experiments
were consistent between replicates.
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Figure 6.4: Formazan crystallisation correlated with lower levels of MTT reduction but
does not affect cellular viability. Quantification of the number of SH-SY5Y cells present-
ing formazan crystals at 2 h (a) and 4 h (b) at different concentrations of short α-synuclein
fibrils, long α-synuclein fibrils, lysozyme fibrils, α-synuclein oligomers and Aβ40 oligomer
after 24 h incubation. At least 15 images from 3 different experiments were quantified.
Final levels of MTT reduction normalised to untreated after 24 h treatment with short
α-synuclein fibrils (c), long α-synuclein fibrils (d), lysozyme fibrils (e) or α-synuclein oli-
gomers (h). Intracellular levels of ATP were measured with the CellTiter-Glo kit using
SH-SY5Y cells treated with (f) 1 µM α-synuclein short fibrils or (g) 0.3, 0.03 and 0.003
µM of lysozyme fibrils. In all the cases, data from 3 different experiments performed
with 3 different preparations of α-synuclein fibrillar aggregates were averaged together.
In all the cases the data is represented as average ± SEM and was analyse by one-way
ANOVA, *p ≤ 0.05, **p ≤ 0.001, ***p ≤ 0.0001.
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Figure 6.5: Acetylated α-synuclein fibrillar species induce formazan crystallisation. SH-
SY5Y cells were incubated for 24 h with vehicle, 0.3 µM and 0.03 µM of short acetylated
α-synuclein fibrils. After 2 h of MTT reduction crystals could be detected in the treated
cells. Representative images of 3 different experiments performed with 3 different prepar-
ations of α-synuclein fibrillar aggregates (at least 5 pictures were taken per condition in
each of these experiments) are shown. The results of these experiments were consistent
between replicates.
results further confirm the hypothesis that only amyloid fibrils, but no other species, are
able to induce early formation of formazan crystals and thus generate a false readout
of reduce cell viability. Furthermore, these results suggests that this is a characteristic
shared between all the amyloid fibrils, with independence of by which protein are they
composed of.
Since SH-SY5Y cells incubated for 24 h with concentrations equal or superior to 0.03
µM of short α-synuclein fibrils presented ubiquitous formazan crystals after 2 h incubation
with MTT, the time course of the formation of these crystals was studied next. With
this aim we incubated SH-SY5Y with 0.3 µM short α-synuclein fibrils for 24 h and after
adding the MTT pictures were acquired every 5 minutes. Formazan crystals can be
detected only 10 minutes after the beginning of the incubation, and at 20 minutes all the
cells treated with the α-synuclein fibrils showed these crystals (Figure 6.9).
Following this observation, and as the formation of formazan crystals seems to be
extremely sensitive to the presence of amyloid fibrils, the incubation time in the presence
of short α-synuclein fibrils necessary to trigger this effect in the cells was determined.
With this aim cells were incubated in either, the presence of α-synuclein fibrils for 2 h
before removing the media and adding the MTT or in the presence of media containing
both MTT and different concentrations of α-synuclein short fibrils. The incubation of SH-
SY5Y cells with fibrils directly in the presence of MTT resulted in a significant amount
of crystals being present after 2h of MTT reduction at fibrillar concentrations of 0.3
µM (17 %) or higher while, in agreement with previous results, the percentage of cells
presenting crystals at this same concentration had increased (37.2 %) at 4 h (Figure
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Figure 6.6: α-Synuclein monomeric and oligomeric species are unable to induce formazan
crystallisation. (a-g) SH-SY5Y cells were incubated for 24 h with increasing concentra-
tions of α-synuclein oligomers following by 2 h of MTT reduction. It is not possible
to observe the presence of formazan crystals at any of the concentrations tested. (h-n)
SH-SY5Y cells were incubated for 24 h with increasing concentrations of α-synuclein
monomers following by 2 h of MTT reduction. It is not possible to observe the presence
of formazan crystals at any of the concentrations tested. Representative images of 3
different experiments performed with 3 different preparations of α-synuclein species (at
least 5 pictures were taken per condition in each of these experiments) are shown. The
results of these experiments were consistent between replicates.
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Figure 6.7: Lysozyme fibrils but not monomers induce formazan crystallisation. (a-g)
SH-SY5Y cells were incubated for 24 h with increasing concentrations of lysozyme fibrils
following by MTT reduction for 2 h. It is possible to observe the presence of formazan
crystals with concentrations as low as 3 nM. (h-n) SH-SY5Y cells were incubated for
24 h with vehicle, 3, 0.3 or 0.03 µM of lysozyme monomers following by 2 h MTT
reduction. It is not possible to observe the presence of formazan crystals at any of the
concentrations tested. Representative images of 3 different experiments performed with 3
different preparations of lysozyme conformers (at least 5 pictures were taken per condition
in each of these experiments) are shown. The results of these experiments were consistent
between replicates.
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Figure 6.8: Aβ40 fibrils but not oligomers or monomers induce formazan crystallisation.
(a-h) SH-SY5Y cells were incubated for 24 h with increasing concentrations of β40 oli-
gomers following by 2 h of MTT reduction. The presence of formazan crystals could only
be observed at 10 µM β40 oligomers. Representative images of 3 different experiments
performed with 3 different preparations of Aβ40 oligomeric species (at least 5 pictures
were taken per condition in each of these experiments) are shown. (i-l) SH-SY5Y cells
were incubated for 24 h with vehicle, 3, 0.3 or 0.03 µM of Aβ40 fibrils. After 2 h of
MTT reduction crystals could be detected in the treated cells. Representative images of
one experiments performed with one preparations of Aβ40 fibrils (at least 5 pictures per
condition were taken) are shown. Due to time constrains this experiment could only be
performed once. (m-p) SH-SY5Y cells were incubated for 24 h with vehicle, 3, 0.3 or 0.03
µM of β40 monomers following by 2 h of MTT reduction. It is not possible to observe the
presence of formazan crystals at any of the concentrations tested. Representative images
of one experiment performed with one preparation of Aβ40 monomer (at least 5 pictures
were taken per condition) are shown. Due to time constrains this experiment could only
be performed once.
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Figure 6.9: Timeline of the crystallisation of formazan. SH-SY5Y cells were incubated
for 24 h with 0.3 µM short α-synuclein fibrils and images at 5, 10, 20 and 30 minutes
after the the incubation in the presence of the MTT solution were taken. After 10
minutes formazan crystals (here marked with an *) can be appreciated in the treated cells.
Representative images of 3 different experiments performed with 3 different preparations
of α-synuclein fibrillar aggregates are shown. The results of these experiments were
consistent between replicates.
6.10). Cells incubated with short fibrillar aggregates for 2 h before the addition of MTT,
presented an increment in the number of cells with crystals after 2 h of MTT reduction at
concentrations of 0.003 µM (14.9 %) (Figure 6.10). This result indicated that this effect
on the MTT test is not only dependent on fibrillar concentration but also on incubation
time, needing only hours to induce the maximum effect. The internalisation of the α-
synuclein fibrils has been detected after just 1 h incubation [102, 30] which is consistent
with the current time frame observed in this experiment, indicating that the effect of the
α-synuclein fibrils on MTT test may be related in its internalisation.
6.2.2 Elucidating the mechanism behind amyloid-induced form-
azan crystallisation
In the past, studies with different Aβ peptides suggested that the induction of early
crystallisation of formazan was due to an increased exocytosis of the intracellular vesicles
containing reduced MTT [159]. As short fibrils have been reported to induce a certain
degree of membrane disruption, allowing an influx of Ca2+ inside the cells [38, 36] which
in turn may trigger exocytotic processes with the aim of resealing the disrupting mem-
brane [165, 166, 167, 168], it was first hypothesised that this crystallisation phenomenon
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Figure 6.10: Time dependence of the crystallisation of formazan. Quantification of the
number of SH-SY5Y cells presenting formazan crystals at 2 h (a) and 4 h (b) at different
concentrations of short α-synuclein fibrils after 24 h, 2 h or 0 h incubation. 15 or more
images from 3 different experiments each one performed with a different preparation of
aggregates were quantified. The data is represented as average ± SEM and was analyse
by one-way ANOVA, *p ≤ 0.05, **p ≤ 0.001, ***p ≤ 0.0001.
is a consequence of an exocytosis process triggered by the binding of the α-synuclein
fibrils to the cellular membrane. With this aim, SH-SY5Y cells were incibated with 3
µM α-synuclein short fibrils in the absence of calcium. After 1 h incubation with MTT,
cells treated with α-synuclein fibrils for 2 h already presented formazan crystals while un-
treated cells remained undisturbed (Figure 6.11). Together with the fact that oligomers,
a more potent disrupting agent for the lipid membranes, were unable to trigger this effect
these data suggest that this process is independent of membrane disruption and calcium
signalling. Thus, toxicity data from previous studies [34, 38, 30, 36] comparing the abil-
ity of different α-synuclein species to induce membrane disruption are still valid and the
conclusions of these studies are unaffected by the artificial decrease in MTT reduction
induced by amyloid fibrils.
Since the enhancement of exocytosis as the mechanism underlying the crystallisation
of formazan at earlier time points have not been experimentally observed, a series of
experiments with the objective of validating this theory were performed. After 4 h of MTT
reduction it was possible to observe the exocytosis and crystallisation on the formazan
in untreated cells (Figure 6.12) using an optical microscope. This supports the theory
that formazan crystals are formed after being exocytated once the reduced MTT comes
in contact with the extracellular media. This suggests that the crystallisation of the
formazan happens in a short period of time, indeed, upon 24 h treatment with α-synuclein
short fibrils, crystals of formazan were detected in cells after only 10 minutes of the
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Figure 6.11: Formazan crystallisation is independent of Ca2+. SH-SY5Y cells were treated
in the presence or absence of Ca2+ for 2 h with 3 µM short α-synuclein fibrils. After 1
hour of MTT reduction formazan crystals could be observed in boths sets of treated cells.
Representative images of 3 different experiments performed with 3 different preparations
of α-synuclein fibrillar aggregates (at least 5 pictures were taken per condition in each of
these experiments) are shown. The results of these experiments were consistent between
replicates.
addition of the MTT solution. Therefore, the enhancement of the exocytosis should
be an early event and exocytotic vesicles should be quickly translocated to the cellular
membrane. To explore this hypothesis, cells incubated with 0.3 µM α-synuclein fibrils
for 24 h immediately after the addition of the MTT were imaged every two minutes. It
was possible to observe the formation of blue positive vesicles after 2 minutes, indicating
the beginning of the MTT reduction. However, these vesicles appeared to remain inside
the cells over time and the formation of the formazan crystals occurred near the original
position observed for each dot (Figure 6.12). These results indicate that α-synuclein
short fibrils are able to induce the crystallisation of the formazan inside the cytoplasm
of the cells rather than on the membrane surface. Moreover it is possible to observe
the retraction of the cellular membrane after the formation of the formazan crystals,
suggesting that these crystals damage the cell membrane as they grow in size with the
result of effectively killing the cells and stopping the reduction of the MTT. Here it
is important to highlight that, if this were to be proven, the MTT readouts would be
faithfully reporting on the viability of the cells, but the observed cellular death would be
a consequence of the interaction between the fibrillar aggregates of α-synuclein and the
fromazan and not of the toxicity induced by this conformers.
To further investigate this possibility, the integrity of the cellular membrane after
the induction of the formazan crystallisation by α-synuclein short fibrils was assessed.
In order to achieve this, SH-SY5Y cells treated for 24 h with 0.3 µM short α-synuclein
fibrils were incubated in the presence of 2 µM Calcein-AM, a cell permeant dye that gets
converted into its fluorescent membrane impermeable form by cellular esterases. After
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Figure 6.12: α-Synuclein fibrils do not enhance the exocytosis of formazan. SH-S5Y5
cells were treated with 0.3 µM short α-synuclein fibrils for 24 h after which the media
was replaced with an MTT solution and pictures were acquired every 2 minutes. After 4
minutes the formazan granules are already visible and at 8-10 minutes the first crystals
appear. During this process the formazan granules remain static inside the cells. The
cellular membrane retracts after the formazan crystals have formed. After 4 h of MTT
reduction it is possible to observe the formazan exocytosis in the untreated cells. Rep-
resentative images of 3 different experiments performed with 3 different preparations of
α-synuclein fibrillar aggregates are shown. The results of these experiments were consist-
ent between replicates.
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30 minutes at 37 °C of incubation, the Calcein-AM dye was replaced by a solution of
MTT and the cells are imaged at 30 minutes and 2.5h, for this last time point 4 µM of
ethidium homodimer (a marker of cellular death) was added to the mixture 30 min in
advance. Due to the possible cytotoxic effect of ethidium homodimer, this marker could
not be co-incubated with Calcenin-AM for the complete duration of the experiment. The
images acquired 30 minutes after the addition of the MTT showed that cells presenting
larger formazan crystals had lost the Calcein-AM stain whereas, cell containing smaller
crystals still retained the Calcein-AM derived florescence to a certain extend, indicating
that the cellular membrane is less affected by the presence of the formazan crystals
(Figure 6.13). This trend could also be appreciated at a second time point, where most
of the cells showing formazan crystals had lost the Calcenin-AM stain and where instead
positive for ethidium homodimer (Figure 6.13). These data corroborate the hypothesis
that large formazan crystals are able to disrupt the cellular membrane, inducing the loss
of membrane integrity and eventually leading to cell death. This is in agreement with
previous reports showing that the formation of these crystals in untreated cells induced
cellular death through apoptotis mediated by the activation of caspase-3 [169]
Taken together these results do not support the hypothesis of the formazan crystal-
lisation being a direct consequence of an enhance exocytosis of the formazan-positive
intracellular granules. Instead the data obtained in this study are consistent with the
formzan crystals forming inside the cellular cytoplasm from where they would be able
to pierce the cellular membrane, compromising the membrane integrity and ultimately
triggering cellular death.
Once the possibility of an enhancement of exocytosis being responsible for the forma-
tion of the formazan crystals was discarded alternative possibilities had to be considered.
One of these possibilities is the formazan crystallisation being triggered by a downstream
signalisation pathway activated upon binding of the fibrillar conformers to the cellular
membrane. Previously, several amyloid conformers have been reported to bind and in-
hibit the activity of the Na2+/K+ ATPasa (NKA) [45, 170, 171], which in turn, activated
a signallisation pathway via Src kinase (involved in the regulation of cellular proliferation,
differentiation, motility, and adhesion). Indeed, the inhibition of the NKA by ouabain has
been reported to inhibit the reduction of MTT producing a false readout of reduced cell
viability [172] in HUVEC cells dependent on the activation of Src. In order to investigate
if this interaction is responsible for the effects on the MTT test previously described in
this study SH-SY5Y cells were incubated with 200 nM ouabain for 24 h before replacing
the media with a solution of MTT, imaged at 2 h and 4 h, and the final levels of reduced
MTT were quantified in a platereader. Surprisingly, no difference in the amount of cells
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Figure 6.13: Formazan crystals disrupt the cellular membrane upon formation. SH-S5Y5
cells were treated with vehicle or 0.3 µM short α-synuclein fibrils for 24 h after which
they were incubated with 2 µM Calcein-AM. After 30 min the Calcein-AM was replaced
with an MTT solution. 30 min and 2.5 h into the reaction and pictures were taken. Cells
presenting large formazan crystals had lost the Calcein-AM fluorescence were untreated
and cells with smaller crystals retained it. Before the 2.5 h timepoint 4 µM of ethidium
homodimer was added for 30 min, cells with formazan crystals had lost the Calcein-AM
signal and were stained by ethidium homodimer. Representative images of 3 different
experiments performed with 3 different preparations of α-synuclein fibrillar aggregates
are shown. The results of these experiments were consistent between replicates.
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presenting formazan crystals or the final levels of reduced product were found between
treated and controls cells (Figure 6.14 a-d). Thus, this indicates that the amyloid fibrils
induce the crystallisation of formazan in SH-SH5Y cells by an alternative mechanism to
the one reported in HUVEC cells.
Figure 6.14: Insights into the mechanism of formazan crystallisation. (a-d) Inhibition
of the NKA does not cause the crystallisation of the formazan. After 2h of MTT re-
duction neither cells treated with 200 nM ouabain for 24 h (a) nor untreated ones (b)
showed formazan crystals. The same results could be observed after 4 h of MTT reduc-
tion (c, cells treated with 200 nm oubain), (d, untreated cells). Representative images
of 3 different experiments performed with 3 different preparations of α-synuclein fibrillar
aggregates (at least 5 pictures were taken per condition in each of these experiments)
are shown. The results of these experiments were consistent between replicates. (e-g)
The presence of α-synuclein fibrils does not alter the intracellular levels of cholesterol.
SH-SY5Y were treated with 0.3 µM short α-synuclein fibrils (e) or vehicle (f) and the
unsterified cellular cholesterol was stained with Flipin III. Representative images of 2
different experiments performed with 2 different preparations of α-synuclein fibrillar ag-
gregates (at least 5 pictures were taken per condition in each of these experiments) are
shown. The quantification of the Flipin III fluorescence (g), represented as the average ±
SEM, showed no significant difference between the two populations. Data were analysed
via a Student t-test.
Another possible explanation for this phenomenon involves the alteration of cellular
levels of cholesterol induced by the presence of amyloid fibrils. The levels of unsterified
cholesterol present in the cells has been identified as an important determinant for the
formation of fromazan crystals [160, 154]. The addition of external cholesterol has been
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shown to induce the early crystallisation of the formazan in untreated cells while its
depletion completely abrogates this reaction in both untreated and Aβ-treated cells [160].
Moreover, Aβ has been shown to increase the amount free cholesterol present inside the
cells which could in turn affect the formazan crystallisation rate [160]. In order to test
if this was also true in the case of α-synuclein, SH-SY5Y cells were incubated in the
presence of 0.3 µM short fibrils for 24 h afterwards free cholesterol staining by filipin
III was performed. Filipin III is an antibiotic that upon interaction with unsterified
cholesterol undergoes a conformation change and becomes fluorescent. Interestingly no
difference between the cholesterol content of the treated and untreated cells was detected
(Figure 6.14 e-g). Since the data acquired in this study suggest that the acceleration of the
formazan crystallisation is a feature common to abroad spectra of amyloid fibrils, there
is a low probability of an increment in the intracellular levels of unsterified cholesterol
being behind the reported enhancement of formazan crystallisation.
Finally, as reduced MTT has been recently shown to accumulate inside lipid droplets
[153, 154], the possibility of α-synuclein fibrils inducing changes in the lipid droplet popu-
lation was explored. With this aim, untreated and cells incubated with short α-synuclein
fibrils, were fixed and stained with Nile Red, a fluorescence probe that binds neutral lip-
ids. Image analysis revealed no differences between the lipid droplets population of the
untreated and treated cells (Figure 6.15 a and b). Interestingly the co-treatment of short
α-synuclein fibrils and 2.5 µM U-18666A, which induces the sequestration of cholesterol
in late endosomes, for 24 h inhibited the enhanced formation of formazan crystals, re-
turning the crystallisation rate to untreated levels (figure 6.15 c-f). This suggest that the
presence of cholesterol inside the lipid droplets is indeed necessary for the amyloid fibrils
to induce this characteristic effect. As both, the fact that the concentration of α-synuclein
fibrils necessary to induce this effect changes with fibrillar size and the time necessary
to first observe this process points toward the induction of the formazan crystallisation
being related to fibrillar internalisation the possibility of a direct interaction between the
amyloid fibrils and the lipid droplets needs to be considered. Although amyloid fibrils
are internalised by endocytosis, they are able to disrupt the endocytotic vesicles effect-
ively escaping the proteolytic pathway [47, 173], which could allow them to interact with
the lipid droplets once in the cytoplasm. Preliminary results (Figure 6.16), in which
co-staining with Nile Red and fibrillar (OC) or oligomeric (A11) specific antibodies was
carry out, shows that this is indeed a possibility worth exploring.
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Figure 6.15: Relationship between formazan crystallisation and lipid droplets. SH-SY5Y
cells untreated (a) and treated (b) with 0.3 µM α-synuclein short fibrils were stained with
Nile Red and imaged in a confocal microscope. No difference could be observed between
the lipid droplets population of both conditions. (c-f) SH-SY5Y cells were treated with
2.5 µM U-18666A for 24 h in the presence (d,f) or absence (c,e) of 0.3 µM short α-
synuclein fibrils. 2 hours after the addition of MTT nor untreated (c) nor fibrillar treated
cells (d) displayed formazan crystals. After 4 h incubation with MTT, both untreated (e)
and treated (f) cells showed a similar number of cells presenting crystals. Representative
images of 3 different experiments performed with 3 different preparations of α-synuclein
fibrillar aggregates are shown.
6.3 Discussion
In conclusion these results showed that amyloid fibrils induce the crystallisation of the
formazan in a time and concentration dependence manner. Once formed, these crystals
pierce the plasmatic membrane inducing cellular death and effectively stopping the MTT
reduction. As this happens as early as 10 minutes of incubation of the cells in the MTT
solution the final readout of the test, performed in a platereader, detects significantly less
formazan in the fibril-treated cells compared to the untreated ones leading towards to the
artifact of a reduced cell metabolic activity and viability. The fact that the addition of
amyloid fibrils does not indeed induce cellular death has been proved with the help of an
alternative cellular viability test that measures the amount of ATP present inside the cells.
Moreover, this phenomenon have been proven to be extremely sensitive to the presence
of amyloid fibrils, with concentration as low as 300 pm triggering a significant effect. The
ability of producing and isolating different species (monomer, oligomers and fibrils) in the
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Figure 6.16: Co-localisation between α-synuclein fibrils and lipid droplets. SH-SY5Y cells
were incubated in the presence of 0.3 µM α-synuclein short fibrils for 24 h. After fixation
cells were stained with Nile Red and OC (anti-fibrillar antibody) or A11 (anti-oligomeric
antibody). Partial co-localisation between the Nile Red positive vesicles and the OC
antibody could be detected. Representative images of one experiment performed with
one preparation of α-synuclein fibrillar aggregates are shown. Due to time constrains this
experiment could not be repeated.
aggregation pathway of amyloidogenic proteins have allowed us to undoubtedly identify
amyloid fibrils as the species responsible for triggering this effect in the case of both,
α-synuclein and Aβ. Although oligomeric species do not trigger this effect and hence
it is possible to use the MTT with the objective of evaluate their effect upon cellular
viability, the high sensitivity of the test means that the presence of any residual fibrillar
aggregate will trigger the formazan crystallisation, and thus potentially result in a false
positive. Furthermore, the inability of the oligomeric species to induce the crystallisation
of the formazan salt have been determined here using off-pathway oligomers. Despite
the fact that they share similar toxicity properties with on-pathway oligomers [34], it
is probable that their structure differs from one another. Since the induction of the
early crystallisation of the formazan seems to be highly dependant on structural features
of the amyloid aggregates and the on-pathway oligomers are the precursors of amyloid
fibrils it is possible that they have a different effect upon the formazan crystallisation than
their stabilised counterparts. Although the transient nature of the oligomeric on-pathway
species make them extremely difficult to isolate, further efforts on this matter need to be
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carried out in order to achieve a clearer picture of the species able to trigger this effect.
Moreover, if on-pathway oligomers are proven to be unable to induce this effect, the high
sensitivity of the test could be used to discriminate among different species forming during
the aggregation reaction, and it could allow the correlation between their structure and
activity. Taking into account all these considerations we encourage complementing the
MTT test with other cell viability tests like LDH release, ATP content or resazurin.
Both, the fact that long α-synuclein fibrils induce this effect at a higher concentration
(3 nm) than short ones (0.3 nm) and that the this effect is triggered in the timescale of
hours after the addition of the α-synuclein fibrils are consistent with the internalisation
of the fibrils being determinant for the triggering of the formazan crystallisation. Prelim-
inary results exposed in this study pointing towards a possible direct interaction between
the α-synuclein fibrils and the lipid droplets further supports this hypothesis (Figure
6.17). If additional experiments confirm this hypothesis, differences in internalisation,
binding rate to the lipid membrane or ability to escape the endocytotic pathway may ex-
plain the differences in the ability to induce the crystallisation of the formazan observed
in this study between different amyloid fibrils at the same concentrations (Figure 6.4).
In this context, the use of fluorescently labelled α-synuclein species could have allowed
us to evaluate some of this aspects, as it would be possible to easily determine their
internalisation rate and once internalised, to follow their journey through the endosomal
pathway and potentially into lipid droplets. Moreover, the repeat of these experiments
in HEK293T cells, which have been recently reported to present an impairment inter-
nalisation of the α-synuclein fibrils [174], might support our efforts in confirming this
hypothesis. If a difference in the ability of α-synuclein fibrils to induce the formation
of formazan crystals were to be detected, this could be indicate that this process is de-
pendent on cellular subtype. This could offer a potential explanation to the difference
between the reduction in MTT reduction previously reported in the literature (10 %)
[34, 30, 114, 38, 116] and the one observed in this study (50 %). Even though, SH-Y5Y
cells have routinely being used both, here and in previous studies [34, 30, 114, 38, 116],
differences in the differentiation protocol used to obtain neuron-like SH-Y5Y in each
lab could potentially affect the metabolism of these cells and consequently explain the
observed differences.
In addition, the fact that the crystallisation of formazan is also triggered by N-
acetylated α-synuclein is specially relevant. It has been reported that in vivo α-synuclein
is constitutively acetylated in the N-terminal region [163] and the presence of this post-
translational modification is able to influence the interaction between α-synuclein fibrils
and cells. For example, N-terminal acetylated synuclein fibrils have been shown to be
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Figure 6.17: Proposed mechanism of MTT crystallisation.
internalised at a faster rate than the WT form [174] via specific interactions with the cel-
lular membrane. Here, the fact that N-acetylated α-synuclein and WT fibrils were able
to induce the same response indicated that the underlying cellular processes respons-
ible for triggering the crystallisation of the formazan may be happening in vivo. Even
though the acetylation of α-synuclein is physiologically relevant, N-acetylated variants of
α-synuclein have not been used in other chapters of these thesis due to different reasons.
The purification of N-acetylated α-synuclein involves the co-transfection of E. Coli with
two plasmids, the α-synuclein one and the NatB (N-terminal acetyltransferase), as we
did not had access to the NatB plasmid at the moment N-acetylated mouse α-synuclein
could not be purified. With respect to the production of the different oligomers variants
used in chapter 4, N-acetylated kinetically trapped oligomers have been shown to present
the same structure and toxic properties than the WT form [36]. This fact allowed the
used the unacetylated version of α-synuclein, with its ease of purification, to prepare the
different oligomeric variants used in this study. Finally, since the N-terminal acetylation
of α-synuclein has been shown to affect the interaction between the cellular membrane
and α-synuclein fibrils the generation of the different fibrillar conformers used in chapter
5 with N-acetylated α-synuclein could have been specially relevant. However, since these
conformers had been kinetically and structurally characterised using the unacetylated
variant of α-synuclein [19] and one of the objectives of the study was to establish a
link between different structural fibrillar polymorphs and different seeding capabilities in
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primary neurons, the use of the unacetylated variant of α-synuclein was preferred. If in
the future the N-acetylated version of α-synuclein were to be used to generate these fibril-
lar conformers, their full biophysical characterisation will be required before performing
the cellular experiments.
The MTT test is still widely used in the field to monitor cellular toxicity of amyloid
aggregates, particularly in the case of α-synuclein [42, 58, 80], which in light of these
results need to be revisited. Moreover, based on the assumption that Aβ is able to
trigger an enhancement of the exocytosis, the formation of formazan crystals has been
used as a tool to monitor Aβ-induced changes in synapsis plasticity [175, 176]. In addition,
these results highlight the importance of using different experimental approaches in order
to validate a working hypothesis, as when using a single method unknown factors may
influence the final results leading the scientists to draw conclusion based on an artefact of
the test in question. In conclusion, the results presented here revealed that the formation
of formazan crystals is not directly linked to the enhancement of the exocytosis rate,





In this PhD thesis I have extensively explored and characterised how the structure of
different amyloids α-synuclein conformers is able to modulate cellular toxicity. Since
different polymorphs of α-synuclein are able to induce different synucleinopathies [57,
58, 59], the understanding of how apparently small structural changes can modulate not
only cellular toxicity but also the spreading of the α-synuclein aggregates in vivo, is
specilly important not only to understand the mechanism behind the onset and progress
of Parkinson’s disease (PD) but also of other synucleinopathies.
First, we aimed to improve the reproducibility of the PFF mouse model of Parkinson’s
disease by biophysically characterising and isolating the different α-synuclein conformers
present in the injected samples. This allowed us to identify two potential sources of
variability: the storing method of the samples and their composition. We first observed
that the storage under cryogenic conditions lead to the fragmentation of the samples,
which could potentially affect the reproducibility of the results obtained. This is especially
relevant in the light of our next results, which showed that shorter fibrillar fragments are
able to induce the pathology and the spreading of the disease more efficiently than other
α-synuclein conformers both, in vitro and in vivo. Moreover, by comparing the ability
to induce a PD-like phenotype of these small fibrillar fragments and kinetically trapped
oligomers, which have been shown to induce higher levels of cellular toxicity than the
fibrils [34], we were able to determine that the ability to recruit endogenous α-synuclein
is key to successfully induce the spreading of α-synuclein aggregates in the brain. Hence
the seeding ability of different α-synuclein conformers in vitro could potentially be an
marker for enhanced toxicity in vivo.
Secondly, the different properties of kinetically trapped oligomers produced from
pathological variants of α-synuclein and their ability to affect cellular toxicity were stud-
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ied. Surprisingly, it was found that G51D oligomers presented a higher structural poly-
morphism than any of the other variants, although the presence of an antiparallel β-sheet
core was conserved between preparations, they presented different degrees of α-helical
content. Moreover, the amount of α-helix present in the preparation proved to be a key
determinant of cellular toxicity, being more toxic those preparation with higher degrees
of α-helical content. This indicates that more parameters beside size and hydrophobi-
city content [123] need to be taken into account when predicting the toxic properties of
amyloids conformers.
The next step was to investigate the relationship between different fibrillar poly-
morphs of α-synuclein and cellular toxicity. We found that different α-synuclein fibrillar
conformers were able to seed the aggregation of endogenous α-synuclein with different
efficiencies. While protofibrils were able to induce a higher degree of aggregation than
F1 fibrils, oligomeric-size aggregates formed in the presence of 10 % methanol presented
a reduced ability to seed the formation of endogenous α-synuclein inclusions. Since dif-
ferent α-synuclein fibrillar polymorphs have been linked to different synucleinopathies,
the understanding of how these modulate cell toxicity could further our knowledge of
the origin of these diseases. As these α-synuclein aggregates have been shown to seed
endogenous α-synuclein at different rates in vitro, once injected into the brains of mice
they could trigger the formation of aggregates at different speeds and in consequence
model different synucleinopathies or different stages of the disease. Because of this, the
injection of these aggregates into brains of mice could improve our understanding of the
relationship between fibrillar structure and pathology.
Finally, we studied the effect of different amyloid aggregates on the MTT test. Our
experiments show that amyloid fibrils are able to induce the crystallisation of the form-
azan salt in a time and concentration dependent manner. Once formed, these crystals
pierce the plasmatic membrane inducing cellular death and effectively stopping the MTT
reduction. As this happens early in the MTT reduction reaction, the formazan levels
are significantly decreased respect to the control cells at the end of the reaction, leading
towards a false conclusion of amyloid aggregates inducing cellular death. The high sens-
itivity of this test means that, although it should not be used to asses cellular variability,
it could be repurposed as a method of detection of amyloid fibrils in solution. As the
MTT test is still widely used in the field to asses the toxicity of amyloids aggregates,
this is especially relevant and highlights the importance of using different experimental
approaches in order to validate a working hypothesis.
In conclusion, this PhD thesis highlights the importance of integrating knowledge from
different fields in order to solve complex problems. Here, we have successfully applied our
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understanding of the biophysical properties of different amyloids aggregates to explain
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